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Abstract 
Introduction:  Sleep disturbances and sleep quality have fluctuated over 
time in the United States (US).  Virtually every physiological process follows a 
circadian pattern, and cellular processes (i.e., cell proliferation, DNA damage 
response, and apoptosis) are often disrupted by sleep disturbances and other 
factors, potentially giving rise to adverse health outcomes such as cancer.  
Additionally, both genetic variation and epigenetic patterns within clock genes, 
which may affect sleep quality, also may increase one’s risk for developing 
cancer. The role of sleep disturbances in the formation of adenomas, precursor 
lesions to colorectal cancer (CRC), has been explored previously; however, little 
is known regarding the influences of genetic variation in the PERIOD3 (PER3) 
variable number tandem repeat (VNTR) and epigenetic patterns of clock genes 
on adenoma formation.  Furthermore, few studies have attempted to fully 
characterize sleep disorder trends in a national sample over time, as it has been 
alleged that sleep quality has declined over time.  Examination of sleep disorder 
trends is of public health significance because individuals affected by sleep 
disturbances may be at an increased risk for cancer development, particularly 
CRC.  Materials and Methods:  In order to examine sleep disorder trends over 
time and to determine the genetic and epigenetic influences of adenoma 
formation, two studies were conducted.  The first study utilizes data from a 
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national sample of US Veterans across an eleven year span to carry out a serial 
cross-sectional study to produce annual prevalences  of sleep disorders, which 
were further stratified by additional factors.  Cases were defined as patients with 
at least two outpatient sleep disorder diagnoses at least 30 days apart based on 
ICD-9 codes and American Academy of Sleep Medicine (AASM) criteria.  
Additional analyses were carried out to determine factors that were associated 
with the development of new sleep disorders in the last year of the study using 
multivariable unconditional logistic regression models to produce odds ratios 
(OR) and 95% confidence intervals (95% CI).   
The second study (Epigenetics and Diet in the Carcinogenesis Process, 
EDCaP) provided information on epigenetic markers and PER3 VNTR variation.  
The epigenetic marker study was carried out at local endoscopy center (South 
Carolina Medical Endoscopy Center, Site 1 [n=107]).  For the PER3 VNTR arm 
of the study, data from Site 1 (n = 93) and an additional endoscopy center were 
pooled (WJB Dorn Veterans Administration Medical Center [Site 2, n=53]). Cases 
were defined as individuals with at least one histologically confirmed adenoma, 
and controls were subjects with a normal colonoscopy, or a normal biopsy not 
requiring heightened surveillance (e.g., hyperplastic polyp).  To determine if 
cases had differential promoter methylation in selected genes or an increased 
odds of possessing at least 5-repeat allele in the PER3 VNTR compared to 
controls, unconditional logistic regression analyses were used to calculate ORs 
and 95% CIs, while adjusting for confounders.  Results: In the study using a 
national sample of US Veterans, apneas and insomnias were the first and 
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second most common sleep disorders diagnosed among Veteran patients, 
respectively.  Total sleep disorder prevalence rose six-fold across the study 
period.  Additional analyses indicated that several comorbid diseases may 
influence the development of sleep disorders.  In the methylation study, 
compared to controls, cases were more likely to be hypomethylated in the 
MINT1, PER1, and PER3 promoters. In the PER3 VNTR study, cases were more 
likely to possess the 5-repeat PER3 genotype relative to controls.  Discussion:  
Given the evidence that diagnosed sleep disorder prevalence has risen over time 
in the national sample study, a subset of individuals may be increasing their risk 
for cancer, potentially through genetic or epigenetic mechanisms.   Epigenetic 
and genetic variations in clock genes appear to influence the development of 
adenomas, which presents an opportunity to develop novel biomarkers in 
accessible tissues (e.g., blood).  It also is important to note that these genetic 
and epigenetic markers may influence sleep disturbances, which have been 
linked to cancer formation in previous studies.      
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Chapter 1 
Introduction and Specific Aims 
1.1 Introduction 
According to the most recent estimates by the American Cancer Society, 
there will have been over 93,000 incident colorectal cancers (CRC) patients and 
more than 39,000 deaths in the United States (US) in 2015, thus making it the 
third most common cancer in both men and women.1 While these statistics are 
alarming, CRC is one of the most preventable cancers. Colorectal adenomatous 
polyps are considered precursor lesions for CRC.2  Certain characteristics of 
adenomas such as size, number, and histology, confer a greater risk within an 
individual.3-6  A deeper understanding of the factors related to the formation of 
these adenomatous polyps and their progression to cancer is needed, but it 
provides an extremely important opportunity for public health interventions. By 
intervening in this pathway from adenoma to carcinoma formation, health 
professionals will have the ability to reduce the number of new CRC cases by as 
much as 90%.5,7 
Colorectal adenomas have been estimated to have developed prior to 70-
90% of all CRCs.8 Despite screening programs, the incidence of CRC and deaths 
due to CRC remains high.9  Current efforts are directed toward detection and 
removal of asymptomatic adenomas.  However, even after removal, the 
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recurrence rate for adenomas, an effective surrogate endpoint for CRC, is 
approximately 40-50%.10-12  Thus, continued surveillance via follow-up 
colonoscopies is extremely important in avoiding cancer progression in the colon; 
however, CRC surveillance compliance is still low (49 – 61% of CRC 
survivors).13-17 It also illustrates the importance of finding alternative means of 
CRC screening. 
Because a series of genetic and epigenetic changes occur along the 
pathway from normal tissue within the gastrointestinal (GI) tract to 
carcinogenesis, it is important to understand the mechanism behind these 
changes to help prevent formation of CRC or to better treat current cases of 
CRC.  Also, it has become important to discover novel biomarkers that predict 
CRC risk, as some heavily-studied genetic markers cannot fully explain CRC 
formation within certain individuals and populations as a whole especially in 
readily-accessible tissues derived from the body (e.g., blood).   Additionally, 
several other genes have been implicated in the carcinogenesis process in the 
GI system;18 hence, further investigation into other gene families such as the 
Period family (PER1, PER2, and PER3) is warranted.19   
The Period (Per) gene family plays a role in immunomodulation20-25 and 
tumor suppression.26, 27 Thus, structural variation,19, 28, 29 deregulated expression 
within tumor tissues,30-32 and epigenetic variation 33 within the Per genes have 
shown some promise as novel biomarkers of cancer.   For example, Chen et al 
found dysregulated expression of PER1, PER2, and PER3 in breast tumor 
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tissues compared to matched normal tissues within subjects.30  Within this same 
gene family, Zhu et al have found that structural variation in one of these genes 
in the form of a variable number tandem repeat (PER3 VNTR), which has been 
previously been linked to various sleep phenotypes,34-40 also has been 
associated with premenopausal breast cancer.19  Furthermore, this gene family 
also has been known to influence sleep quality within people, suggesting a 
mechanistic role in these genes in the pathway of sleep disruption, altered gene 
variation and function within this family, and cancer formation and mortality in 
both animals and humans.41-46 Variation within the PER3 gene also may explain 
cancer susceptibility in certain subgroups of people that are more likely to 
experience sleep disruption.19, 47  Additionally, little is known on the trends of 
sleep disorders over time in a national sample.  Because prior literature has 
noted an association between sleep disruption and cancer, it is necessary to 
characterize an at-risk population.   . 
1.2 Specific Aims 
The specific aims of this proposal are as follows: 
Aim 1a: To characterize sleep disorder prevalence among US Veterans over time 
and determine what factors that may be driving an increased prevalence of sleep 
disorders in Fiscal Years (FYs) 2000-2010, or new sleep disorder diagnoses in 
FY2010 
Research Question 1.1: Are sleep disorder diagnoses increasing 
nationally among U.S. veterans or within specific subgroups? 
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Research Question 1.2: Are comorbidities such as obesity, diabetes, 
cardiovascular disease, and post-traumatic stress disorder (PTSD) 
influencing the increase of sleep disorders in US Veterans? 
Research Question 1.3: What factors are increasing one’s risk for the 
development of a new sleep disorder diagnosis? 
Aim 2: To determine the association between Period (PER) gene methylation 
patterns and other gene methylation markers from a panel of 20 candidate 
markers and adenoma formation through the use of logistic regression 
Research Question 2.1: Do methylation patterns in peripheral blood 
leukocytes (PBLs) within the PER1, PER2, and PER3 genes differ for 
those with adenomas compared to those without adenomas, after 
adjustment for confounding factors? 
Research Question 2.2: Is there a significant amount of concordance 
between methylation patterns of the PER1, PER2, and PER3 genes in 
PBLs, normal tissue, and polyp tissue? 
Research Question 2.3: Do methylation levels of PER1, PER2, and PER3 
genes in the PBLs, normal tissue, and polyp tissue predict mRNA levels of 
the PER1, PER2, and PER3 genes in PBLs and tissue, respectively? 
Research Question 2.4: Do mRNA levels of PER1, PER2, and PER3 in 
PBLs predict adenoma risk, after adjustment for confounding factors? 
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Research Question 2.5: Do mRNA levels of PER1, PER2, and PER3 in 
PBLs agree with mRNA levels of PER1, PER2, and PER3 found in normal 
and/or polyp tissue? 
Aim 3: To evaluate the influence of the variable tandem repeat (VNTR) in the 
PER3 gene on colorectal adenoma risk 
Research Question 3.1:  Are individuals with the PER3 4/5 and 5/5 
genotype at an increased risk for adenoma formation compared to 
individuals with the PER3 4/4 genotype? 
Research Question 3.2:  Does methylation or mRNA expression of the 
PER1, PER2, or PER3 genes differ among those with different PER3 
VNTR genotypes? 
Research Question 3.3:  Does methylation modify the relationship 
between genetic variation in the PER3 VNTR gene and adenoma 
formation? 
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Chapter 2  
Background 
National Sample of US Veterans 
2.1 Adverse health outcomes associated with sleep disorders   
Previous studies have found that more than 80% of people with clinically 
significant sleep-disordered breathing are undiagnosed;48 and prior research has 
shown that sleep duration and sleep disorders have been associated with 
adverse health outcomes, which include but are not limited to: earlier mortality 
(total and cause-specific),44, 49-51 cardiovascular  disease (CVD),52, 53 type 2 
diabetes, 53, 54 obesity, 53, 54 and psychiatric disorders.55-58  Furthermore, sleep 
duration or sleep disorders have also been linked with cancer.   In a study 
examining cancer incidence in a large multicenter Spanish cohort, individuals 
with severe apnea, with the Apnea-hypopnea index (AHI) of 43 or higher as a 
proxy, had an increased cancer incidence density ratio compared to those with 
the lowest AHI category; however, this association was only observed in 
individuals aged 65 or younger. More recently, two meta-analyses revealed 
inconsistent effects between short sleep duration and other circadian 
disturbances such as shiftwork and exposure to light at night and breast 
cancer.59, 60   Although both meta-analyses did not observe an association in 
studies that examined short sleep duration, a positive association between 
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shiftwork and breast cancer risk was detected in the study by He et al.59  This 
subgroup tends to have shorter sleep duration compared to permanent day  
workers.61 With the co-occurrence of sleep disorders and another chronic 
disease, quality of life is severely impacted as well.62, 63  Little research has been 
conducted on the etiology of sleep disorders in a national sample, and 
identification of risk factors could improve detection and treatment of sleep 
disorders. 
2. 2 Sleep disorders in the United States   
A 2010 study characterized the prevalence of sleep disorders and sleep 
habits in the United States using the NHANES 2005-2006 sample.64  Among all 
physician-diagnosed sleep disorders, sleep apnea was the most prevalent sleep 
disorder in the civilian, non-institutionalized population (4.2%).  In addition to 
physician-diagnosed sleep disorders, 7% of the sample reported having trouble 
falling asleep and a similar amount (6.9%) reported waking up in the night and 
difficulty going back to sleep.  Office visits for sleep disorders have significantly 
increased across a decade,65 which potentially indicates either a true increase in 
prevalence, increased awareness, or both. However, common sleep disorders 
such as sleep apnea and insomnia remain underdiagnosed and therefore go 
untreated. 
Ram et al found several differences in sleep-related metrics and/or 
symptoms have been observed when stratified by demographic characteristics.64  
Middle-aged adults were more likely to report worse sleep characteristics 
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compared to younger and older adults.  In regard to gender, women were more 
likely to report worse sleep habits such as trouble falling asleep, feeling unrested 
during the day, not getting enough sleep and taking sleeping pills.  Sleep-related 
difficulties such as difficulty concentration and remembering were reported at 
higher rates among women.  In regard to race/ethnicity, while EAs had higher 
rates of sleeping pill use and excessive daytime sleepiness, AAs reported higher 
rates of sleep-related difficulties, shorter sleep durations, and longer sleep 
latencies (minutes needed to fall asleep). 65 Despite this study’s strengths, 
several limitations must be noted.  First, it relied on data that was self-reported 
that was not validated through physical examinations or medical chart reviews; 
second, self-report of these sleep symptoms are subject to recall bias, where 
subjects with a physician-diagnosed sleep disorder may recall symptoms 
differently from individuals who do not have a physician-diagnosed sleep 
disorder; and third, as a result of NHANES being a cross-sectional study design, 
it is difficult to determine the temporal relationship between sleep 
disorders/habits and daily activities and trends in sleep habits across time.   
Previous studies have also supported some of the findings found in the 
national sleep disorder prevalence data, particularly in terms of differences by 
race and ethnicity.66, 67  Other studies have found that black participants had a 
doubling of risk for obstructive sleep apnea, reduced sleep satisfaction, and more 
frequent napping compared to white participants.66, 68  However, Ram et al’s 
findings could not be replicated in a more recent study examining office visits for 
sleep disturbances over time.65  For example, Ford et al reported that men higher 
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rates of office visits for medical care for sleep difficulties compared to women. 
Moreover, no racial differences could be detected for any sleep disorder or 
insomnia, and EAs had higher office visits related to sleep apnea compared to 
AAs. Lack of consistency may be due to failure to control for factors that may 
impact prevalence rates, such as physical and mental comorbidities and 
socioeconomic status;69, 70 additionally, previous studies have not been 
adequately powered to examine differences in prevalence rates by various 
factors. Regardless, increased burden of sleep disorders and disturbances in 
certain subgroups could partially explain disparities that have been observed in 
other diseases. Given that sleep disorders in general are undiagnosed, the 
characterization of sleep disorders and factors contributing to the development of 
sleep disorders deserve further investigation. 
As a result of the drawbacks in the recent prevalence studies and previous 
studies, it is of high importance to examine populations where data does not rely 
on self-report of sleep disorder diagnoses across time.  One potential source of 
looking at objective measures of sleep disorder diagnoses is in the Veterans’ 
Health Administration’s (VHA) electronic medical record system.  Furthermore, 
this group presents a unique opportunity to see the effects of various 
comorbidities on sleep disorders.  Because this group is particularly susceptible 
to post-traumatic stress disorder (PTSD), a condition that has been linked to both 
sleep disorders 71 and early mortality,72, 73 veterans are at a much higher than 
usual risk for adverse outcomes.  Preliminary de-identified data extracted from 
Veterans’ Integrated Services Network 7 (VISN-7) between 2000 and 2008 
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suggests that sleep disorder diagnoses may have increased over time among 
veterans, despite no differences in first time sleep disorder diagnoses and total 
first time diagnoses from VISN-7 medical centers, community-based outpatient 
clinics, and primary care clinics.  If a relationship between sleep disorders and 
certain adverse health outcomes (e.g., mortality) exists, this group bears a 
heavier burden of disease and mortality compared to civilians.     
Sleep disruption has increased and sleep quality has decreased in the 
United States for a variety of reasons and certain subgroups, such as veterans, 
may be at an increased risk for unfavorable health outcomes.  It is critical to 
assess factors that may be driving the increase in sleep disorder prevalence.  
Because veterans are a vulnerable population, better behavioral therapies to 
achieve improved sleep quality could effectively reduce costs associated with 
subsequent adverse effects of sleep disruption.  The public health implications of 
increased sleep disorder prevalence among veterans are not fully understood. 
Sleep disorders are associated with increased mortality and cancer, likely 
through pathways involving immunomodulation and tumor suppression, it stands 
to reason that sleep disorders may increase cancer risk. In support of this, sleep 
apnea was associated with increased cancer incidence.51 A descriptive 
characterization of the sleep disorder epidemiology is vital for beginning to 
understand the impact on long term comorbid disease and mortality risks. 
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EDCaP Study 
2. 3  Colorectal cancer (CRC) in the United States   
While the number of incident cases and deaths due to CRC is alarming, 
these numbers have decreased in the last two decades in the United States due 
to removal of precancerous lesions during screening, 74, 75 which has increased 
three to eight-fold during this same time period.76  Another factor contributing to 
the decline is the improvement in treatment of CRC, allowing for the survival of 
over 1 million cases of CRC.  Despite the decrease in incident cases of CRC and 
deaths due to CRC, the lifetime risk for being diagnosed with CRC is 5% for men 
and women, with men being at a higher risk compared to women (57.2 per 
100,000 vs 42.5 per 100,000, respectively).  Men are also at a higher risk for 
death due to CRC compared to women (21.2 per 100,000 vs 14.9 per 100,000, 
respectively).77  Differences in rates by gender can be attributed to hormones 
and exposure to other risk factors that are related to gender.78-80  In addition to 
gender differences, burdens in CRC incidence and mortality by race/ethnicity are 
evident.  EAs have a lower incidence rate compared to AAs (44.7 per 100,000 vs 
53.1 per 100,000, respectively).77   Also, AA men are more likely to die from CRC 
compared to EA men (30.5 per 100,000 vs. 20.9 per 100,000, respectively).  
Similarly, AA women are more likely to die from CRC compared to EA women.77  
These statistics are reflected at a state level such as in South Carolina.81  In 
addition to gender and racial/ethnic differences, there is geographic variation in 
CRC incidence and mortality that is likely driven by access to screening and 
treatment centers.9  Because of this combination of factors, only 62% of eligible 
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adults, defined as adults 50 to 75 years of age, have been screened for CRC.  As 
a result, there has been an increase in research effort in finding markers of 
increased risk within readily accessible samples such as blood to improve CRC 
screening compliance.    
2. 4 Risk factors for CRC   
Previous studies have indicated several factors that do or may increase 
the risk for CRC.  Lifestyle and environmental factors such as diets high in total 
fat and red meat, sedentary lifestyle, cigarette smoking, low doses of vitamin D 
and/or calcium, alcohol consumption, tobacco use, and obesity.82  Previous 
studies have also found that personal history of colorectal adenomas increase 
the risk of developing CRC.  Research has shown that patients with adenomas 
had a 25% increased risk of CRC at that particular site.83 Removal of adenomas 
has also been shown to decrease the risk of incident CRC.   
Another factor playing a role in the carcinogenesis process is chronic 
inflammation, where several factors may interfere with the balance between anti-
tumor immunity and tumor-promoting inflammation.  According to prior studies, 
up to 20% of cancers are linked to chronic infections,84 30% are due to inhalation 
of pollutants (e.g., tobacco smoke),85 and 35% to dietary factors.86  Inflammation 
also appears to play a role at several stages during the carcinogenesis process.  
In terms of tumor initiation, a pro-inflammatory environment may increase the 
likelihood of mutations, genomic instability, and epigenetic modifications, thus 
extending survival of premalignant cells.  These pro-inflammatory conditions 
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allow premalignant cells to accumulate further mutations and form early tumor 
nodules.  Early tumor nodules continue to thrive in the presence of inflammation, 
facilitating their growth into advanced tumors, and subsequently, spread of these 
mutated cells (metastasis).   
In addition to these risk factors, several genes have been found to play a 
significant role in CRC risk, where molecular events involving these genes result 
in chromosomal instability, gene hypermethylation of cytosine-phosphate-
guanine (CpG) islands, and microsatellite instability.  In 1990, Fearon and 
Vogelstein proposed a mechanism explaining how multiple genes play a role in 
colorectal carcinogenesis.87  For example, loss of the Adenomatous Polyposis 
Coli (APC) gene, which is responsible for tumor suppression, is one of the 
earliest events in the chromosomal instability colorectal tumor pathway and 
germline mutations have been shown to be associated with conditions that 
predispose individuals to colorectal tumors, such as familial adenomatous 
polyposis (FAP).87  However, germline mutations that lead to FAP are a minority 
(5-6%) of CRC cases.  A large number of CRC cases (approximately 75%) are 
sporadic, meaning that there is no apparent family history of CRC and may be 
due to a common exposure, a genetic background (i.e., sporadic mutation) that 
would put an individual at a high risk for developing CRC, or a combination of 
both.88  More recently, a study looking at 13000 genes found that tumors have an 
average of 90 mutant genes.  Among these genes, 69 genes were relevant to the 
pathogenesis of CRC, and individual CRCs had an average of nine mutant genes 
per tumor, revealing a multigenic process in the carcinogenesis in the colon.18  
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Also, this study revealed that there may be alternative explanations as to why 
certain populations are more susceptible to cancer than others, such as shift 
workers, who have been found to have gene dysregulation, particularly in the 
Period (PER) gene family.  Details on molecular changes in the carcinogenesis 
process are described further in section 2.5 below.       
2. 5  Clock genes, circadian disruption, sleep disruption, and cancer   
While several genes have been identified as being linked to CRC 
formation, some genes, known as clock genes, which are involved in circadian 
rhythm regulation, have not been studied as frequently.  In prokaryotic and 
eukaryotic organisms, most physiological and behavioral (such as sleep and 
wakefulness, body temperature, blood pressure, immune responses) functions 
are expressed rhythmically according to light-dark cycles to allow for adaptation 
to changes in the environment and ensure survival.  There are three components 
in this circadian rhythm: input pathway, central pacemaker, and output pathway.  
The central pacemaker, which is located in the suprachiasmatic nucleus (SCN) of 
the anterior hypothalamus, is of particular interest due to its role in 
synchronization of the rhythm with the environment.  At least nine core clock 
genes have been found to play a role in circadian oscillation: PER1, PER2, 
PER3, CRY1, CRY2, CLOCK, BMAL1, TIM, and CK1ε ,33 which are responsible 
for ~2-10% of the diurnal expression of most tissues in the mammalian 
genome.89 Because of the central role that circadian rhythm plays in both 
homeostatic and non-homeostatic functions,26, 90 it is essential for the body to 
maintain this rhythm.  However, a variety of environmental (e.g., shiftwork) 91-93 or 
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genetic factors (genetic polymorphisms or epigenetic modifications) 30, 94 can 
confuse the master clock, thus disrupting the phase or amplitude of circadian 
rhythms and the physiological processes they help regulate, such as cell 
proliferation and apoptosis.95 Disruption of these processes has been suspected 
of increasing the risk of cancer in certain populations (e.g., shiftworkers).96  
Effects found in epidemiological studies have been confirmed in studies using 
mouse model systems.  For example, ablation of the SCN in mice resulted in an 
accelerated tumor growth rate compared to mice with an intact SCN.97   
Differential methylation of clock genes can lead to differential epigenetic 
regulation of gene expression, and thus alter individual susceptibility to certain 
cancers.30  While consistent evidence between circadian rhythm disruption and 
cancers of the breast and prostate exists,42, 98-102 very few studies have examined 
the role of circadian rhythm disruption due to genetic and/or environmental 
factors and CRC in human populations; however, these few studies suggest a 
relationship.103-105  For example, Schernhammer et al found a 35% increase in 
risk for CRC for nurses who engaged in long-term rotating shift work three nights 
per month compared to those who never worked rotating night shifts.106 
As a consequence of circadian rhythm disruption, disordered sleep may 
arise.  Certain groups such as shiftworkers are more likely to suffer from 
disordered sleep than those who work day shifts.  For example, nurses who work 
night shifts have shorter sleep duration compared to their sleep duration after a 
day shift.107  It is believed that the pathway between this factor and outcome may 
be mediated by the immune system dysregulation following sleep loss.  
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Experimental sleep deprivation and epidemiological studies looking at fatigue 
have found increased circulating levels of inflammatory markers such as 
interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), with 
significant elevations,20-25 even after one night of sleep loss.23  Because previous 
studies have shown that sleep deprivation affects the inflammatory process and 
that sleep quality has decreased across time, it may be important to elucidate the 
relationship between sleep disruption and cancer.   
Several mechanisms have been proposed that link sleep disruption to 
cancer formation.  The first may be due to reduced melatonin release as a result 
of sleep disruption, thus leading to a reduction in natural killer (NK) cells and 
cytokines responsible for cancer inhibition (IL-2, IL-12, and TNF-α)  and 
development of cancer cells; however, evidence supporting this mechanism is 
limited.  Another mechanism suggests that the carcinogenesis process arises 
due to issues with melatonin acting upon cells locally by halting the cell 
proliferation process in cancer cells.41   
Not only have sleep disorders been implicated in the carcinogenesis 
process, but factors related to sleep disorders (such as sleep disordered 
breathing) also played a role on cancer-related mortality,44 possibly through 
reduced oxygen delivery to tumor tissues, a factor that predicts cancer 
progression and poor prognosis.108, 109  In summary, genes related to circadian 
rhythm regulation have a role in sleep disruption and inflammatory processes 
related to tumor suppression/cancer inhibition either through genetic variation or 
alterations in function due to epigenetic changes.  Also, there is reason to believe 
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that these genes could serve as a marker for both cancer risk and survival due to 
the physiological role that sleep has on carcinogenesis and cancer-related 
mortality.  While previous studies have made strides in closing the gap, these 
gaps in research warrant further study. 
2. 6 Biological markers for CRC   
The adenoma-carcinoma sequence within the colon has been widely 
studied due to the ability to observe genetic alterations at several stages.  Not 
only do gene variants existing in the form of single nucleotide polymorphisms 
(SNPs) play a role in conferring risk, but gene expression and the epigenetic 
modifications that influence gene expression (via methylation, histone 
modification, phosphorylation) are believed to influence the carcinogenesis 
process in the GI tract.  Epigenetic modifications often involve methylation at the 
CpG islands within the promoter regions of the genes and methylation of these 
areas lead to gene silencing (reduced gene expression in the form of lower 
mRNA levels).  Therefore, methylation of genes responsible for tumor 
suppression, DNA repair, and other physiological processes that control cell 
division and growth could lead to dysregulation of metabolic processes, thus 
leading to cancer formation.  Epigenetic events are often due to simply inheriting 
epigenetic markers from parents or from external sources from the environment, 
such as diet.  Because of the reversibility of epigenetic modifications and their 
influence on the carcinogenesis process, this area is being actively studied as a 
potential therapeutic modality.   
18 
 
2.6.a Genetic markers in CRC  
Genetic markers have been explored to predict risk for cancer.  Unique 
genetic markers are particularly favorable because certain cancers cannot be 
fully explained by heavily studied genes (BRCA1, BRCA2, APC), especially 
among younger individuals with cancer.110, 111  For example, in 2005, Zhu et al 
found that women who had at least one 5-repeat allele (~50% are heterozygous 
for the 5-repeat allele and 10% are homozygous for the 5-repeat allele) in the 
PER3 variable number tandem repeat (VNTR) had an increased risk for 
premenopausal breast cancer.19  This gene, where individuals may possess a 
4/4, 4/5, or 5/5 genotype, may be responsible for variations in circadian rhythm 
(diurnal preference, delayed sleep phase syndrome, sleep-wake patterns).34-40   
This may be due to the fact that certain individuals with the 4/5 or 5/5 genotype 
may have a different pattern of secretion of hormones related to sleep-wake 
cycles (i.e., melatonin).  Other studies have revealed apparent tumor suppressor 
properties of the Period genes (PER1, PER2, and PER3), particularly in cancers 
of the breast, endometrial lining, and prostate.19, 27, 30, 112-116  Among these genes, 
PER3 has been studied extensively and it has been associated with various 
phenotypes potentially including adverse health outcomes (bipolar disorder, 
heroin dependence, poorer cognitive performance after sleep deprivation) and 
recently has been considered a candidate genetic marker of cancer risk.19, 29  
Other genes that play a role in circadian timing, such as CLOCK, BMAL1, and 
NPAS, have also presented associations with cancer risk, providing evidence of 
the link between clock gene variation and cancer. The pathophysiological 
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processes that drive many of these associations remain to be determined.  With 
regard to PER3, it is believed that variation in the VNTR affects patterns of 
cortisol secretion,117 and disturbances in cortisol secretion have been linked to 
hyperactivity of pro-inflammatory processes118 and increases in pro-inflammatory 
cytokines, such as IL-6,24 which create an ideal microenvironment for the 
carcinogenesis process to take place 
2.6.b Gene expression in CRC  
Due to the series of molecular alterations that lead to CRC, gene 
expression has also been examined as a way to broaden knowledge on which 
genes act as either oncogenes or tumor suppressors.  Inter-individual variation of 
gene expression levels has been found by tissue type.  For many genes involved 
or suspected to be involved in CRC formation, tumor tissues in the colon 
compared to normal, adjacent tissue exhibited differential expression.30, 119, 120  
However, some tumor tissues are difficult to obtain in order to examine gene 
expression; therefore, it is important to develop other alternative, less invasive 
methods to detect predictive biomarkers, particularly in blood.  Because disease 
status is believed to cause biochemical changes in blood, it is believed that these 
changes caused by disease state will alter gene expression levels of certain 
genes in blood cells.121, 122 
To complement gene expression levels found in blood, some studies have 
looked at relationships between gene expression levels in blood, normal tissue, 
and tumor tissue. For example, in a study by Schena et al, investigators set out 
to compare expression levels of several genes known to be a part of the 
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nucleotide excision repair pathway (ERCC1, ERCC2, ERCC4, XPA, XPC, 
XRCC1, XRCC3, APEX, OGG1, and MGMT) in normal and tumor tissues from 
non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer 
(HNSCC) patients with blood expression levels within the same person.  First, it 
was found that expression of these genes were generally higher in these target 
tissues compared to blood.  Second, moderately high (Pearson’s correlations 
coefficient (r) of 0.5 to 0.7) positive correlations were found between gene 
expression levels in blood and tumor tissue, tumor and normal tissue, and blood 
and normal tissues.  This finding highlights the potential usefulness of gene 
expression levels detected in peripheral blood as a proxy for those levels in 
tumor tissue.  However, there are some drawbacks to using gene expression 
levels in blood.  For example, certain genes that are highly expressed in target 
tissues may not necessarily be expressed in blood.  Also, as gene expression is 
dependent on cDNA concentration and quality, cDNA quality is dependent on 
mRNA quality.  Because mRNA degrades readily under suboptimal conditions, 
gene expression levels may not be accurate, thus producing a spurious 
relationship between gene expression levels and the outcome of interest (e.g., 
tumor formation).  Relationships between gene expression levels in PBLs, 
normal tissue, and adenoma polyp tissue has yet to be fully characterized for the 
Period gene family.   
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2.6.c Epigenetic markers in CRC  
A 2012 report by the Centers for Disease Control and Prevention showed 
that both eligible men and women (people over the age of 50 years) still fell short 
of the Healthy People 2020 target CRC screening rate of 70.5%. 123  Because of 
various factors that limit the ability of individuals to be screened for CRC, 124-128 
several studies have undertaken the task of identifying epigenetic markers in 
blood to assess risk of CRC.  This method of assessing risk is particularly 
favorable due to the fact that patient compliance is likely to increase due to the 
ease of obtaining samples, thereby increasing the chance of detection of disease 
in earlier stages and improving survival of CRC, especially among groups who 
have low screening rates (e.g., racial/ethnic minorities, those without health 
insurance).123  For example, in a 2007 pilot study by Cui, loss of imprinting (LOI), 
an epigenetic event in the IGF2 gene, had a significant relationship with both 
family history and personal history of CRC, suggesting that LOI of IGF2 could 
serve as a predictor of CRC risk.129  Although LOI in this same gene could not be 
evaluated in PBLs, another study by Woodson et al confirmed findings by Cui et 
al by discovering that LOI in IGF2 was associated with a fivefold increased risk of 
adenoma formation in women.130  More recently, a study by Tänzer et al 
examined the epigenetic markers in SEPT9 in plasma and its association with 
colorectal lesions (hyperplastic and adenomatous polyps).  Researchers found 
that prevalences in methylation differed by case status: 9% in controls; 29% of 
subjects with precancerous lesions presented; and 73% of CRC patients.131  
Additionally, as a result of common differential methylation patterns being found 
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in tumor tissues (MLH1, p16, and methylated in tumors [MINT1, MINT2, and 
MINT31]), a subtype of CRC has been identified:  CpG Island Methylation 
Phenotype (CIMP).132  This phenotype has been observed in a feature present in 
variable amounts among adenomas (0-44%),133, 134  colon cancers (30-40%), and 
distal and rectal cancers (3-12%).135-138  Discovery of this particular molecular 
marker in CRC led to further understanding of alternative carcinogenesis 
pathways, especially in terms of epigenetics.  In regards to the epigenetic profiles 
of PER1, PER2, and PER3, and their association with cancer risk, Chen et al 
found deregulated expression of PER1, PER2, and PER3 in breast tumor tissues 
compared to normal tissues.  Furthermore, it was found that promoter 
methylation influenced expression of these genes.30  No published studies have 
looked at epigenetic markers of these genes in circulating blood cells and their 
association with cancer risk in human populations.   
2. 7 Summary and public health significance   
Sleep disorders and variation of clock genes have demonstrated 
associations with various health outcomes that can have a significant impact on 
disease morbidity and mortality. Thus far, no study has assessed trends in sleep 
disorders among veterans at a national level (Specific Aim 1), evaluated the 
performance of PBL methylation levels in PER1, PER2, and PER3 on predicting 
colorectal adenoma formation (Specific Aim 2), or has investigated the impact of 
PER3 variation on adenoma risk (Specific Aim 3).  Results derived from this 
project not only would have the ability to identify vulnerable sub-populations 
among Veterans who are at risk for the development of sleep disorders but also 
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will add to the scientific body of knowledge on adenoma formation and could 
provide information on alternative strategies to identify colorectal adenoma cases 
more effectively. Furthermore, disparities in CRC incidence and mortality 
observed along racial/ethnic, gender, and geographic lines could partially be 
explained by sleep disorders and/or differential methylation of certain clock 
genes.
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3.1 Abstract 
Introduction: Sleep disturbances are alleged to be on the rise in the 
United States (US), and veterans are particularly vulnerable to factors that elicit 
or exacerbate sleep disorders. A large proportion of individuals affected by sleep 
disorders are untreated and susceptible to accidents, injuries, long-term 
sequelae (e.g., risk of cardiovascular disease, cancer, psychiatric disorders), and 
earlier mortality. Few studies have examined the scope and magnitude of sleep 
disorder diagnoses in the US. This serial cross-sectional study characterized 
secular trends in diagnosed sleep disorders among veterans seeking care in the 
US over an eleven-year span (Fiscal Years [FY] 2000-2010, N=9,798,034). 
Materials and Methods: Data from the Veterans Administration Informatics and 
Computing Infrastructure (VINCI) electronic medical record were accessed. 
Cases were defined as patients with at least two outpatient sleep disorder 
diagnoses at least 30 days apart using American Academy of Sleep Medicine-
specified diagnostic codes. Age-adjusted annual prevalence was summarized by 
sex, race, combat exposure, body mass index (kg/m2) and comorbid diagnoses 
(cardiovascular disease, cancer, mental disorders). Results: Sleep apnea (47%) 
and insomnia (26%) were the most common diagnoses among patients with 
sleep disorders. There was a six-fold relative increase in total sleep disorder 
prevalence over the study period. Post-traumatic stress disorder (PTSD) tripled 
over the same time period, and veterans with PTSD had the highest prevalence 
of sleep disorders (16%) among the comorbid conditions evaluated.  
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Discussion: The results indicate a growing need for integration of sleep disorder 
management in patient care and health care planning among veterans. 
 
3.2 Introduction 
Sleep is considered a physiological necessity, and inadequate sleep has 
been associated with a wide range of adverse physical, mental and behavioral 
outcomes.139 Previous studies have linked abnormal sleep duration or a sleep 
disorder diagnosis with an increased incidence of: obesity, hypertension or 
metabolic syndrome,53, 54, 140, 141 type 2 diabetes,53, 54, 142 cardiovascular 
disease,52, 143, 144 stroke,145, 146 and cancer59, 60, 147-150 (although results for cancer 
have been less consistent). Other studies have linked inadequate sleep with an 
increased risk of psychiatric disorders (e.g., depression, post-traumatic stress 
disorder [PTSD]), suicides, accidents, injuries, reduced quality of life, and 
increased mortality.65, 139, 144, 151-158  The impacts of sleep disruption may be 
mediated by several pathophysiological processes. These include sympathetic 
nervous system hyperarousal, the disruption of circadian rhythms, 
neuroendocrine or immune system dysregulation, inflammation, or metabolic 
dysfunction.159-162    
Military personnel are particularly vulnerable to sleep disturbances due to 
the irregularity of their sleep/wake schedules, austere living conditions (e.g., 
extremes in temperature, noise, physical exertion), the stress of combat, 
elevated rates of physical and psychological injury, and issues associated with 
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post-deployment psychosocial reintegration.155, 163  Some of these conditions can 
have residual effects well after the period of service is over. Therefore, veterans 
can be plagued with multiple comorbidities that adversely influence sleep. Some 
of these are over-represented in this population (e.g., musculoskeletal pain, 
traumatic brain injury [TBI], smoking, substance abuse, hypertension, 
depression, PTSD), while others mirror trends in the general US population (e.g., 
obesity, aging-related chronic disease).155, 156, 163-166 Consequently, sleep 
disruption tends to be more common among veterans than in the general 
population.155, 167-170 However, the national scope and characteristics of this 
problem have not been described previously.  
Despite evidence indicating that a lack of recognition or poor management 
of sleep disorders can have myriad detrimental health consequences, many 
patients can remain undiagnosed or untreated. Sleep disorders also may be 
overlooked by physicians;171, 172 it was estimated that 80-90% of people with 
clinically significant sleep-disordered breathing may remain undiagnosed.48  In a 
representative sample of United States (US) adults, 26% of survey respondents 
met criteria for high-risk obstructive sleep apnea173 in contrast to an estimated 
prevalence of ~4-10%.64, 174, 175 An increasing trend in office visits for sleep 
disorders was reported from 1999 to 2010, although it is unclear whether this 
was due to a true increase in sleep disorder prevalence, increasing awareness 
among physicians or their patients, or a combination of both.65  Differences in 
sleep disorder case definitions, diagnostic criteria, population demographics, or 
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the presence of co-morbid disease also can contribute to inconsistencies among 
population-based sleep disorder estimates.  
The co-occurrence of a sleep disorder with another co-morbid chronic 
disease can predict poor quality of life62, 63 and earlier mortality relative to those 
without a sleep disorder.144, 158, 176 This suggests that appropriate sleep disorder 
management may improve quality of life and longevity. In some studies, 
psychiatric disorders were predictive of sleep problems,55, 57 but in other cases 
sleep disorders predicted increased risks for psychiatric disorders.177-179 This 
apparent bi-directionality can complicate etiologic studies, but it also provides an 
opportunity to implement more effective disease prevention and control 
strategies through delivery of care that integrates appropriate sleep 
management.  
The information described above suggests that sleep disorder surveillance 
can play an important role in patient care and long-term health care planning. 
The characterization of trends in sleep disorder diagnoses among population 
subgroups may allow clinicians to identify and target high-risk patients who would 
benefit from management of sleep disorders and their sequelae. Most 
epidemiologic studies examining sleep disorders have been limited to: highly 
specific study populations (e.g., sleep clinics), relatively small population sizes, or 
to a single type of sleep disorder or risk factor of interest.  This study evaluated 
all diagnosed sleep disorders in a national sample of US veterans who utilized 
health services through the Veterans Health Administration (VHA) between 
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Fiscal Years (FY) 2000 and 2010. The VHA is the largest integrated health care 
system utilizing electronic medical records (EMRs) in the US.180  The approach 
facilitated the examination of comorbid diseases that appear at higher rates 
among veterans relative to the general population (e.g., PTSD and other mental 
health disorders), as well as other individual or clinical factors that may influence 
the onset or severity of sleep disorders.  
3.3 Materials and Methods 
Study Population   
The study population consisted of all US veterans seeking care in the VHA 
system between FY2000 and FY2010. Following regulatory approvals, outpatient 
electronic medical records were accessed from MedSAS Dataset and VA 
Corporate Data Warehouse files in the VINCI system. Requested data elements 
from different VA system files were linked via social security number by a system 
data manager, and then scrambled and replaced with a unique patient ID 
number.  Unique identifiers were inaccessible to the study investigators. Patients 
excluded were: <18 years old on January 1 of each year, veterans who died in a 
given fiscal year, spouses of veterans receiving care, and non-veterans.    
Case Ascertainment  
De-identified outpatient sleep disorder diagnoses were grouped according 
to American Academy of Sleep Medicine (AASM) International Classification of 
Sleep Disorder181 categories based on the following ICD-9 codes: apneas 
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(organic sleep apnea [327.20-29], unspecified sleep apnea [780.57]); insomnias 
(organic insomnias [327.00-09], insomnias, unspecified [780.51-780.52], 
nonorganic insomnias [307.41-307.42]); other sleep disorders (other organic 
sleep disorder [327.80], specific disorders of sleep of nonorganic origin [307.40-
307.49], other sleep disturbances, unspecified [780.50, 780.56, 780.59], other 
sleep disorders [291.82, 292.85]); hypersomnias (organic hypersomnias [327.10-
19], nonorganic hypersomnias [307.43-.44], hypersomnias, unspecified [780.53-
780.54], other hypersomnias [347.00-347.01, 347.10-347.11]); parasomnias 
(organic parasomnias [327.40-327.49], nonorganic parasomnias [307.46-
307.47]); sleep disruption movement disorders (organic sleep related movement 
disorders [327.51-327.59], sleep related movement disorder, unspecified 
[780.58], Restless Legs Syndrome [333.94]); and circadian rhythm disorders 
(organic circadian rhythm sleep disorders [327.30-39], circadian rhythm sleep 
disorder of nonorganic origin [307.45], disruption of 24 hour sleep-wake cycle, 
unspecified [780.55]). Veterans were assigned a specific sleep disorder 
diagnosis if their ICD-9 code occurred at least two times within a given fiscal 
year, and the codes occurred thirty or more days apart.182 This method was used 
to reduce the chance of misclassification due to “rule out” diagnoses, which are 
ICD-9 codes that are entered by providers as the reason for ordering a diagnostic 
test). 
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Covariates 
Data on covariates (age, race/ethnicity, sex, smoking status, body mass 
index [BMI], income, comorbid diagnoses, sleep-related medical procedures, 
service period [World War II, Korean War, Vietnam War, Persian Gulf War, 
Operation Enduring Freedom/Operation Iraqi Freedom, and other], and combat 
deployment) were retrieved from the VHA’s Vital Status and MedSAS databases. 
Income was divided into three categories: less than $20,000 a year, $20,000 or 
more, or unknown.58 Race and ethnicity were categorized as: Non-Hispanic 
White, Non-Hispanic Black, Hispanic or Mexican, or “Other” (includes American 
Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, or more 
than one race). Missing race may be associated with lower rates of utilization and 
fewer comorbid diseases,183 and thus was included as a separate category.  Age, 
in years, was calculated by subtracting the year of birth from the fiscal year of 
contact with the VHA system and grouped into the following categories: 18-29 
years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 
years or older.  The twenty-one Veterans Integrated Service Networks (VISNs) 
were collapsed into US census regions (VISNs 1-5: Northeast; 10-15 and 23, 
Midwest; 6-9, 16, 17, South; 18-22, West). Those with missing or infrequent 
VISN assignment were coded as unknown. BMI was calculated using height and 
weight after excluding biologically implausible values; height was restricted to 48-
84 inches (122-213 cm), and weight was restricted to 75-500 pounds (34-227 
kg).184  If a value for height was missing for a given record, any appearance of 
height across the study period was used.  Multiple entries for biologically 
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plausible values of weight were averaged within the fiscal year.  BMI was 
categorized into the following groups: underweight (<18.5 kg/m2), normal (18.5 to 
<25 kg/m2), overweight (≥ 25 and < 30 kg/m2), and obese (≥30 kg/m2). The 
underweight BMI category (<1% of study population) was combined with the 
normal BMI group.  Smoking status was assessed as described previously;185 
data extracted from EMRs were compared to self-reported smoking data found in 
the Veterans Aging Cohort Study (VACS-8) and VACS Virtual Cohort (VACS-VC) 
study, which yielded kappa (κ) statistics of 0.66 and 0.61, respectively.   
ICD-9 codes for comorbid disease were grouped into the following 
categories: asthma (493), cancer (150-151, 153-155, 157, 162, 172, 174, 183, 
185, 188-189, 191, 200, 202, 204-208.9), chronic obstructive pulmonary disease 
(COPD) (496.0), cardiovascular disease (CVD) (390-459), diabetes (249-250), 
fibromyalgia (729.1), gastrointestinal (GI) disease (520-579), human 
immunodeficiency virus (HIV) (042-044), any mental disorder (290-319), renal 
disease (508-589), and stroke (434.91) using the same criteria as described for 
sleep disorders. Diagnoses of any mental disorder/mental disability were broken 
down into the following subgroups for further analyses: depression [296.3], post-
traumatic stress disorder [PTSD] [309.81], other mental health disorders with the 
exception of PTSD and depression [e.g., psychosis [290-299], neurotic disorders, 
personality disorders, and other nonpsychotic mental disorders [300–316], 
mental disability [317–319]).   
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Sleep-related medical procedures were ascertained using the following 
current procedural technology (CPT) codes: 0203T (sleep study, unattended, 
simultaneous recording of: heart rate, oxygen saturation, respiratory analysis and 
sleep type; type II device), 0204T (sleep study, unattended, simultaneous 
recording of: heart rate, oxygen saturation, respiratory analysis and sleep type; 
type IV device), 95805 (multiple sleep latency or maintenance of wakefulness 
testing, recording analysis and interpretation of physiological measurements of 
sleep during multiple trials to assess sleepiness), 95806 (sleep study, 
unattended, simultaneous recording of heart rate, oxygen saturation, respiratory 
airflow and respiratory effort [EEG, thoracoabdominal movement] with Type III 
device), 95807 (sleep study, simultaneous recording of ventilation, respiratory 
effort, ECG or heart rate, and oxygen saturation, attended by a technologist), 
99508 (home visit for polysomnography and sleep studies), G0398 (home sleep 
study test [HST] with Type II portable monitor, unattended; minimum of 7 
channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and 
oxygen saturation), G0399 (HST with Type III portable monitor, unattended; 
minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate, and 1 
oxygen saturation), and G0400 (HST with Type IV portable monitor, unattended; 
minimum of 3 channels).   
Statistical Analysis 
Annual sleep disorder prevalence was calculated as the proportion of total 
sleep disorder diagnoses among eligible patients seeking care in the VHA 
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system each fiscal year of the study.   The numerator was defined as the total 
number of primary sleep disorder diagnoses (or specific sleep disorder subtype) 
that occurred during each fiscal year, and the denominator was the total number 
of Veterans seeking care through the VHA during in the same fiscal year.  Annual 
prevalence was adjusted for possible changes in the age distribution over time 
via direct age standardization using the 2000 US standard population and the 
following age groups: 18-29,  30-39, 40-49, 50-59, 60-69, 70-79, and 80 years or 
older.186  Absolute change in prevalence across the study period was defined as 
the age-adjusted prevalence estimate for FY2000 subtracted from the age-
adjusted prevalence for a given fiscal year.  Two-sample proportion tests were 
used to compare proportions of select factors in FY2000 and FY2010.  Relative 
changes were described as well. Prevalence and absolute change in prevalence 
of sleep disorders were stratified by comorbid CVD and cancer diagnoses, as 
they represent the top causes of mortality in the US, PTSD (a common diagnosis 
among US Veterans), and other selected factors (sex, race, BMI, combat 
exposure).   
 3.4 Results 
Data for 9,786,778 veteran patients were included in the analysis (Table 
3.1).  Changes in the population from FY2000 to FY2010 are found in Table 3.2.  
The following groups seeking care in the VHA system had the greatest absolute 
increases over time: white veterans, those aged 60-69 years of age and over 80 
years of age, unmarried veterans, those living in the southern region of the US, 
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those who served in the Persian Gulf, obese veterans, current smokers, and 
those with at least one mental health disorder. Figure 3.1 summarizes inclusions 
and exclusions among patients who sought care through the VHA during the 
study period. The study population was comprised primarily of men (93%) who 
were married (54%).  Among veteran patients diagnosed with at least one sleep 
disorder (n of unique individuals: 751,502; n of diagnoses: 953,575), apneas 
made up the majority of the diagnoses (47%, Figure 3.2); followed by insomnias 
(26%), other sleep disorders (11%), hypersomnias (10%), movement disorders 
(4%), parasomnias (3%), and circadian rhythm sleep disorders (0.1%). A majority 
of those diagnosed with a sleep disorder were prescribed at least one sleep 
medication (91%, data not shown), and the proportion of veterans with any sleep 
disorder who were prescribed a sleep medication for the entire time they sought 
VHA care within the study period ranged from 24% to 64% based on the number 
of years of follow-up (data not shown).   
Total sleep disorder diagnoses increased nearly six-fold over the eleven-
year study period (Figure 3.3). Sleep apnea and insomnia prevalence exhibited 
more than a seven-fold relative increase; age-adjusted sleep apnea prevalence 
increased from 0.4% in FY2000 to 3.0% in FY2010 (a relative increase of 650%); 
and age-adjusted insomnia prevalence increased from 0.2% in FY2000 to 1.5% 
in FY2010 (a 650% relative increase). The prevalence of other sleep disorders 
rose from 0.4% in FY2000 to 0.6% in FY2010 (a relative increase of 50%). Less 
prevalent sleep disorder subtypes also increased over time (relative increases 
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were: movement disorders: 1,048%; hypersomnias: 50%; parasomnias: 750%; 
circadian rhythm disorders: 900%).   
When the pattern of CPT codes for sleep procedures was inspected over 
time, there was nearly a three-fold increase in the proportion of veteran patients 
receiving a sleep-related procedure during the study period (0.2% in FY2000, 
0.15% in FY2010). These proportions were considerably lower than diagnosed 
sleep disorders; 1/6th to 1/13th of the observed prevalence of sleep disorder 
diagnoses (Figure 3.4). CPT code 95807 (sleep study, simultaneous recording of 
ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended 
by a technologist for obstructive sleep apnea) was the most common code in 
FY2000 (0.09%) and exhibited a small increase in prevalence by the end of the 
study period (0.11%). CPT code 95806 (sleep study, unattended, simultaneous 
recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory 
effort) was the second most common procedure for sleep in FY2000 (0.05%), but 
became the most common sleep procedure by FY2010 (0.30%), which 
corresponds to a five-fold relative increase during the study period.   
Veterans diagnosed with CVD had a larger absolute increase in sleep 
apnea prevalence over time compared to veterans without CVD (5.8% and 1.6%, 
respectively, Figure 3.5). Veterans with a CVD diagnosis also experienced an 
absolute increase of insomnia prevalence (2.6%) more than double the absolute 
increase among veterans without CVD (1.1%).  Less common sleep disorder 
subtypes also exhibited greater increases in sleep disorder prevalence among 
those with CVD compared to those without CVD.   
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Figure 3.6 presents changes in sleep disorder prevalence stratified by 
cancer diagnosis.  From FY2000 to FY2010, absolute increases sleep apnea and 
insomnia prevalence were 3.7% and 2.0%, respectively, among veterans with 
cancer. These absolute rate increases were greater than those recorded among 
veterans who were not diagnosed with cancer (2.5% and 1.3%, respectively).  
The remaining sleep disorders, with the exception of other sleep disorders, 
exhibited larger increases in prevalence among those diagnosed with cancer 
compared to those who were not. 
Absolute changes in sleep apnea and insomnia over the study period 
were the largest among veterans with PTSD (5.7% and 4.3%, respectively, 
Figure 3.7).  Smaller absolute increases in prevalence were observed for the 
other sleep disorder subtypes, ranging from 0.02% (circadian rhythm disorders) 
to 1.4% (other sleep disorders). Increases in sleep disorder subtypes over time 
also were observed when the data were stratified by any mental health disorder 
diagnosis (Figure 3.8), any depression diagnosis (Figure 3.9), or by mental 
health disorders other than PTSD or depression (Figure 3.10), the largest 
absolute increases were observed among those with sleep apnea. 
   Since combat can be related to development of PTSD and mental health 
disorders, sleep disorder types were stratified by combat exposure as well 
(Figure 3.11). In FY2010, the prevalence of sleep apnea and insomnia was 7.6 
times and 6.3 times greater among combat veterans than noncombat veterans, 
respectively. A similar pattern was observed for other sleep disorders; by 2010, 
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there was a greater than seven-fold relative difference in total sleep disorder 
prevalence among veterans or without combat experience.   
Sleep disorder prevalence also was examined across BMI categories 
(Figures 3.12a-3.12g).  As expected, obese veterans (BMI ≥30 kg/m2) 
experienced the largest increase (5.6%) in sleep apnea prevalence over time 
(1.4% in FY2000, 7.0% in FY2010, Figure 3.12a). For insomnia, veterans who 
were underweight or had normal BMI were the fastest growing group, with a 
1.8% absolute increase in insomnia prevalence over time (0.3% in FY2000, 2.1% 
in FY2010, Figure 3.12b).   
Figure 3.13 presents sleep disorder prevalence stratified by gender.  Male 
veterans consistently had a higher prevalence of sleep apnea across the study 
period. Female veterans either had the same or higher insomnia prevalence until 
FY2008; thereafter, their rates were exceeded by those of male veterans. 
Figures 3.14a-3.14g present trends in sleep disorder prevalence by race and 
ethnicity. The prevalence of sleep apnea increased by 3.1% among Hispanic or 
Mexican-American veterans over the study period (0.5% in FY2000 to 3.6% in 
FY2010, Figure 3.14a), the largest increase among all race/ethnicity groups that 
were evaluated. This group also had the highest prevalence of sleep apnea 
among those studied. Veterans of unknown race/ethnicity had the largest 
absolute increase (1.5%) in insomnia prevalence over time (0.3% in FY2000 to 
1.8 % in FY2010, Figure 3.14b). The northeast and southern US regions 
dominated increases observed in sleep disorder prevalence (Figures 3.15a-
3.15g). Specifically, the northeast region experienced the greatest absolute 
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increases in sleep apnea, circadian rhythm disorders, parasomnias, and other 
sleep disorders; whereas the southern region experienced increases in 
insomnias, hypersomnias, and movement disorders.     
3.5 Discussion 
Results from this study indicate a notable rise in sleep disorder diagnoses, 
especially for sleep apnea and insomnia, among US veterans who sought care 
through the VHA from FY2000 through FY2010. The largest increases were 
noted among veterans grouped according to certain demographic or clinical 
characteristics, particularly those with PTSD, other mental health disorders, or 
combat experience. The increasing trends observed in this study are consistent 
with recent results from the National Ambulatory Medical Care Survey,65 where a 
442% relative increase in office visits for sleep apnea was reported within a 
similar time period (1999-2010).65 Those investigators acknowledged uncertainty 
as to whether this represented a true increase in prevalence or if it was due to 
heightened awareness, or a combination of factors. In 2004, veterans requiring 
the use of breathing assistance equipment, such as continuous positive airway 
pressure (CPAP) devices, were granted a service-connected disability benefit for 
sleep apnea,187 which likely led to more veterans discussing sleep complaints 
with their provider. However, increases in sleep disorders in the present study 
were still observed prior to 2004; for example, apnea prevalence nearly doubled 
between FY2000 and FY2003. Thus, the changes in sleep disorder prevalence 
may not have been attributable solely to this administrative change. In addition, 
rates for other sleep disorders not covered by the new disability rating also 
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increased during the same period. Potential administrative bias was evaluated in 
this study by examining trends in the utilization of clinical procedures (CPT 
codes) for a sleep disorder diagnosis. The increases in prevalence observed for 
sleep apnea or other sleep disorders did not match the magnitude or frequency 
of diagnostic procedures for sleep that were recorded during the same period 
(Figure 3.4). Some veterans may have sought medical care outside of the VHA 
system.188 A previous investigation found that ~28% of veterans reported dual-
use primary care (VA and non-VA).189 It is unknown whether such patients may 
have preferentially sought care for sleep disorders at non-VHA facilities, but the 
possibility cannot be excluded.   
Other study uncertainties included a lack of information on the relative 
proportions or influx of certified sleep physicians entering the VHA system during 
the study period, or the extent to which updates in diagnostic criteria may have 
influenced national trends in sleep disorder diagnoses among VHA providers. 
The Accreditation Council on Graduate Medical Education (ACGME) initiated a 
national sleep medicine training and certification program in 2004-2005,190 which 
coincides with an increase in movement disorder diagnoses that were virtually 
absent within the VHA medical record in prior years. This suggests that providers 
may not have been trained to recognize these sleep disorders, and that veterans 
may have been under-diagnosed for these conditions prior to the initiation of this 
program. The trajectory of sleep disorder diagnoses over the study period 
suggests that upward trends may continue beyond FY2010.  
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Only a few studies have examined the prevalence of diagnosed sleep 
disorders in a national sample, and several of those studies focused on 
veterans.58, 183, 191  Prior investigations examined prevalence over a shorter time 
frame (i.e., across one or two fiscal years) and/or evaluated a single type of sleep 
disorder.58, 183, 191  In the current study, sleep apnea prevalence ranged from 
0.4% to 3.0%, and insomnia prevalence ranged from 0.4% to 1.5%. A large 
cohort study examining the relationship between sleep apnea and psychiatric 
comorbidities reported a sleep apnea prevalence of 2.9% in a two-year period 
(FY1998-FY2001),191 which exceeds the current study’s prevalence of 0.4% in 
FY2001. Another investigation of sleep apnea among veterans ≥65 years old 
utilized criteria similar to the present study (apnea cases were defined as 
individuals with two outpatient diagnoses at least seven days apart, or one 
inpatient diagnosis) and reported a sleep apnea prevalence of 4.4%.183  
In the current study, age-adjusted sleep disorder prevalence did not differ 
notably from crude rates (data not shown). When the current study population 
was restricted to veterans ≥65 years old in FY2005, a sleep apnea prevalence of 
3.6% was obtained, which is reasonably consistent with the previous studies.183, 
191 A recent study of insomnia prevalence reported that 3.4% of veterans in 
FY2010 had insomnia,58 which is more than double the prevalence found in the 
current study in the same year (1.5%), but is consistent with the prevalence of 
self-reported, physician-diagnosed insomnia that was recently described in a 
nationally representative sample of the non-institutionalized US population 
(1.2%).64 Inconsistencies in sleep disorder prevalence reported among different 
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studies may be due to differences in case definitions (e.g., some studies used a 
single occurrence of sleep disorder, which could overestimate case frequencies), 
or a tendency for physicians to consider sleep impairment as a comorbid 
symptom rather than a diagnosable disorder. Differences in population 
demographics, comorbidities, or the time period studied also may contribute to 
differences among published studies.    
An increase in the prevalence of comorbid diseases may have contributed 
to the increasing trend of sleep disorder diagnoses in the current study. Veterans 
with cardiovascular disease, cancer, or mental health disorders (particularly 
PTSD) experienced higher rates of sleep disorder diagnoses, a phenomenon that 
has been observed in other populations.192-194 Veterans tend to have more 
mental disorders compared to the general population,49, 144, 158, 176, 195-197 and the 
co-occurrence of sleep disorders among those with PTSD or other psychiatric 
disorders has been described previously.55, 57, 177-179, 198  The current study used 
two occurrences of a PTSD diagnosis to identify veterans with PTSD, which has 
a positive predictive value (PPV) of 82%, whereas a single diagnosis only had a 
PPV of 75%.199 A 12-month prevalence study of DSM-IV disorders indicated that 
3.5% of Americans had PTSD,200 which is similar to what was observed in the 
present study during the same time period (FY2001-2003, 3.3-3.5%). PTSD 
prevalence in this study also was consistent with the previously reported range 
among veterans (2-17%).201 PTSD rates among veterans increased three-fold 
over the eleven-year period, an absolute increase of almost 7%. It was the 
greatest change among the mental health disorders evaluated, resulting in a 
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PTSD prevalence of 10% by FY2010. The US’ multiple-front war effort that 
occurred during this period likely contributed to this striking trend.202   
Sleep disturbances are a significant component of PTSD; some studies 
report that sleep disturbances can predict the development of PTSD or 
depression.156 However, there is no clear consensus on the cause-effect 
relationship between sleep disorders and psychiatric outcomes, and these 
relationships may be bi-directional. For example, one study found that insomnia 
preceded a current anxiety disorder in less than 20% of cases, that anxiety 
appeared prior to insomnia in 44% of cases, and that these disorders co-
occurred in approximately 40% of the cases.179 In a community-based sample of 
adolescents with comorbid disorders, nearly 75% of subjects had anxiety prior to 
their insomnia diagnosis, but prior insomnia was not associated with onset of 
anxiety disorders in that study. Another investigation found that generalized 
anxiety disorder and/or depression predicted increases in sleep problems over 
time.177  This suggests that mental health disorders including PTSD may drive 
increases in sleep disorder prevalence among veterans over time, although the 
cross-sectional nature of the current study precludes an ability to infer causality. 
Some studies indicate that sleep problems can persist even after amelioration of 
PTSD or TBI symptoms, and that sleep improvement can facilitate better 
responses to PTSD therapy.156 Others reported that successful treatment of 
sleep apnea led to clinically meaningful improvements in PTSD symptoms.203  
This highlights the importance of integrated strategies to ameliorate the long-term 
combined impacts of mental and sleep-related disorders among VHA patients.  
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An aging population has been frequently cited as a factor that could be 
driving an increase in sleep disorder prevalence, particularly sleep apnea. The 
use of age-standardization in the present study eliminated potential biases that 
may have been introduced due to a shift in the age distribution among veteran 
patients during the study period. Additionally, examination of changes within 
specific age groups over time did not provide strong evidence for aging to explain 
the observed trends. One unexpected finding was that sleep apnea prevalence 
did not display a monotonic increase with age (data not shown), which has been 
previously cited as a strong predictor of this disorder.204  Instead, the prevalence 
of sleep apnea was highest among veterans 40-69 years old (data not shown). 
Also, veterans in both the 40-49 and 50-59 age groups decreased by almost 7%, 
while those aged 60-69 years increased by 6%. A previous study using either 
clinical or laboratory-based criteria found that sleep apnea prevalence peaked 
among middle-aged men.205 Discrepancies with other reports may be due to 
differences in the criteria used to diagnose sleep apnea, the types of sleep apnea 
included in the analyses (i.e., obstructive, central, and mixed), not accounting for 
apnea therapy or other comorbid conditions, or a combination of these factors. 
Other reasons to explain this finding also have been offered.58  First, older 
veterans may be less likely to seek medical care for sleep disruption symptoms.  
Moreover, as older veterans are more likely to be retired and the consequences 
of sleep disruption may be less likely to interfere with daily activities. Although 
veteran patients ≥80 years old exhibited the largest increase among age groups 
over time (Table 3.2), they consistently had among the lowest rates of sleep 
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disorder diagnoses in this population. Another explanation may be related to 
provider practices.58 As more veterans return from recent conflicts, more PTSD 
or other comorbid diagnoses arise, which may make it more likely that providers 
diagnose these veterans with sleep disorders relative to older veterans.58  
The obesity epidemic has been cited as another factor driving elevated 
sleep disorder prevalence, and veterans have experienced increases in obesity 
over time similar to the general population.165, 184 The increased prevalence of 
obesity could account, in part, for increases in sleep apnea prevalence observed 
in this study over time.  Previous investigations have reported an increased 
incidence of insomnia among obese individuals.206 However, the prevalence of 
insomnia, the second-most common sleep disorder, rose fastest among veteran 
patients in the normal BMI category, which suggests that other factors, such as 
comorbid disease, may have had a predominant role in the trends observed in 
the present study. Obesity and overweight are risk factors for many major chronic 
diseases including CVD and cancer.  
The strengths of this study included its large sample size, use of validated 
methods for characterizing sleep outcomes and important covariates, and a 
medical care system that ensured equal access to care. Furthermore, prevalence 
estimates were age-adjusted to account for changes in age distribution, and CPT 
codes for sleep procedures were examined to evaluate potential reporting bias 
over time.  This study consisted of serial cross-sectional data, and was therefore 
subject to limitations typically associated with this type of study design, including 
a lack of appropriate temporality between sleep disorder diagnoses and their 
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predictors or modifiers. Furthermore, this investigation used only data from 
veterans who sought care through the VHA system, resulting in an over-
representation of older men with multiple comorbidities; thus potentially limiting 
the generalizability of the results to other populations or to veterans who did not 
utilize VHA services.207 Sleep disorder prevalence may have been overestimated 
due to the distribution of age or comorbid disease in this population. However, 
prevalence values were age-adjusted and stricter criteria for case definitions (two 
diagnostic codes thirty or more days apart) were used to reduce potential 
misclassification. This likely resulted in more conservative estimates of sleep 
disorder prevalence relative to some other studies.  
In summary, results from this study suggest that prevalence of sleep 
disorder diagnoses increased among US veterans between FY2000 and 
FY2010, which may have important implications for the health and longevity of 
this population. Sleep disturbances are linked with increased mortality; for 
example recent meta-analyses reported 10-12% increases in mortality risk 
among those with short sleep duration.152, 153 Also, clinically significant, untreated 
sleep apnea has been associated with increases in cardiovascular disease and 
all-cause mortality.208 Since many sleep disorders are undiagnosed and therefore 
untreated, clinicians should take special care to recognize high-risk patients. 
Early identification and adequate treatment of individuals in the expanding 
population of sleep disorder patients may lead to lower health care utilization and 
improved quality of life. The cross-sectional nature of the current study design 
precludes resolution of the complex interrelationships between obesity, comorbid 
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disease, and sleep disorder diagnoses.  Thus, further examination of these 
issues using other study designs is warranted. 
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Table 3.1.  Characteristics of veterans who sought care through the Veterans 
Health Administration (VHA) system: FY2000 to FY2010) 
Characteristic Categories 
Total population  
(N =9,786,778)1 
N (%) 
Sex 
Female  664,880 (6.8) 
Male 9,121,898 (93.2) 
Race 
White 2,730,235 (27.9) 
Black or African American  575,770 (5.9) 
Hispanic  241,914 (2.5) 
Other  162,966  (1.7) 
Unknown 6,075,893 (62.1) 
Marital Status 
Married 5,272,298 (53.9) 
Not Married 3,755,025 (38.4)        
Unknown   759,455 (7.8) 
Comorbid diseases2 
Asthma   263,306 (2.7)        
Cancer   768,351 (7.9) 
CVD 5,088,157 (52.0)        
COPD   875,006 (8.9)   
Diabetes 1,873,235 (19.1)        
Fibromyalgia    114,406 (1.2)        
GI Disease 3,077,094 (31.4)        
HIV    33,755 (0.3) 
Hypertension 4,258,724 (43.5) 
Mental disorder 3,469,637 (35.5) 
     Depression   420,284 (4.3) 
     PTSD   757,673 (7.7) 
     Other mental disorder 3,224,565 (33.0) 
Renal Disease    430,010 (4.4)         
Stroke     11,324 (0.1) 
Abbreviations: COPD, Chronic Pulmonary Obstructive Disease; CVD, 
Cardiovascular Disease; HIV, Human Immunodeficiency Virus; PTSD, Post-
Traumatic Stress Disorder. 1Number of veterans entering the system with age 
and gender information; 2Disease categories are not mutually exclusive. 
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Table 3.2.  Distribution and absolute percent change in population characteristics in veterans seeking care through the 
Veterans Health Administration, FY2000 - FY2010 
Characteristic Categories 
FY2000  
(n=3,467,444) 
(%, SE) 
FY2010  
(n=5,634,519) 
(%, SE) 
Percentage point 
change from FY2000 to 
FY2010  
% (95% CI) 
Sex 
Female 12.10 (0.02) 13.84 (0.01) 1.74 (-1.77,  5.25) 
Male 87.90 (0.02) 86.16 (0.01) -1.74 (-5.25, 1.77) 
Race/Ethnicity 
White 20.60 (0.02) 33.22 (0.02) 12.62 (8.63, 16.62) 
Black/African American 7.82 (0.01) 9.88 (0.01) 2.06 (-1.16, 5.28) 
Hispanic 2.43 (0.01) 4.60 (0.01) 2.17 (-0.39, 4.73) 
Other 1.57 (0.01) 2.75 (0.01) 1.18 (-1.10, 3.46) 
Unknown 67.58 (0.03) 49.55 (0.02) -18.03 (-22.25, -13.82) 
Age Category 
(years)* 
18-29 2.97 (0.01) 4.82 (0.01) 1.85 (-0.79, 4.48) 
30-39 6.71 (0.01) 5.69 (0.01) -1.02 (-4.00, 1.97) 
40-49 15.65 (0.02) 9.11 (0.01) -6.54 (-10.02, -3.05) 
50-59 23.17 (0.02) 16.28 (0.02) -6.89 (-10.72, -3.06) 
60-69 23.38 (0.02) 29.76 (0.02) 6.38 (2.37, 10.40) 
70-79 23.56 (0.02) 17.68 (0.02) -5.89 (-9.75, -2.02) 
80 years or older 4.56 (0.01) 16.66 (0.02) 12.10 (8.88, 15.31) 
Marital Status 
Married 48.59 (0.03) 47.67 (0.02) -0.92 (-0.99, -0.85) 
Not Married 41.58 (0.03) 45.19 (0.02) 3.64 (3.57, 3.71) 
Unknown 9.52 (0.03) 6.72 (0.02) -2.72 (-2.72, -2.72) 
Annual Income 
Less than 20K  67.90 (0.03) 59.58 (0.02) -8.31 (-12.51, -4.12) 
More than 20K 25.82 (0.02) 32.98 (0.02) 7.16 (3.08, 11.24) 
Unknown 6.29 (0.01) 7.44 (0.01) 1.15 (-1.89, 4.20) 
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VA Region 
Northeast 6.77 (0.01) 7.18 (0.01) 0.41 (-2.65, 3.47) 
South 19.31 (0.02) 23.87 (0.02) 4.56 (0.68, 8.44) 
Midwest 7.83 (0.01) 9.06 (0.01) 1.22 (-1.97, 4.42) 
West 9.93 (0.02) 11.56 (0.01) 1.63 (-1.73, 5.00) 
Unknown 56.16 (0.03) 48.33 (0.02) -7.83 (-12.11, -3.55) 
Service Period 
World War II 11.26 (0.02) 3.00 (0.01) -8.26 (-11.30, -5.21) 
Korean War 6.55 (0.01) 4.48 (0.01) -2.07 (-4.98, 0.83) 
Vietnam War 26.76 (0.02) 18.42 (0.02) -8.34 (-12.27, -4.42) 
Persian Gulf War 28.88 (0.02) 50.83 (0.02) 21.95 (17.77, 26.13) 
OEF/OIF 0.23 (0.00) 1.83 (0.01) 1.60 (-0.17, 3.37) 
Other 26.32 (0.02) 21.44 (0.02) -4.88 (-8.84, -0.91) 
Combat Exposure 
No 83.72 (0.02) 83.75 (0.02) 0.03 (-3.66, 3.72) 
Yes 16.28 (0.02) 16.25 (0.02) -0.03 (-3.72, 3.66) 
BMI (kg/m2) 
Normal 14.76 (0.02) 15.73 (0.02) 0.97 (-2.67, 4.60) 
Overweight 20.81 (0.02) 27.43 (0.02) 6.63 (2.68, 10.58) 
Obese 18.24 (0.02) 30.80 (0.02) 12.56 (8.63, 16.49) 
Unknown 46.19 (0.03) 26.04 (0.02) -20.15 (-24.32, -15.98) 
Smoker Status 
Never 2.36 (0.01) 17.45 (0.02) 15.09 (12.05, 18.14) 
Former 8.07 (0.01) 17.73 (0.02) 9.66 (6.22, 13.09) 
Current 2.09 (0.01) 20.48 (0.02) 18.39 (15.31, 21.47) 
Unknown 87.49 (0.02) 44.35 (0.02) -43.14 (-47.00, -39.28) 
Comorbid 
diseases 
Asthma 1.25 (0.01) 1.66 (0.01) 0.41 (-1.68, 2.50) 
Cancer 1.81 (0.01) 1.83 (0.01) 0.02 (-2.20, 2.24) 
CVD 22.07 (0.02) 23.47 (0.02) 1.40 (1.34, 1.46) 
COPD 2.56 (0.01) 2.15 (0.01) -0.41 (-2.78, 1.96) 
Diabetes 7.90 (0.01) 9.66 (0.01) 1.76 (-1.46, 4.98) 
Fibromyalgia  0.38 (0.00) 0.74 (0.00) 0.36 (-1.27, 1.99) 
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GI Disease 12.69 (0.02) 14.57 (0.01) 1.88 (-1.67, 5.43) 
HIV 0.58 (0.00) 0.45 (0.00) -0.13 (-1.76, 1.50) 
Hypertension 16.02 (0.02) 19.48 (0.02) 3.46 (-0.28, 7.20) 
Mental disorder 19.81 (0.02) 30.67 (0.02) 10.86 (6.90, 14.82) 
Depression 2.16 (0.01) 3.41 (0.01) 1.25 (-1.19, 3.69) 
PTSD 3.43 (0.01) 10.07 (0.01) 6.64 (3.70, 9.58) 
Other  17.81 (0.02) 23.04 (0.02) 5.23 (1.39, 9.07) 
Renal Disease 0.61 (0.004) 1.33 (0.005) 0.72 (0.71, 0.73) 
Stroke 0.02 (0.00) 0.01 (0.00) -0.01 (-0.68, 0.66) 
*Not age-standardized. Abbreviations: FY, Fiscal Year;  SE, Standard Error; CI, Confidence Interval; OEF/OIF, 
Operation Enduring Freedom/Operation Iraqi Freedom; BMI, Body Mass Index; CVD, Cardiovascular Disease, COPD, 
Chronic Obstructive Pulmonary Disease; GI, Gastrointestinal; HIV, Human Immunodeficiency Virus; PTSD, Post-
Traumatic Stress Disorder 
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Figure 3.1.  Flowchart of veterans who entered the Veterans Health Administration (VHA) system from FY2000 to FY2010 
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Figure 3.2.  Proportions of sleep disorder subtypes diagnoses among all sleep disorder diagnoses (n of unique 
individuals=751,502; n of diagnoses = 953,575), FY2000 – FY2010 
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Figure 3.3.  Age-adjusted prevalence of sleep disorders among United States Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.4.  Age-adjusted prevalence of CURRENT PROCEDURAL TERMINOLOGY (CPT) CODES for sleep procedures 
among all Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.5.  Age-adjusted prevalence of sleep disorders by CARDIOVASCULAR DISEASE status among all Veterans 
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)  
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Figure 3.6.  Age-adjusted prevalence rate of sleep disorders by CANCER status among all Veterans seeking care through 
the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)  
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Figure 3.7.  Age-adjusted prevalence of sleep disorders by POST-TRAUMATIC STRESS DISORDER (PTSD) status 
among all Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.8.  Age-adjusted prevalence of sleep disorders by MENTAL DISORDER status among all Veterans seeking care 
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)  
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Figure 3.9.  Age-adjusted prevalence of sleep disorders by DEPRESSION status among all Veterans seeking care 
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.10.  Age-adjusted prevalence of sleep disorders by OTHER MENTAL HEALTH DISORDER status among all 
Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.11.  Age-adjusted prevalence of sleep disorders by COMBAT EXPOSURE among all Veterans seeking care 
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12a.  Age-adjusted prevalence of APNEAS by BODY MASS INDEX (BMI) groups among all Veterans seeking 
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12b.  Age-adjusted prevalence of INSOMNIAS by BODY MASS INDEX (BMI) groups among all Veterans 
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12c.  Age-adjusted prevalence of OTHER SLEEP DISORDERS by Body Mass Index (BMI) groups among all 
Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12d.  Age-adjusted prevalence of HYPERSOMNIAS by Body Mass Index (BMI) groups among all Veterans 
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12e.  Age-adjusted prevalence of MOVEMENT DISORDERS by Body Mass Index (BMI) groups among all 
Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12f.  Age-adjusted prevalence of PARASOMNIAS by Body Mass Index (BMI) groups among all Veterans seeking 
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.12g.  Age-adjusted prevalence of CIRCADIAN RHYTHM DISORDERS by Body Mass Index (BMI) groups among 
all Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.13.  Age-adjusted prevalence of sleep disorders by gender among all Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 
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Figure 3.14a.  Age-adjusted prevalence of APNEAS by race/ethnicity among all Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.14b.  Age-adjusted prevalence of INSOMNIAS by race/ethnicity among all Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.14c.  Age-adjusted prevalence of OTHER SLEEP DISORDERS by race/ethnicity among all Veterans seeking 
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.14d.  Age-adjusted prevalence of HYPERSOMNIAS by race/ethnicity among all Veterans seeking care through 
the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.14e.  Age-adjusted prevalence of MOVEMENT DISORDERS by race/ethnicity among all Veterans seeking care 
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.14f.  Age-adjusted prevalence of PARASOMNIAS by race/ethnicity among all Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.14g.  Age-adjusted prevalence of CIRCADIAN RHYTHM DISORDERS by race/ethnicity among all Veterans 
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15a.  Age-adjusted prevalence of APNEAS by region among all Veterans seeking care through the Veterans 
Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15b.  Age-adjusted prevalence of INSOMNIAS by region among all Veterans seeking care through the Veterans 
Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15c.  Age-adjusted prevalence of OTHER SLEEP DISORDERS by region among all Veterans seeking care 
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15d.  Age-adjusted prevalence of HYPERSOMNIAS by region among all Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15e.  Age-adjusted prevalence of MOVEMENT DISORDERS by region among all Veterans seeking care through 
the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15f.  Age-adjusted prevalence of PARASOMNIAS by region among all Veterans seeking care through the 
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778) 
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Figure 3.15g.  Age-adjusted prevalence of CIRCADIAN RHYTHM DISORDERS by region among all Veterans seeking 
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Chapter 4 
The National Veteran Sleep Disorder Study II: Determinants of New Sleep 
Disorders among United States Veterans2  
                                                          
2Alexander M, Ray MA, Hébert JR, Youngstedt SD, Zhang H, Steck SE, Bogan 
RK, Burch JB. Submitted to Sleep Medicine. 
 
 86 
 
4.1 Abstract 
Introduction: Individuals with untreated or poorly managed sleep 
disorders are vulnerable to an increased risk of chronic disease, a poor quality of 
life, and earlier mortality. Sleep disturbances are common among veterans but 
few studies have examined factors influencing sleep disorder diagnoses in this 
population. This study identified risk factors for sleep disorder diagnoses among 
United States veterans seeking care in FY2010 through the Veterans 
Administration (VA) (N=5,492,156). Materials and Methods: De-identified 
electronic medical record data were accessed, and incident sleep disorder 
diagnoses were defined using American Academy of Sleep Medicine specified 
ICD-9 codes. Unconditional multiple logistic regression was used to calculate 
odds ratios (ORs) and 95% confidence intervals (CIs) that identified demographic 
characteristics or pre-existing clinical conditions associated with a new sleep 
disorder diagnosis, after adjustment for potential confounding. Results: There 
were 128,679 new sleep disorder diagnoses in the study population (2.3% of all 
patients). Conditions that resulted in the greatest adjusted odds of sleep disorder 
onset included a pre-existing history of post-traumatic stress disorder (OR: 2.56 
95% CI: 2.51-2.62), and obesity (OR: 2.41, 95% CI: 2.35-2.47).  Patients with a 
sleep disorder diagnosis also were more likely to have a pre-existing diagnosis 
of: asthma, cancer, cardiovascular disease, chronic obstructive pulmonary 
disease, diabetes, fibromyalgia, gastrointestinal illness, renal disease, or a 
mental disorder compared to those without sleep disorders. Discussion: Results 
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from this study can assist health care providers in identifying high risk patients 
and in developing effective prevention and control strategies for sleep disorders.  
4.2 Introduction 
Sleep disorders arise due to complex circumstances that can include 
genetic, environmental, behavioral, or psychosocial risk factors. They often co-
occur with chronic diseases,179 but due to the interplay between sleep disorders 
and other comorbidities, the directionality of the relationship is often unclear.  For 
example, sleep disorders can act as independent predictors of psychiatric 
disorders,55, 57 but it also has been reported that psychiatric disorders are 
predictive of sleep disturbances.177-179  The number of outpatient visits that occur 
due to sleep complaints has been increasing over time.65  However, few studies 
have examined the role of pre-existing diseases on sleep disorder development 
while accounting for other known risk factors. Also, the use of hypnotics to treat 
sleep disorders is a common practice, although this practice may have 
deleterious health or safety consequences.209 Thus, alternative strategies for 
sleep disorder prevention or treatment that target modifiable risk factors may be 
prudent for health care providers to consider. The identification of predictive 
factors also may allow clinicians to target high-risk groups that could benefit from 
timely diagnosis and treatment.  
 Despite the presence of symptoms, a large proportion of those afflicted 
with a sleep disorder can remain undiagnosed or untreated.  For example, more 
than 80% of individuals with clinically significant sleep apnea may remain 
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undiagnosed.48  Under-diagnosis or poor sleep disorder management can have 
adverse health consequences. Previous studies have linked sleep disorders with 
higher health care utilization183 and increased risks for: obesity,53, 54 type 2 
diabetes,53, 54 cardiovascular disease,52 cancer,59, 60, 147-150 or psychiatric 
disorders.55-58 Alterations in circadian rhythms, neuroendocrine function, the 
immune system and inflammation, or energy utilization and metabolism have 
been suggested as biological processes altered by sleep disruption that can 
influence chronic disease risks.159-162  The co-occurrence of a sleep disorder with 
another comorbid chronic disease can predict a poor quality of life62, 63 and earlier 
mortality relative to those with the comorbid disease but without a sleep 
disorder.49, 144, 158, 176, 195, 196  These findings underscore the importance of 
identifying independent sleep disorder risk factors, particularly in vulnerable 
populations.    
Sleep disruption is common among veterans and they tend to be 
susceptible to the onset of sleep disorders.155, 156, 163, 165, 167, 168  However, 
etiological models for new sleep disorder diagnoses have not been previously 
described in a national sample of veterans or others in the United States (US). 
To address this issue, this study identified independent risk factors for new sleep 
disorder diagnoses, including an assessment of pre-existing chronic diseases or 
disorders, by studying US veterans who utilized health services in FY2010 
through the Veterans Health Administration (VHA), which is the largest integrated 
health care system utilizing electronic medical records (EMRs) in the US.180 The 
approach allowed for an examination of objectively determined pre-existing 
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diseases that occur at higher rates among veterans relative to the general 
population (e.g., PTSD, other mental health disorders), as well as demographic 
characteristics that may influence sleep disorder onset.      
4.3 Materials and Methods 
Study Population   
The study population consisted of all US veterans seeking care through 
VHA system in FY2010, along with data extracted from EMRs since FY2000. 
Following regulatory approvals, veteran’s outpatient records were accessed from 
the MedSAS Dataset files and the VHA Corporate Data Warehouse (CDW) in the 
Veterans Administration Informatics and Computing Infrastructure (VINCI) 
system. Requested data elements from different VHA system files were linked by 
social security number, and each patient’s social security number was then 
scrambled and replaced with a unique subject identifying number. Thus, personal 
identifying information was inaccessible to the study investigators;65, 179, 209 only 
the VINCI data manager was able to access or link social security numbers with 
unique subject identifiers. Patients <18 years old on January 1 as of FY2010, 
spouses of veterans receiving care, non-veterans, or veterans who died in 
FY2010 were excluded.   
Case Ascertainment  
De-identified outpatient sleep disorder diagnoses were grouped according 
to the American Academy of Sleep Medicine’s International Classification of 
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Sleep Disorders (see Table 4.1 for ICD-9 codes defining: sleep apnea, insomnia, 
hypersomnia, circadian rhythm disorder, parasomnia, sleep disruption movement 
disorder, and other sleep disorders).181 Veterans were assigned a specific sleep 
disorder diagnosis if the diagnostic ICD-9 code appeared two or more times in 
their medical record, and at least two codes in the record occurred thirty or more 
days apart.182  The first occurrence of the diagnostic code was used to define the 
date of the primary diagnosis. No previous sleep disorder diagnoses were 
associated with these veterans dating back to October 1, 1999. Sleep disorders 
that were neither sleep apnea nor insomnia were collapsed into one category 
(other sleep disorders). The comparison group was comprised of all other eligible 
veteran patients seeking care in FY2010 without a sleep disorder diagnosis.    
Covariates 
Covariate data (age, sex, smoking status, body mass index [BMI], income, 
pre-existing diagnoses) were retrieved from VHA databases (Vital Status File and 
MedSAS, Table 1). Annual income was grouped into three categories (less than 
$20,000, $20,000 or more, or unknown) because a large proportion of veterans 
had an annual income less than $20,000. Age in years was calculated by 
subtracting the year of birth from 2010.  
BMI was calculated by dividing weight in pounds (lbs) by height in inches 
(in) squared and multiplying by a conversion factor of 703 to obtain BMI in 
kilograms/meter2. Biologically implausible heights and weights were excluded 
(height was restricted to 48-84 inches [122-213 cm], and weight was restricted to 
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75-500 pounds [34-227 kg].184  If height was missing, any appearance of height 
across FY2010 was used. Multiple entries for biologically plausible values of 
weight were averaged. Those in the underweight BMI category (<1% of study 
population) were merged into the normal BMI category, and the following 
categories were used in the analysis: low-to-normal: <25 kg/m2, overweight: ≥25 
to <30 kg/m2, and obese: ≥30 kg/m2.  
The following ICD-9 codes dating back as far as October 1, 1999 were 
used to categorize pre-existing disease: cancer (150-151, 153-155, 157, 162, 
172, 174, 183, 185, 188-189, 191, 200, 202, 204-208.9), diabetes (249-250), 
mental disorder or mental retardation (290-319, except for 309.81), 
cardiovascular disease (CVD) (390-459), post-traumatic stress disorder (PTSD, 
309.81), chronic obstructive pulmonary disease (COPD, 496.0), asthma (493), 
fibromyalgia (729.1), gastrointestinal (GI) disease (520-579), human 
immunodeficiency virus (HIV) infection (042-044), and renal disorder (580-589) 
using the same criteria as described for sleep disorders. Smoking status (current, 
former, never) was assessed as described previously.185 To validate smoking 
status, data extracted from the EMRs was compared to self-reported smoking 
data found in the Veterans Aging Cohort Study (VACS-8) and VACS Virtual 
Cohort (VACS-VC) studies, which yielded kappa (κ) statistics of 0.66 and 0.61, 
respectively.   
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Statistical Analysis 
All analyses were conducted using SAS 9.3 statistical software (Cary, 
NC). Patients with a pre-existing sleep disorder diagnosis or without at least one 
visit prior to FY2010 were excluded from the analysis. Veterans with a new sleep 
disorder diagnosis concurrent with a first-time diagnosis of a chronic disease or 
disorder of interest also were excluded; thus only pre-existing diseases and 
disorders were evaluated.  
Unconditional multivariable logistic regression was used to determine 
whether pre-existing diseases or other personal or lifestyle factors were 
associated with a first time sleep disorder diagnosis in 2010, after adjusting for 
other covariates. Odds ratios (ORs) with corresponding 95% confidence intervals 
(CIs) were used to assess the relationship between each variable of interest and 
any sleep disorder diagnosis, or a specific sleep disorder subtype (sleep apnea, 
insomnia, all other sleep disorders).  
Initially, covariates listed in Table 4.2 were evaluated separately in relation 
to each sleep disorder type, and those associated with a new diagnosis (p-value 
≤0.20) were further evaluated in multivariable models. Models were further 
reduced via manual backward selection, and all variables with a p-value ≤0.05 
were retained in the final adjusted model.  
Due to the high rate of missing race/ethnicity data (>50%), sensitivity 
analyses were conducted to determine if estimates for the various risk factors 
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differed among the following models: a.) race/ethnicity excluded entirely from the 
model, b.) race/ethnicity included except those with missing race/ethnicity data, 
and c.) including all those with race/ethnicity data; those with missing 
race/ethnicity data were coded was as a separate category. Estimates in the 
model did not appreciably change for each of these scenarios; therefore, 
race/ethnicity was left out of the final models and not reported.   
Because 8.4% of individuals with a new sleep disorder diagnosis had 
multiple new sleep disorder subtypes, sensitivity analyses also were carried out 
to examine any changes in estimates for models that included or excluded these 
individuals. Among those with sleep apneas, 9% had some other sleep disorder 
diagnosis, 3% had an insomnia diagnosis, and <0.1% had both insomnia and 
some other sleep disorder diagnosis. Among those with insomnia, 5% had a 
sleep apnea diagnosis, 6% had some other sleep disorder diagnosis, and 
approximately 2% had sleep apnea and some other sleep disorder diagnosis. 
Among those with ‘other’ primary sleep disorder diagnoses (hypersomnia, 
circadian rhythm disorder, parasomnia, sleep disruption movement disorder, 
other), 19% also had comorbid sleep apnea, 7% had comorbid insomnia, and 2% 
had comorbid sleep apnea and insomnia. When sensitivity analyses were 
performed among those with more than one sleep disorder either included or 
excluded from the analysis, no major differences in the effect estimates (>10%) 
were observed. Results presented below were based on data from individuals 
with more than one sleep disorder.  
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4.4 Results 
In FY2010, 5,484,890 veterans were eligible for evaluation. The majority 
of this analytical sample was male (93%) and married (55%) (Table 4.2), and had 
an average age (± standard deviation) of 63±16 years. A total of 128,679 incident 
sleep disorder cases were identified (2.3% of the study population).   
Those with a new sleep disorder diagnosis were more likely to be male, 
married, have a higher income, and a higher BMI compared to those without 
sleep disorders (Table 4.2). Veterans with a new sleep disorder diagnosis were 
six years younger than those without sleep disorders, on average (57±15 years 
vs. 63±16 years, respectively).  Additionally, those with a new sleep disorder had 
a higher proportion of the following pre-existing diseases compared to those 
without a sleep disorder: asthma, cancer, CVD, COPD, diabetes, fibromyalgia, 
GI, or renal disease, or a mental health disorder.  Similar differences were found 
when comparing only veterans with sleep apnea, insomnia, or other sleep 
disorders relative to those without a sleep disorder, except for patients with HIV 
(see Tables 4.3, 4.4, and 4.5, respectively).   
Table 4.6 presents crude and adjusted ORs for associations between 
variables of interest and new sleep disorder diagnoses. Veterans with a new 
sleep disorder diagnosis were more likely to be overweight or obese (OR: 1.36, 
95% CI: 1.32, 1.39; OR: 2.41 95% CI: 2.35, 2.47, respectively) relative to those 
without a sleep disorder. Veterans who developed a new sleep disorder also 
were more likely to have a pre-existing diagnosis of PTSD or another type of 
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mental health disorder compared to those without a sleep disorder (PTSD OR: 
2.56, 95% CI: 2.51, 2.62; other mental health disorder OR: 2.16, 95% CI: 2.12, 
2.20, Table 4.6).  The next largest risk estimates for sleep disorders among those 
with pre-existing diseases were: CVD (OR: 1.71, 95% CI: 1.68, 1.74), 
fibromyalgia (OR: 1.69, 95% CI: 1.56, 1.83), COPD (OR: 1.67, 95% CI: 1.62, 
1.72), asthma, (OR: 1.66, 95% CI: 1.59, 1.74), GI disorder (OR: 1.46, 95% CI: 
1.44, 1.49), renal disorder (OR: 1.24, 95% CI: 1.19, 1.30), diabetes (OR: 1.06, 
95% CI: 1.04, 1.08), and cancer (OR: 1.06, 95% CI: 1.02, 1.10) (Table 4.6). After 
adjustment, male veterans and those who were married also had increased odds 
of a new sleep disorder diagnosis (Table 4.6). 
Veterans who developed sleep apnea had a two- or greater than six-fold 
odds of being overweight or obese, respectively (Table 4.7), relative to veterans 
without a sleep disorder.  The following pre-existing diseases were each 
associated with increased odds of a new sleep apnea diagnosis, in order of 
decreasing magnitude of the effect estimates: PTSD (OR: 2.00, 95% CI: 1.94, 
2.05), COPD (OR: 1.95, 95% CI: 1.88, 2.03), CVD (OR: 1.86, 95% CI: 1.82, 
1.90), asthma (OR: 1.76, 95% CI: 1.66, 1.86), other mental health disorders (OR: 
1.67, 95% CI: 1.63, 1.71), fibromyalgia (OR: 1.58, 95% CI: 1.41, 1.78), GI 
disease (OR: 1.42, 95% CI: 1.38, 1.45), renal disorder (OR: 1.30, 95% CI: 1.23, 
1.37), and diabetes (OR: 1.14, 95% CI: 1.12, 1.17)  (Table 4.7).  Veterans 
diagnosed with sleep apnea were almost one-third less likely to have an HIV 
infection (OR: 0.70, 95% CI: 0.58, 0.86) (Table 4.7).  
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The odds of pre-existing PTSD or another mental health disorder were 
four times or three times greater among those with new onset of insomnia, 
respectively, relative to those without insomnia (Table 4.8). The next largest 
association between a pre-existing disease and an insomnia diagnosis was 
fibromyalgia (OR: 1.63, 95% CI: 1.42, 1.87), followed by: GI disease (OR: 1.50, 
95% CI: 1.45, 1.55), CVD (OR: 1.46, 95% CI: 1.41, 1.51), asthma (OR: 1.27, 
95% CI: 1.15, 1.40), COPD (OR: 1.24, 95% CI: 1.17, 1.31), renal disorder (OR: 
1.23, 95% CI: 1.13, 1.34), and cancer (OR: 1.16, 95% CI: 1.09, 1.25)  (Table 
4.8).  Unlike the association between diabetes and any new sleep disorder, those 
with diabetes were less likely to be diagnosed with insomnia (OR: 0.84, 95% CI: 
0.81, 0.88, Table 8).   
Finally, veterans with other sleep disorders were nearly two times more 
likely to be overweight or obese (Table 4.9).  Similar to insomnia, pre-existing 
PTSD had the largest association with other sleep disorder diagnoses (OR: 3.16, 
95% CI: 3.04, 3.29), followed by: other mental health disorders (OR: 2.44, 95% 
CI: 2.36, 2.53), fibromyalgia (OR: 1.89, 95% CI: 1.65, 2.17), asthma (OR: 1.66, 
95% CI: 1.53, 1.81), CVD (OR: 1.65, 95% CI: 1.60, 1.71), COPD (OR: 1.61, 95% 
CI: 1.52, 1.71), GI diseases (OR: 1.54, 95% CI: 1.49, 1.60), and renal disorder 
(OR: 1.19, 95% CI: 1.09, 1.29) (Table 4.9).   
4.5 Discussion 
This study identified several determinants of new sleep disorder 
diagnoses in a national sample of veterans. Non-disease determinants of a new 
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sleep disorder diagnosis included: male sex, being married, and being 
overweight or obese. Pre-existing diseases that were associated with a new 
sleep disorder diagnosis included: asthma, cancer, CVD, COPD, diabetes, 
fibromyalgia, GI disease, renal disorder, and mental health disorders, especially 
PTSD. Several disease risk factors identified in this study were consistent with 
findings from prior investigations among veterans,179, 210, 211 namely the link 
between PTSD and sleep disorders.170, 191, 212 Knowledge of risk factors for new 
sleep disorder diagnoses, particularly pre-existing diseases, provides an 
opportunity to improve the quality of life among veterans who may be at a higher 
risk for developing long-term sequelae of sleep disorders. This may include 
several types of chronic disease or psychiatric disorder,52-58 and early mortality49, 
59, 144, 158, 176, 195, 196 relative to those without sleep disorders.  
There were some unexpected findings in this study.  First, the 
development of a new sleep disorder was less likely with increasing age, which is 
contrary to some reports,213 although there have been inconsistencies. For 
example, older age was a risk factor for sleep apnea in one previous study,204 
whereas results from another study indicated that sleep apnea prevalence 
peaked among middle-aged rather than older men.205 Another study among 
veterans over 65 years of age found that increasing age was protective of new 
sleep apnea diagnoses.183 Results from the present study were consistent with a 
previous study that examined correlates of prevalent insomnia among veterans in 
FY2010 after adjusting for several confounders. A lower prevalence of insomnia 
among older veterans was observed, and multivariable analyses did not identify 
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an association between age and insomnia.58  Because those with prevalent sleep 
disorders were excluded from the present study, it is possible that older veterans 
who were retained in the analysis tended to be healthier and less likely to be 
diagnosed with a sleep disorder relative to younger veterans. An alternative 
explanation for this observation may be a tendency for medical providers to 
overlook sleep problems as symptoms of another comorbid disease rather than a 
separate disorder requiring diagnosis, or because older veterans are less likely to 
discuss sleep complaints with their physician. Although the relatively small 
reduction in odds with increasing age was statistically significant, the clinical 
significance of this observation is uncertain. Finally, middle age veterans may 
have other attributes that differ from older veterans, such as a greater likelihood 
of participation in the recent Middle East war effort.  
Another unexpected finding was the inverse association of tobacco 
consumption with sleep disorder diagnosis. Nicotine acts as a stimulant and it 
interferes with the release of neurotransmitters that play a key role in regulation 
of the sleep-wake cycle, and thus may be involved in the onset of sleep 
disturbances.214, 215 Because smoking status was assessed within the same time 
period as the sleep disorder diagnosis, these associations could be attributed to 
reverse causation.  That is, individuals who were diagnosed with a new sleep 
disorder may have avoided smoking in an effort to improve their sleep and 
health.  
An unexpected protective association between HIV infection and sleep 
apnea also was observed. In an era where HIV patients with antiretroviral 
 99 
 
therapy are living longer, this subpopulation may be experiencing increased 
morbidity from conditions unrelated to HIV infection. Few large-scale studies 
have examined this issue. A positive association between HIV infection and 
sleep apnea was recently observed in a large cohort study.216  However, a prior 
study among veterans observed a three-fold lower prevalence of sleep apnea 
among those with HIV compared to those without HIV.217 The investigators 
reported that veterans with HIV had fewer sleep apnea risk factors, but noted that 
sleep apnea also may be underdiagnosed in this population.   
Veterans have elevated rates of mental health disorders compared to the 
general population.  The prevalence of pre-existing PTSD in the current study 
population (5.7%) falls within the range of previously reported rates among 
veterans (2-17%).201 Results from the current study suggest that pre-existing 
PTSD or other mental health disorders may have a considerable role in the 
development of a new sleep disorder, more so than other pre-existing medical 
conditions. Those with a new diagnosis of any sleep disorder, sleep apnea, 
insomnia, or other sleep disorders were two to four times more likely to have pre-
existing PTSD; one of the strongest associations observed. These observations 
are consistent with results reported in a prospective study of incident chronic 
insomnia, which was defined as not having insomnia at baseline and 
subsequently developing insomnia that lasted at least one year.218 Associations 
between psychiatric disturbances, especially anxiety disorders (e.g., PTSD), and 
sleep disorders have been described previously,55, 57, 58, 177-179, 191, 212  although 
the inter-related nature of these conditions may have produced inconsistencies in 
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terms of cause and effect.219  Relationships between sleep and psychiatric 
disturbances may be bi-directional, and also may be subject to misclassification 
bias if symptomatic patients remain undiagnosed. Through careful selection of 
veterans with and without pre-existing diseases, the design of this study allowed 
for sleep disorder risk factors to be assessed while preserving the temporality of 
the relationship. Previous investigators have observed that anxiety disorders 
tended to precede an insomnia diagnosis rather than co-occur or occur as a 
consequence of insomnia.177-179 For example, anxiety appeared prior to insomnia 
in 44% of people diagnosed with insomnia, which is higher than the proportion of 
those who developed an anxiety disorder after insomnia diagnosis (20%), or 
those who had co-occurring diagnoses (40%).179 Also, sleep disturbances have 
persisted despite successful treatment of PTSD,220 suggesting that although 
disturbed sleep is a core PTSD symptom, it also may be a pre-disposing factor, 
or may develop as a separate disorder during the course of PTSD.  
While there is a growing literature on the role of anxiety disorders in the 
development of insomnia, little is known about their role in the development of 
sleep apnea. A recent study found an association between higher PTSD 
symptom severity and risk for obstructive sleep apnea (OSA) among Iraq and 
Afghanistan veterans presenting at a VHA outpatient PTSD clinic.221 In the 
current study, veterans with a new sleep apnea diagnosis were nearly twice as 
likely to have pre-existing PTSD after controlling for several other known 
predictors including BMI. The underlying mechanism has yet to be fully 
elucidated, but it has been suggested that those afflicted with PTSD may lack the 
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ability to suppress anxiety while dreaming, resulting in an increase in the 
frequency of sleep disordered breathing events.222 This may have clinical 
implications since PTSD reduces adherence to continuous positive airway 
pressure (CPAP) therapy,223 and untreated sleep apnea has been associated 
with numerous adverse sequelae including all-cause mortality and cardiovascular 
disease.208 Longitudinal studies are needed to confirm this association while 
accounting for sleep apnea treatments.  
While it is possible for underlying disease processes to influence 
subsequent sleep disorder development, there are other explanations for the 
observed relationships. First, veterans with a chronic disease or mental health 
disorder are more likely to use VHA care, thus increasing their likelihood of being 
diagnosed with a sleep disorder. A study of utilization of VHA non-mental health 
services indicated that veterans with PTSD or mental disorders other than PTSD 
had 91% and 55% higher utilization, respectively, than those without a mental 
disorder. The increased utilization may be related to combat exposure, which has 
been associated with both mental and physical ailments, and the combination of 
these conditions increases the likelihood of a veteran seeking services in a 
primary care setting.224 It also is possible that VHA clinicians in primary care 
settings are more likely to look for sleep issues when evaluating veterans with 
mental health disorders. In 2005, the VHA expanded its capacity for mental 
health services, which included the integration of mental health providers into 
primary care settings.225 However, one study found that mental health status and 
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primary care visits had only a modest effect on utilization of non-mental health 
services.224   
Veterans are experiencing an obesity epidemic similar to the general 
population,165, 184 and results from the present study suggest that weight 
management may provide an opportunity to prevent sleep disorders associated 
with this condition. Obese veterans in the present study were about twice as 
likely to receive a diagnosis of any sleep disorder, sleep apnea, or other sleep 
disorders relative to non-obese individuals. However, the ORs for insomnia 
marginally decreased as BMI increased, which is inconsistent with previous 
reports.206, 218 This suggests that current BMI may not predict insomnia or that 
other factors, such as unstudied comorbid conditions, or their treatment, could 
influence the relationship between BMI and insomnia. For example, psychiatric 
disorders increase the risk of obesity,226-228 and both factors increase the 
likelihood of sleep disturbances. Explaining the nature of these complex 
relationships requires further examination using either prospective or 
experimental study designs.    
Strengths of this study included a large sample size, the use of validated 
measures for outcomes and important variables of interest, and a medical care 
system that ensured equal access to care. The robust sample size provided 
ample statistical power and tended to reduce standard errors of the effect 
estimates (inflated standard errors can arise due to multicollinearity when 
multiple risk factors with overlapping effects are evaluated). Since the objective 
was to examine multiple sleep disorder risk factors, steps were taken to reduce 
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the likelihood of multicollinearity, including careful a priori consideration of 
variables to be included in the analyses. For example, combat exposure is 
associated with the onset of mental health disorders; therefore, combat and 
mental health disorders were not simultaneously included in the analyses. 
Similarly, analyses of hypertension, metabolic syndrome, and stroke were 
avoided since they have risk factors that overlap with CVD.   
Some limitations are also noteworthy. Information on medication use or 
substance abuse was not included in the analysis, which may have impacted the 
strength or direction of the reported associations. Data on treatment efficacy or 
management of specific pre-existing diseases also was not available, which may 
have impacted sleep disorder onset. Caution is advised when interpreting small, 
unanticipated effects since residual confounding may have been present, and 
since statistical significance does not always correspond to clinical significance. 
Finally, this investigation was limited to veterans seeking care through the VHA 
system, who tend to be older males with multiple comorbidities.207 This limits the 
potential for generalizability to all veterans, or to the general US population. It is 
also possible that multiple synchronous sleep disorder diagnoses could have 
influenced the results (~8% of new sleep disorder diagnoses in FY2010). 
However, no appreciable change in the risk estimates was observed after 
removal of individuals with multiple sleep disorder diagnoses from the analysis.  
In summary, sleep disorders are reportedly on the rise and these 
conditions can have long-term deleterious health consequences.65 In this study, a 
predictive analysis of factors influencing sleep disorder onset was performed 
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among US veterans seeking care in the VHA system in FY2010. The findings 
suggest that early identification and targeting of high-risk groups, such as 
veterans with PTSD or elevated BMI, may lead to more focused sleep disorder 
prevention or management strategies that may convey lower health care 
utilization, improved quality of life, and reduced mortality risk to those individuals.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
 
Table 4.1. International Classification of Sleep Disorders181 
Sleep Disorder ICD-9 codes 
Sleep Apnea Organic Sleep Apnea (327.20-29) Unspecified Sleep Apnea (780.57) 
Insomnia 
Organic Insomnias (327.00-09) 
Insomnias, unspecified (780.51-780.52) 
Non Organic Insomnias (307.41-
307.42) 
Hypersomnia 
Organic Hypersomnias (327.10-19) 
Non Organic Hypersomnias (307.43-
.44) 
Hypersomnias, unspecified (780.53-
780.54) 
Other Hypersomnias (347.00-347.01, 
347.10-347.11) 
Circadian Rhythm Disorder 
Organic Circadian Rhythm Sleep 
Disorders (327.30-39) 
Circadian Rhythm Sleep disorder of 
Non Organic (307.45) 
Disruption of 24 hour sleep wake cycle, 
unspecified (780.55) 
Parasomnia 
Organic Parasomnias (327.40-327.49) 
Non Organic Parasomnias (307.46-
307.47) 
Sleep Disruption Movement 
Disorders 
Organic sleep related movement 
disorders (327.51-327.59) 
Sleep Related Movement Disorder, 
unspecified (780.58) 
Restless Legs Syndrome (333.94) 
Other Sleep Disorders 
Other Organic Sleep Disorder (327.80) 
Specific disorders of sleep of Non 
Organic origin (307.40-307.49) 
Other Sleep disturbances, unspecified 
(780.50, 780.56, 780.59) 
Other Sleep Disorders (291.82, 292.85) 
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Table 4.2.  Characteristics of United States veterans with and without a primary sleep disorder diagnosis who sought 
care in the Veterans Health Administration (VHA) in FY2010 
Characteristic Classification Total Population  (N = 5,484,890)1 
Sleep Disorder  
(N = 128,679)1 
No Sleep Disorder  
(N = 5,356,211)1 p-value
2 
Age (years) Mean (SD) 63 (16) 57 (15) 63 (16) <0.01 
Sex Male 
N (%) N (%) N (%)  
5,119,403 (93) 120,560 (94) 4,998,843 (93) <0.01 
Female  365,487 (7)   8,119 (6)  357,368 (7)  
Marital Status 
Not Married 2,205,522 (40)   50,710 (39) 2,154,812 (40) <0.01 
Married 3,014,017 (55)   73,601 (57) 2,940,416 (55)  
Unknown  265,351 (5)   4,368 (3)   260,983 (5)  
Annual Income 
<$20,000 3,012,254 (55)   71,837 (56) 2,940,417 (55) <0.01 
≥$20,000 2,144,375 (39)    56,711 (44) 2,087,664 (39)  
Unknown  328,261 (6)          131 (0.1)   328,130 (6)  
BMI (kg/m2) 
Normal    964,244 (18)    15,087 (12)    949,157 (18) <0.01 
Overweight    1,712,320 (31)    36,999 (29) 1,675,321 (31)  
Obese 1,705,000 (31)    74,119 (58) 1,630,881 (30)  
Unknown 1,103,326 (20)    2,474 (2) 1,100,852 (21)  
Tobacco Use 
Never    920,168 (17)    30,458 (24)    889,710 (17) <0.01 
Former 1,249,110 (23)    37,395 (29) 1,211,715 (23)  
Current    956,402 (17)    30,192 (23)    926,210 (17)  
Unknown 2,359,210 (43)    30,634 (23) 2,328,576 (43)  
Asthma  
No 5,409,347 (99)   123,611 (96) 5,285,736 (99) <0.01 
Yes          54,461 (1)     2,961 (2)    51,500 (1)  
Cancer 
No  5,260,565 (96)   122,332 (95) 5,138,233 (96) <0.01 
Yes   163,904 (3)     4,100 (3)  159,804 (3)  
CVD No  3,371,891 (61)     52,173 (41) 3,319,718 (62)  
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Table 4.2.  Characteristics of United States veterans with and without a primary sleep disorder diagnosis who sought 
care in the Veterans Health Administration (VHA) in FY2010 
Characteristic Classification Total Population  (N = 5,484,890)1 
Sleep Disorder  
(N = 128,679)1 
No Sleep Disorder  
(N = 5,356,211)1 p-value
2 
Yes  1,820,644 (33)     58,582 (46) 1,762,062 (33)  
COPD 
No  5,246,370 (96)    116,863 (91) 5,129,507 (96) <0.01 
Yes  177,253 (3)      7,160 (6)  170,093 (3)  
Diabetes 
No 4,547,121 (83)      95,089 (74) 4,452,032 (83) <0.01 
Yes    813,430 (15)      26,189 (20)    787,241 (15)  
Fibromyalgia No 5,458,590 (99)    126,501 (98) 5,332,089 (99) <0.01 Yes       13,243 (0.2) 924 (0.7)      12,319 (0.2)  
GI disease 
No  4,606,681 (84)      86,897 (68) 4,519,784 (84) <0.01 
Yes     653,361 (12)      26,831 (21)   626,530 (12)  
HIV Infection No   5,465,179 (99)      63,016 (49) 5,336,966 (99) 0.28 Yes         17,921 (0.3)      49,688 (39)       17,518 (0.3)  
Mental disorder 
None    4,083,480 (75)      55,400 (43) 4,028,080 (75) <0.01 
PTSD3     310,470 (6)      16,723 (13)  293,747 (5)  
Other4       748,787 (14)      29,587 (23)    719,200 (13)  
Renal disorder 
No    5,338,066 (97)    123,048 (96)  5,215,018 (97) <0.01 
Yes       95,334 (2)      3,107 (2)     92,227 (2)  
Note: All numbers are presented as counts and percentages unless otherwise indicated.  1Cells may not add up to total 
for column due to missing values; 2Chi-square test for differences in proportions for categorical variables or Student’s t-
test for differences in means for continuous variables; 3Any diagnosis of PTSD, does not exclude other pre-existing 
mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety disorders, emotional and 
behavioral disorders, and mood disorders).  Abbreviations: BMI: body mass index; CVD, cardiovascular disease; 
COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human immunodeficiency virus; PTSD, post-
traumatic stress disorder 
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Table 4.3.  Characteristics of United States veterans with and without a primary SLEEP APNEA diagnosis who sought 
care in the Veterans Health Administration (VHA) in FY2010 
Characteristic Classification Total Population  (N = 5,426,333)1 
Apneas  
(N = 70,122)1 
No Apneas  
(N = 5,356,211)1 p-value
2 
Age (years) Mean (SD) 63 (16) 58 (13) 63 (16) <0.01 
Sex Male 
N (%) N (%) N (%)  
5,065,833 (94) 66,990 (96) 4,998,843 (93) <0.01 
Female  360,500 (7) 3,132 (4)  357,368 (7)  
Marital Status 
Not Married 2,178,818 (40) 24,006 (34) 2,154,812 (40) <0.01 
Married 2,984,256 (55) 43,840 (63) 2,940,416 (55)  
Unknown  263,259 (5) 2,276 (3)  260,983 (5)  
Annual Income 
<$20,000 2,977,794 (55) 37,377 (53) 2,940,417 (55) <0.01 
≥$20,000 2,120,340 (39) 32,676 (47) 2,087,664 (39)  
Unknown  328,199 (6)        69 (0.1)  328,130 (6)  
BMI (kg/m2) 
Normal    952,469 (18) 3,312 (5)    949,157 (18) <0.01 
Overweight 1,690,661 (31) 15,340 (22) 1,675,321 (31)  
Obese 1,681,033 (31) 50,152 (72) 1,630,881 (30)  
Unknown 1,102,170 (20) 1,318 (2) 1,100,852 (21)  
Tobacco Use 
Never   906,634 (17) 16,924 (24)    889,710 (17) <0.01 
Former 1,232,979 (23) 21,264 (30) 1,211,715 (23)  
Current    939,838 (17) 13,628 (19)    926,210 (17)  
Unknown 2,346,882 (43) 18,306 (26) 2,328,576 (43)  
Asthma 
No 5,352,660 (99) 66,924 (95) 5,285,736 (99) <0.01 
Yes    53,316 (1) 1,816 (3)    51,500 (1)  
Cancer No 5,205,036 (96) 66,803 (95) 5,138,233 (96) 0.41 Yes  161,911 (3) 2,107 (3)  159,804 (3)  
CVD No 3,344,548 (62) 24,830 (35) 3,319,718 (62) <0.01 
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Table 4.3.  Characteristics of United States veterans with and without a primary SLEEP APNEA diagnosis who sought 
care in the Veterans Health Administration (VHA) in FY2010 
Characteristic Classification Total Population  (N = 5,426,333)1 
Apneas  
(N = 70,122)1 
No Apneas  
(N = 5,356,211)1 p-value
2 
Yes 1,796,450 (33) 34,388 (49) 1,762,062 (33)  
COPD 
No 5,192,395 (96) 62,888 (90) 5,129,507 (96) <0.01 
Yes  174,210 (3) 4,117 (6)  170,093 (3)  
Diabetes 
No 4,500,153 (83) 48,121 (69) 4,452,032 (83) <0.01 
Yes    804,090 (15) 16,849 (24) 787,241 (15)  
Fibromyalgia No 5,401,182 (99) 69,093 (99) 5,332,089 (99) <0.01 Yes      12,754 (0.2)      435 (0.6)       12,319 (0.2)  
GI disease 
No 4,567,647 (84) 47,863 (68) 4,519,784 (84) <0.01 
Yes    640,749 (12) 14,219 (20)    626,530 (12)  
HIV Infection No 5,406,918 (99) 69,952 (99) 5,336,966 (99) <0.01 Yes      17,659 (0.3)      141 (0.2)      17,518 (0.3)  
Mental disorder 
None 4,063,737 (75) 35,657 (51) 4,028,080 (75) <0.01 
PTSD3  302,482 (6)   8,735 (12)   293,747 (5)  
Other4    733,366 (14) 14,166 (20)     719,200 (13)  
Renal disorder 
No 5,281,718 (97) 66,700 (95) 5,215,018 (97) <0.01 
Yes    94,106 (2) 1,879 (3)    92,227 (2)  
Note: All numbers are presented as counts and percentages unless otherwise indicated 
1Cells may not add up to total for column due to missing values; 2Chi-square test for differences in proportions for 
categorical variables or Student’s t-test for differences in means for continuous variables; 3Any diagnosis of PTSD, does 
not exclude other pre-existing mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety 
disorders, emotional and behavioral disorders, and mood disorders).  Abbreviations: BMI: body mass index; CVD, 
cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human 
immunodeficiency virus; PTSD, post-traumatic stress disorder 
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Table 4.4.   Characteristics of United States veterans with and without a primary INSOMNIA diagnosis who sought care 
in the Veterans Health Administration (VHA) in FY2010 
Characteristic Classification Total Population  (N = 5,394,500)1 
Insomnia  
(N = 38,289)1 
No Insomnia  
(N = 5,356,211)1 p-value
2 
Age (years) Mean (SD) 63 (16) 55 (17) 63 (16) <0.01 
Sex Male 
N (%) N (%) N (%)  
5,033,736 (93) 34,893 (91) 4,998,843 (93) <0.01 
Female  360,764 (7) 3,396 (9) 357,368 (7)  
Marital Status 
Not Married 2,173,430 (40) 18,618 (49) 2,154,812 (40) <0.01 
Married 2,958,722 (55) 18,306 (48) 2,940,416 (55)  
Unknown  262,348 (5) 1,365 (4)  260,983 (5)  
Annual Income 
<$20,000 2,963,517 (55) 23,100 (60) 2,940,417 (55) <0.01 
≥$20,000 2,102,812 (39) 15,148 (40) 2,087,664 (39)  
Unknown  328,171 (6)         41 (0.1)  328,130 (6)  
BMI (kg/m2) 
Normal    957,541 (18)   8,384 (22)   949,157 (18) <0.01 
Overweight 1,690,139 (31) 14,818 (39) 1,675,321 (31)  
Obese 1,645,260 (31) 14,379 (38) 1,630,881 (30)  
Unknown 1,101,560 (20)    708 (2) 1,100,852 (21)  
Tobacco Use 
Never    898,691 (17)   8,981 (23)    889,710 (17) <0.01 
Former 1,222,063 (23) 10,348 (27) 1,211,715 (23)  
Current   937,535 (17) 11,325 (30)    926,210 (17)  
Unknown 2,336,211 (43)   7,635 (20) 2,328,576 (43)  
Asthma 
No 5,322,840 (99) 37,104 (97) 5,285,736 (99) <0.01 
Yes    52,166 (1)    666 (2)   51,500 (1)  
Cancer No 5,174,528 (96) 36,295 (95) 5,138,233 (96) <0.01 Yes  161,055 (3) 1,251 (3)  159,804 (3)  
CVD No 3,338,285 (62) 18,567 (48) 3,319,718 (62) <0.01 
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Yes 1,776,727 (33) 14,665 (38) 1,762,062 (33)  
COPD 
No 5,165,002 (96) 35,495 (93) 5,129,507 (96) <0.01 
Yes  171,897 (3) 1,804 (5)  170,093 (3)  
Diabetes No 4,483,727 (83) 31,695 (83) 4,452,032 (83) <0.01 Yes    792,417 (15)   5,176 (14)   787,241 (15)  
Fibromyalgia 
No 5,369,607 (99) 37,518 (98) 5,332,089 (99) <0.01 
Yes       12,622 (0.2)       303 (0.8)       12,319 (0.2)  
GI disease 
No 4,545,038 (84) 25,254 (66) 4,519,784 (84) <0.01 
Yes    634,473 (12)  7,943 (21)    626,530 (12)  
HIV Infection 
No 5,375,047 (99) 38,081 (99) 5,336,966 (99) <0.01 
Yes      17,696 (0.3)      178 (0.5)       17,518 (0.3)  
Mental disorder 
None 4,039,287 (75) 11,207 (29) 4,028,080 (75) <0.01 
PTSD2 298,893 (6) 5,146 (13) 293,747 (5)  
Other3 729,498 (14) 10,298 (27) 719,200 (13)  
Renal disorder No 5,251,903 (97) 36,885 (96) 5,215,018 (97) <0.01 Yes 92,990 (2) 763 (2) 92,227 (2)  
Note: All numbers are presented as counts and percentages unless otherwise indicated 
1Cells may not add up to total for column due to missing values; 2Chi-square test for differences in proportions for 
categorical variables or Student’s t-test for differences in means for continuous variables; 3Any diagnosis of PTSD, does 
not exclude other pre-existing mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety 
disorders, emotional and behavioral disorders, and mood disorders).  Abbreviations: BMI: body mass index; CVD, 
cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human 
immunodeficiency virus; PTSD, post-traumatic stress disorder 
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Table 4.5.  Characteristics of United States veterans with and without a primary OTHER SLEEP DISORDER diagnosis 
who sought care in the Veterans Health Administration (VHA) in FY2010 
Characteristic Classification Total Population  (N = 5,387,8851 
Other Sleep 
Disorders  
(N = 31,674)1 
No Other Sleep 
Disorders  
(N = 5,356,211)1 
p-value2 
Age (years) Mean (SD) 63 (16) 57 (15) 63 (16) <0.01 
Sex Male 
N (%) N (%) N (%)  
5,028,180 (93) 29,337 (93) 4,998,843 (93) <0.01 
Female   359,705 (7) 2,337 (7)  357,368 (7)  
Marital Status 
Not Married 2,167,417 (40) 12,605 (40) 2,154,812 (40) <0.01 
Married 2,958,404 (55) 17,988 (57) 2,940,416 (55)  
Unknown  262,064 (5) 1,081 (3)  260,983 (5)  
Annual Income 
<$20,000 2,958,211 (5) 17,794 (56) 2,940,417 (55) <0.01 
≥$20,000 2,101,511 (39) 13,847 (44) 2,087,664 (39)  
Unknown  328,163 (6)        33 (0.1)  328,130 (6)  
BMI (kg/m2) 
Normal    953,480 (18)    4,323 (14)    949,157 (18) <0.01 
Overweight 1,685,317 (31)    9,996 (32) 1,675,321 (31)  
Obese 1,647,666 (31)  16,785 (53) 1,630,881 (30)  
Unknown 1,101,422 (20)   570 (2) 1,100,852 (21)  
Tobacco Use  
Never    897,234 (17)  7,524 (23)    889,710 (17) <0.01 
Former 1,220,969 (23)  9,254 (29) 1,211,715 (23)  
Current    934,175 (17)  7,965 (25)    926,210 (17)  
Unknown 2,335,507 (43)  6,931 (21) 2,328,576 (43)  
Asthma 
No 5,316,166 (99) 30,430 (96) 5,285,736 (99) <0.01 
Yes    52,269 (1)    769 (2)    51,500 (1)  
Cancer No 5,168,338 (96) 30,105 (95) 5,138,233 (96) <0.01 
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Yes  160,896 (3) 1,092 (3)  159,804 (3)  
CVD 
No 3,333,044 (62) 13,326 (42) 3,319,718 (62) <0.01 
Yes 1,776,691 (33) 14,629 (46) 1,762,062 (33)  
COPD No 5,158,291 (96) 28,784 (91) 5,129,507 (96) <0.01 Yes  171,953 (3) 1,860 (6)  170,093 (3)  
Diabetes 
No 4,475,845 (83) 23,813 (75) 4,452,032 (83) <0.01 
Yes    793,626 (15) 6,385 (20)    787,241 (15)  
Fibromyalgia 
No 5,363,084 (99) 30,995 (98) 5,332,089 (99) <0.01 
Yes       12,619 (0.2)   300 (1)       12,319 (0.2)  
GI disease 
No 4,540,794 (84) 21,010 (66) 4,519,784 (84) <0.01 
Yes    633,798 (12)   7,268 (23)    626,530 (12)  
HIV Infection 
No 5,368,505 (99) 31,539 (99) 5,336,966 (99) 0.10 
Yes       17,643 (0.3)      125 (0.4)       17,518 (0.3)  
Mental disorder 
None 4,040,261 (75) 12,181 (38) 4,028,080 (75) <0.01 
PTSD2  298,571 (6) 4,824 (15)   293,747 (5)  
Other3   727,050 (13) 7,850 (25)     719,200 (13)  
Renal disorder 
No 5,245,383 (97) 30,365 (96) 5,215,018 (97) <0.01 
Yes    92,978 (2) 751 (2)    92,227 (2)  
Note: All numbers are presented as counts and percentages unless otherwise indicated 
1Cells may not add up to total for column due to missing values; 2Chi-square test for differences in proportions for 
categorical variables or Student’s t-test for differences in means for continuous variables; 3Any diagnosis of PTSD, does 
not exclude other pre-existing mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety 
disorders, emotional and behavioral disorders, and mood disorders). Abbreviations: BMI: body mass index; CVD, 
cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human 
immunodeficiency virus; PTSD, post-traumatic stress disorder 
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Table 4.6.  Crude and adjusted odds ratios for a sleep disorder diagnosis in 
FY2010 among United States veterans who sought care in the Veterans Health 
Administration (VHA). 
Characteristic Classification Crude Adjusted
1 
OR (95% CI) OR (95% CI) 
Age Continuous years 0.98 (0.98, 0.98) 0.97 (0.97, 0.97) 
 Sex 
Female ref ref 
Male 1.06 (1.04, 1.09) 1.29 (1.25, 1.33) 
Marital Status 
Not Married ref ref 
Married 1.06 (1.05, 1.08) 1.26 (1.24, 1.28) 
Annual Income <$20,000 ref ref 
≥$20,000 1.11 (1.10, 1.12) 0.95 (0.94, 0.97) 
BMI (kg/m2) 
Normal ref ref 
Overweight 1.39 (1.36, 1.42) 1.36 (1.32, 1.39) 
Obese 2.86 (2.81, 2.91) 2.41 (2.35, 2.47) 
Tobacco Use 
Never ref ref 
Former 0.90 (0.89, 0.92) 0.91 (0.89, 0.93) 
Current 0.95 (0.94, 0.97) 0.74 (0.73, 0.76) 
Asthma  
No ref ref 
Yes 2.46 (2.39, 2.55) 1.66 (1.59, 1.74) 
Cancer No ref ref Yes 1.08 (1.04, 1.09) 1.06 (1.02, 1.10) 
CVD 
No ref ref 
Yes 2.12 (2.09, 2.14) 1.71 (1.68, 1.74) 
COPD 
No ref ref 
Yes 1.85 (1.80, 1.89) 1.67 (1.62, 1.72) 
Diabetes No ref ref Yes 1.56 (1.54, 1.58) 1.06 (1.04, 1.08) 
Fibromyalgia 
No ref ref 
Yes 3.16 (2.96, 3.38) 1.69 (1.56, 1.83) 
GI disease 
No ref ref 
Yes 2.23 (2.20, 2.26) 1.46 (1.44, 1.49) 
Mental disorder 
None ref ref 
PTSD2 4.14 (4.07, 4.21) 2.56 (2.51, 2.62) 
Other3 2.99 (2.95, 3.03) 2.16 (2.12, 2.20) 
Renal disorder 
No ref ref 
Yes 1.43 (1.38, 1.48) 1.24 (1.19, 1.30) 
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1 Each Odds ratio is adjusted for all other variables; 2Any diagnosis of PTSD, 
but may have other mental health disorders; 3Any mental health diagnosis 
other than PTSD (e.g., anxiety disorders, emotional and behavioral disorders, 
mood disorders); ORs for unknown categories were not reported for marital 
status (n = 265,619), income (n = 328,267), BMI (n = 1,103,374), or tobacco 
use (n = 2,361,066). Abbreviations: BMI: body mass index; OR, odds ratio; CI, 
confidence interval; CVD, cardiovascular disease; COPD, chronic obstructive 
pulmonary disease; GI, gastrointestinal; PTSD, post-traumatic stress disorder 
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Table 4.7. Crude and adjusted predictors of primary SLEEP APNEA (Cases) 
relative to subjects without sleep apnea, United States Veterans Health 
Administration (VHA) patients, FY2010 
Characteristic Classification Crude Adjusted
1 
OR (95% CI) OR (95% CI) 
Age Continuous years 0.98 (0.98, 0.98) 0.97 (0.97, 0.97) 
Sex 
Female ref ref 
Male 1.53 (1.48, 1.59) 1.69 (1.62, 1.77) 
Marital Status 
Not Married ref ref 
Married 1.34 (1.32, 1.36) 1.43 (1.40, 1.46) 
Annual 
Income 
<$20,000 ref ref 
≥$20,000 1.23 (1.21, 1.25) 0.99 (0.97, 1.01) 
BMI (kg/m2) 
Normal ref ref 
Overweight 2.62 (2.53, 2.73) 2.28 (2.17, 2.39) 
Obese 8.81 (8.51, 9.13) 6.13 (5.86, 6.41) 
Tobacco Use  
Never ref ref 
Former 0.92 (0.90, 0.94) 0.93 (0.90, 0.95) 
Current 0.77 (0.76, 0.79) 0.69 (0.67, 0.71) 
Asthma 
No ref ref 
Yes 2.79 (2.66, 2.92) 1.76 (1.66, 1.86) 
CVD 
No ref ref 
Yes 2.61 (2.57, 2.65) 1.86 (1.82, 1.90) 
COPD No ref ref Yes 1.98 (1.91, 2.04) 1.95 (1.88, 2.03) 
Diabetes No ref ref Yes 1.98 (1.95, 2.02) 1.14 (1.12, 1.17) 
Fibromyalgia 
No ref ref 
Yes 2.73 (2.48, 3.00) 1.58 (1.41, 1.78) 
GI disease 
No ref ref 
Yes 2.14 (2.10, 2.19) 1.42 (1.38, 1.45) 
HIV Infection 
No ref ref 
Yes 0.62 (0.52, 0.73) 0.70 (0.58, 0.86) 
Mental 
disorder 
None ref ref 
PTSD2 3.35 (3.28, 3.44) 2.00 (1.94, 2.05) 
Other3 2.23 (2.19, 2.27) 1.67 (1.63, 1.71) 
Renal disorder 
No ref ref 
Yes 1.59 (1.52, 1.67) 1.30 (1.23, 1.37) 
1 Estimates are mutually adjusted for all other variables; 2Any diagnosis of 
PTSD, but may have other mental health disorders; 3Any mental health 
diagnosis other than PTSD (e.g., anxiety disorders, emotional and behavioral 
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disorders, and mood disorders); ORs for unknown categories were not 
reported for marital status (n = 265,619), income (n = 328,267), BMI (n = 
1,103,374), and tobacco use (n = 2,361,066). Abbreviations: BMI: body mass 
index; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; 
COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, 
human immunodeficiency virus; PTSD, post-traumatic stress disorder 
 
118 
 
Table 4.8. Crude and adjusted predictors of new INSOMNIA (Cases) relative to 
subjects without insomnia, United States Veterans Health Administration (VHA) 
patients, FY2010 
Characteri
stic Classification 
Crude Adjusted1 
OR (95% CI) OR (95% CI) 
Age Continuous years 0.98 (0.98, 0.98) 0.98 (0.98, 0.98) 
Annual 
Income 
<$20,000 ref ref 
≥$20,000 0.92 (0.91, 0.94) 0.87 (0.84, 0.89) 
BMI 
(kg/m2) 
Normal ref ref 
Overweight 1.00 (0.98, 1.03) 1.03 (0.99, 1.07) 
Obese 0.99 (0.97, 1.02) 0.90 (0.87, 0.94) 
Tobacco 
Use  
Never ref ref 
Former 0.85 (0.82, 0.87) 0.87 (0.84, 0.90) 
Current 1.21 (1.17, 1.25) 0.77 (0.74, 0.80) 
Asthma 
No ref ref 
Yes 1.84 (1.71, 1.99) 1.27 (1.15, 1.40) 
Cancer 
No ref ref 
Yes 1.11 (1.05, 1.17) 1.16 (1.09, 1.25) 
CVD No ref ref Yes 1.49 (1.46, 1.52) 1.46 (1.41, 1.51) 
COPD 
No ref ref 
Yes 1.53 (1.46, 1.61) 1.24 (1.17, 1.31) 
Diabetes 
No ref ref 
Yes 0.92 (0.90, 0.95) 0.84 (0.81, 0.88) 
Fibromyal
gia 
No ref ref 
Yes 3.50 (3.12, 3.92) 1.63 (1.42, 1.87) 
GI 
disease 
No ref ref 
Yes 2.27 (2.21, 2.33) 1.50 (1.45, 1.55) 
Mental 
disorder 
None ref ref 
PTSD2 6.30 (6.09, 6.51) 4.20 (4.03, 4.37) 
Other3 5.15 (5.01, 5.29) 3.52 (3.40, 3.64) 
Renal 
disorder 
No Ref ref 
Yes 1.17 (1.09, 1.28) 1.23 (1.13, 1.34) 
1 Estimates are mutually adjusted for all other variables; 2Any diagnosis of 
PTSD, but may have other mental health disorders; 3Any mental health 
diagnosis other than PTSD (e.g., anxiety disorders, emotional and behavioral 
disorders, and mood disorders); ORs for unknown categories were not 
reported for marital status (n = 265,619), income (n = 328,267), BMI (n = 
1,103,374), and tobacco use (n = 2,361,066). Abbreviations: BMI: body mass 
index; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; 
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COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; PTSD, 
post-traumatic stress disorder 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
 
Table 4.9. Crude and adjusted predictors of new OTHER SLEEP DISORDER 
(Cases)  relative to subjects without other sleep disorders, United States 
Veterans Health Administration (VHA) patients, FY2010 
Characteristic Classification Crude Adjusted
1 
OR (95% CI) OR (95% CI) 
Age Continuous years 0.98 (0.98, 0.98) 0.98 (0.98, 0.98) 
Marital Status 
Not Married ref ref 
Married 1.05 (1.02, 1.07) 1.27 (1.23, 1.31) 
Annual Income <$20,000 ref ref ≥$20,000 1.10 (1.07, 1.12) 0.94 (0.91, 0.97) 
BMI (kg/m2) 
Normal ref ref 
Overweight 1.31 (1.26, 1.36) 1.31 (1.25, 1.38) 
Obese 2.26 (2.19, 2.34) 1.95 (1.86, 2.04) 
Tobacco Use 
Never ref ref 
Former 0.90 (0.88, 0.93) 0.92 (0.88, 0.95) 
Current 1.02 (0.99, 1.05) 0.76 (0.73, 0.80) 
Asthma  
No ref ref 
Yes 2.59 (2.41, 2.79) 1.66 (1.53, 1.81) 
Cancer No ref ref Yes 1.17 (1.10, 1.24) 1.11 (1.03, 1.19) 
CVD 
No ref ref 
Yes 2.07 (2.02, 2.12) 1.65 (1.60, 1.71) 
COPD 
No ref ref 
Yes 1.95 (1.86, 2.04) 1.61 (1.52, 1.71) 
Diabetes No ref ref Yes 1.52 (1.48, 1.56) 1.05 (1.01, 1.09) 
Fibromyalgia 
No ref ref 
Yes 4.19 (3.74, 4.70) 1.89 (1.65, 2.17) 
GI disease 
No ref ref 
Yes 2.50 (2.43, 2.56) 1.54 (1.49, 1.60) 
Mental disorder 
None ref ref 
PTSD2 5.43 (5.25, 5.62) 3.16 (3.04, 3.29) 
Other3 3.61 (3.51, 3.71) 2.44 (2.36, 2.53) 
Renal disorder No ref ref Yes 1.40 (1.30, 1.50) 1.19 (1.09, 1.29) 
1 Estimates are mutually adjusted for all other variables; 2Any diagnosis of 
PTSD, but may have other mental health disorders; 3Any mental health 
diagnosis other than PTSD (e.g., anxiety disorders, emotional and behavioral 
disorders, and mood disorders); ORs for unknown categories were not 
reported for marital status (n = 265,619), income (n = 328,267), BMI (n = 
1,103,374), and tobacco use (n = 2,361,066). Abbreviations: BMI: body mass 
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index; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; 
COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; PTSD, 
post-traumatic stress disorder 
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Chapter 5 
Case-Control Study of Candidate Gene Methylation and Adenomatous 
Polyp Formation3 
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5.1 Abstract 
Introduction: Colorectal cancer (CRC) is one of the most common and 
preventable forms of cancer, yet it remains the second leading cause of cancer-
related death. Colorectal adenomatous polyps (adenomas) are precursor lesions 
that develop in 70-90% of all CRC cases. Identification of peripheral biomarkers 
for adenomas would help to enhance efficiency of screening efforts. This 
exploratory study examined the methylation status of 20 candidate markers in 
peripheral blood leukocytes to determine whether epigenetic modification of 
these genes was associated with adenoma case status. Materials and 
Methods: Patients recruited from a local endoscopy clinic provided informed 
consent, and completed an interview to ascertain demographic, lifestyle, and 
adenoma risk factors. Cases were defined as individuals with a 
histopathologically confirmed adenoma, and controls included patients with a 
normal colonoscopy, or those with histopathological findings not requiring 
heightened surveillance (normal biopsy, hyperplastic polyp).  Methylation-specific 
polymerase chain reaction was used to characterize candidate gene promoter 
methylation. Odds ratios and 95% confidence intervals (OR, 95% CI) were 
calculated using unconditional multivariable logistic regression to test the 
hypothesis that candidate gene methylation differed between cases and controls, 
after adjustment for potential confounding factors.  Results: Complete data were 
available for 107 participants; 36% had adenomas (men: 40%, women: 31%).  
Hypomethylation of the MINT1 locus (OR: 5.3, 95% CI: 1.0-28.2), and the PER1 
(OR: 2.9, 95% CI: 1.1-7.7) and PER3 (OR: 11.6, 95% CI: 1.6-78.5) clock gene 
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promoters was more common among adenoma cases. While specificity was 
moderate to high for the three markers (71-97%), sensitivity was relatively low 
(18-45%). Discussion: Follow-up of these epigenetic markers is suggested to 
further evaluate their utility for adenoma screening or surveillance.  
5.2 Introduction 
Despite recent decreases in colorectal cancer (CRC) incidence and 
associated mortality, CRC remains one of the  most common and deadly forms 
of cancer in the United States, with a lifetime risk for diagnosis of 5%.1  
Colonoscopies not only present an opportunity screen for CRC, but to also 
remove colorectal adenomas (precursor lesion for CRC), thus facilitating primary 
CRC prevention.  However, in 2012, the Centers for Disease Control and 
Prevention reported that CRC screening rates among eligible men and women 
fell far short of the Healthy People 2020 target of 70.5%.123  Only ~25-60% of 
eligible adults undergo CRC screening due to socioeconomic, racial, geographic, 
or other barriers that contribute to a lack of compliance,229-232 highlighting a need 
for accessible screening methods.  
Stool-based tests (fecal occult blood test [FOBT] or the fecal 
immunochemical test [FIT]) have been developed as a less invasive alternative 
to colonoscopies.  Despite high sensitivity for CRC, this screening modality has 
reduced adenoma detection sensitivity (FOBT: 7-23%; FIT: 13-26%) compared to 
a colonoscopy, which has the ability to detect 73-94% of adenomas.233-236 A 
recent meta-analysis of stool-based DNA, another alternative CRC screening 
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strategy, found that these tests may provide a diagnostic benefit for CRC or 
advanced adenoma detection in high-risk, but not average-risk, populations,237 
and is a cost-prohibitive screening tool.238 Interestingly, methylation markers 
provided better diagnostic performance for adenoma detection than did 
mutations (67% sensitivity vs. 10% sensitivity, respectively),237 FOBT, or FIT 
(≤26%).235, 236 Because blood-based measures can increase compliance with 
CRC screening and surveillance, genetic and epigenetic biomarkers in circulation 
are under active investigation.239, 240  
The polyp→carcinoma sequence within the colon has been widely 
studied, and both genetic87 and epigenetic241 alterations have been observed at 
different stages of CRC development. An extensive literature describes the 
genetic lesions involved in this process, and an estimated 30% of CRC cases 
can be attributed to heritable factors.242 However, highly penetrant genetic 
markers account for only ~5% of CRC cases.242 Epigenetic modification 
represents an important and early event in the adenoma→CRC sequence. 
Methylation within gene promoter regions can lead to gene silencing and reduced 
gene expression.241, 243 Promoter methylation of genes responsible for tumor 
suppression, DNA repair, or other critical pathways involved in the 
carcinogenesis process may reduce their expression and thereby promote tumor 
development. Aberrant methylation of several CRC-related loci (e.g., MLH1, 
CDKN2A [p16], MINT1, MINT2, MINT31) corresponds to a specific CRC subtype, 
the CpG island methylator phenotype (CIMP), 132 which occurs in 0-44% of 
adenomas,133, 134 and up to 50% of CRCs.244  However, associations between 
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aberrant gene methylation and cancer have not always been consistent, possibly 
due to differences in the various molecular pathways leading to CRC 
development.245 For example, MINT1, MINT2, and MINT12 are putative tumor 
suppressors, but were less methylated in adenomas from individuals with 
multiple polyps relative to those with at least one polyp and high microsatellite 
instability (MSI-H) in their adenomas.245 Also, hypermethylation of MINT31 has 
been associated with increased CRC risk,246 but also has been associated with 
longer disease-free survival among CRC patients.247  These findings highlight the 
need for more research on the relationship between promoter gene methylation 
and adenoma development or progression. 
Few studies have examined epigenetic markers in peripheral blood 
leukocytes (PBLs) for early detection of adenomas or CRC. Global 
hypomethylation of retrotransposable (LINE-1) elements in PBLs has been 
associated with increased odds of adenoma formation in some studies,248-251 and 
other studies targeting candidate genes also have had some success identifying 
patients with adenomas or CRC, although the results among these investigations 
have been mixed.240, 252-256 Epigenetic changes in PBLs may reflect those 
observed in target tissues257 or may serve as biologically relevant indicators of 
behavioral, environmental, psychosocial, or lifestyle factors that contribute to 
adenoma formation.241, 258   
This exploratory case-control study tested the hypothesis that adenoma 
case status was associated with aberrant methylation of candidate gene 
promoters in PBL DNA relative to control colonoscopy patients. A panel of twenty 
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candidate gene markers was selected for evaluation following a literature review 
based on their potential role in adenoma formation or CRC risk: APC, BRCA1, 
CDKN2AP16, CYP24A, CYP27B1, ER-alpha, IGF2, MGMT, MINT1, MLH1, 
NGFR, PER1, PER2, PER3, SEPT9, SFRP4, SFRP5, TIMP3, TMEFF2, and 
WIF1.105, 240, 241, 259-264  
5.3 Materials and Methods 
The Epigenetics and Diet in the Carcinogenesis Process (EDCaP) study 
was performed among patients undergoing a colonoscopy procedure at a 
community endoscopy center in Columbia, SC.265 Prior to their clinic visit, 138 
participants provided informed consent, including permission to access medical 
records, in accordance with the University of South Carolina’s Institutional 
Review Board approval process. Participants completed a questionnaire to 
provide information on: demographic (sex, marital status, income, race/ethnicity), 
lifestyle (smoking history, diet, physical activity), and occupational (employment 
status, job industry, type of shift, history of shiftwork) factors, as well as personal 
and family medical history (ever being diagnosed with other diseases, personal 
cancer history, family CRC history).  
A total of 256 subjects scheduled for a screening or surveillance 
colonoscopy were eligible to participate, and 154 were enrolled.  Among those 
subjects, 138 had complete questionnaire data, and 107 of those participants 
provided biospecimens for methylation analysis (Figure 5.1).  Information on 
cecal intubation, visualization of the appendix, and bowel preparation were 
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abstracted from the patient’s medical record to evaluate colonoscopy quality. 
Cases were defined as individuals with a complete colonoscopy procedure and 
at least one histologically confirmed adenoma based on review by a consulting 
clinical pathology laboratory. Controls included patients with a complete 
procedure and normal findings, or histopathological findings not requiring 
heightened surveillance (normal biopsy, hyperplastic polyp).266  
Biological sample collection and laboratory assays 
An on-site nurse drew 40cc of blood from each participant for DNA and 
RNA extraction.  DNA samples obtained from blood were aliquoted and archived 
for future studies in genetic and epigenetic factors in colorectal polyp formation. 
Normal gastrointestinal (GI) tissue and a polyp samples (if available) were also 
extracted during the colonoscopy procedure.  All biological samples were stored 
at -80oC after collection.   
Methylation assays 
A peripheral whole blood sample was collected from each participant 
using vacutainers containing EDTA anticoagulant. Genomic DNA was isolated 
using the PUREGENE genomic DNA purification kit (Gentra Systems, 
Minneapolis, MN) according to the manufacturer’s protocol from peripheral whole 
blood, normal GI tissue, and polyp tissue.  Sodium bisulfite conversion of DNA 
was performed using EpiTect kits (QIAGEN, Germantown, MD, USA). Briefly, 
DNA (2 µg) was added to the reaction buffer and bisulfite DNA conversion was 
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conducted in a Bio-Rad S1000 thermal cycler (Bio-Rad Laboratories, Hercules, 
CA, USA) using the manufacturer’s suggested program for the conversion 
reaction. Converted DNA was eluted from a spin column in TE buffer and either 
used immediately or stored at –20°C.  DNA oligonucleotides for primer pairs 
were purchased from Integrated DNA Technologies (Coralville, IA, USA, Table 
5.1). To ensure that the polymerase chain reaction (PCR) primers were specific 
for the detection of methylated DNA, a control human DNA set (EpiTect Control 
DNA, QIAGEN Sciences, Germantown, MD) containing positive (bisulfite 
converted, 100% methylated) and negative (bisulfite converted, 0% methylated) 
control DNA was used. To quantify methylation specific PCR (MSP) results, the 
QIAxcel system was used (QIAGEN Sciences, Germantown, MD), which utilizes 
a multiplexed fluorescence detection method with a resolution of 3-5 bp for DNA 
fragments. The detection sensitivity of QIAxcel system was 0.1 ng/μl DNA in 
undiluted amplification reactions. The QIAxcel system was equipped with the 
BioCalculator software that produces a tabular display of a variety of peak 
properties, including number of peaks as well as the height, width, and area of 
each peak. The height of the peak was used for separation of the results into 
three methylation categories: high (peak height >0.30), medium (peak height 
0.29-0.05), and low (peak height <0.05), or none (no methylation detected). 
Results were categorized as either unmethylated or methylated (combination of 
medium/low, and high methylation categories). The methylation status of each 
sample was normalized via a two-step process. First, a NanoDrop™ Lite 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) was used to 
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measure concentrations of the DNA templates.  Subsequent experiments used 
the same amount of DNA template for each MSP reaction. To facilitate 
quantification, equal volumes of the MSP products were loaded on the QIAxcel 
system for analysis. Second, BRCA1 gene methylation was used as an internal 
standard since the same amount of DNA template had extremely high 
methylation in each sample.  The measured peak height of BRCA1 methylation 
was then used to normalize the methylation of the genes of interest for each 
sample.  All methylation assays were performed blinded to case status. 
Real-time quantitative PCR (qPCR) 
RNA was extracted from PAXgene tubes using PAXgene Blood RNA Kit 
from QIAGEN (Germantown, MD, USA).  RNA quality was checked via Agilent 
Bioanalyzer 2100 and concentration was quantified on NanoDrop.  cDNA was 
synthesized from total RNA using gene-specific primers according to the Verso 
cDNA Kit (Abgene, Rochester, New York).  Reverse transcriptase reactions 
contained 1 μg of total RNA (1-5 μl of total RNA), 4 μl 5X cDNA synthesis buffer, 
1 μl 5 μM dNTP mix, 1 μl 400 ng/μl  random hexamers, 1 μl RT Enhancer, 1 μl 
Verso Enzyme Mix, and a variable amount of PCR grade water to have a total of 
a 20 μl.  The 20 μl reactions were incubated in an MJ Research PTC-225 
Thermo Cycler in a 96-well plate for 30 min at 42°C, 2 min at 95°C, and then held 
at 4°C.  cDNAs were stored at -20 oC.  
Gene-specific primers were created using Primer3 software.  Forward and 
reverse sequences were confirmed for their presence within exons and lack of 
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single nucleotide polypmorphisms using NCBI’s Basic Local Alignment Search 
Tool (BLAST).  PCR cycling information is found in Table 5.2.  All reactions were 
performed in singleplex mode.  Each reaction contained 10 μl 2x SYBR Green 
PCR master mix (Bio-Rad Laboratories, Hercules, CA), 2 μl of each primer, 0.5-2 
μl of cDNA template, and a variable amount of PCR grade water to have a total 
reaction amount of 20 μl. The standard curve method was employed and β-actin 
was used as the endogenous control to determine levels of expression of cDNA 
in study participants.  A two-fold 10-point serial dilution was created through the 
use of diluted PCR products of β-actin and markers who presented an 
association with polyp status.  The standard curve produces a linear relationship 
between number of threshold cycles (Ct) and the initial known amounts of cDNA, 
allowing the determination of the cDNA concentration of unknown samples based 
on their Ct value, thereby also giving the number of mRNA copies for each gene 
present in unknown samples.  The threshold cycle (Ct) is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold.  
Each sample was analyzed in duplicate, with a negative template control 
included in each run to check for DNA contamination. 
Statistical analysis 
Statistical analyses were performed using SAS® version 9.2 (Cary, NC). 
Frequency distributions of study variables by case status were examined using 
the chi-squared test for differences between proportions. Student’s t-test was 
used for comparisons among cases and controls for normally distributed 
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continuous variables.  In instances of non-normally distributed continuous 
variables, the Wilcoxon–Mann–Whitney test was used to compare cases and 
controls. Unconditional multiple logistic regression was used to estimate odds 
ratios (OR) with 95% confidence intervals (CIs), comparing candidate gene 
methylation among adenoma cases relative to controls, after adjustment for the 
effects of potential confounding factors.  Variables considered for inclusion in 
adjusted models were known or suspected adenoma or CRC risk factors (age, 
sex, race, body mass index [BMI], CRC family history, smoking history, work-
related factors, diet, vitamin and supplement use, physical activity, 
sociodemographic characteristics [income, education], personal history of 
inflammatory bowel disease), and variables that differed among participants and 
non-participants (fruit and vegetable intake). Final models included variables that 
were statistically significant (p≤0.05) in the saturated model, or whose inclusion 
produced ≥10% change in the parameter estimate for the methylation marker of 
interest.  Each candidate gene was selected a priori, thus no correction for 
multiple testing was performed.267 Due to sparse data, individuals who received a 
colonoscopy due to symptoms (presence of gastrointestinal bleeding, fecal occult 
blood, iron deficiency, or constipation, n=3) were grouped with patients 
undergoing a screening colonoscopy.  Sensitivity analyses were conducted to 
determine whether associations were driven by data from people with a right-
sided polyp, as right-sided hyperplastic polyps have been linked with the serrated 
adenoma, MSI-H CRC pathway.268  Sensitivity and specificity, and positive and 
negative predictive values (PPV, NPV, respectively) were calculated for 
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methylation markers with a statistically significant association with adenoma case 
status.   
To evaluate agreement of DNA methylation levels found in PBLs, normal 
colon tissue, and polyp tissue, the Kappa agreement statistic was used, which 
takes on a value of 0 to 1, ranging to no agreement to complete agreement.  
Also, linear regression was used to assess how much variation in gene 
expression was attributable to methylation status.   
Regarding gene expression and adenoma formation, unadjusted logistic 
regression was also used to examine the crude association between expression 
levels in PBLs and adenoma formation.  To detect the true association between 
expression levels in PBLs of these genes and adenoma formation, multiple 
logistic regression techniques were used and confounders were included into the 
model.  Potential confounders were screened for in a manner similar to the 
protocol for determining the relationship between methylation levels and 
adenoma formation.  Spearman correlations were used to assess the relationship 
between gene expression levels across PBLs, normal tissue, and polyp tissue, 
where values range from -1 to +1, where a negative sign indicates an inverse 
relationship, and a positive sign signifies a positive relationship.   All associations 
were considered statistically significant at the p≤0.05 level.   
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5.4 Results 
Complete data were obtained from 107 of the 154 patients (70%) who 
consented to participate (Figure 5.1). The mean age among participants was 60 
years old (standard deviation [SD]: ±9 years).  European Americans (EAs) 
comprised the majority of subjects (73%), and 46% of the population was female 
(Table 5.3). With regard to colonoscopy quality, most participants (96%) had a 
bowel preparation that was rated as fair or better, and the cecal intubation rate 
was 100%. No cases of advanced adenoma (>10 mm in size in any dimension, 
high-grade dysplasia, villous histology), serrated adenomatous polyps, or CRC 
were identified. The detection rate for any polyp was 65%, and the adenoma 
detection rate was 36% (male: 40%, female: 31%), with a mean of 0.7 (SD: ±0.5) 
adenomas per person. All procedures with a right-sided hyperplastic polyp (n=7) 
were synchronous with adenoma detection in the same patient.  Cases were 
more likely to be smokers compared to controls (68% vs. 45%, p=0.02), and 
were less likely to ever regularly take vitamin D supplements (5% vs. 29%, p 
<0.01).  Though not statistically significant, cases also had a tendency to be ≥65 
years of age (p=0.07), married (p=0.16), to currently drink alcohol (p=0.13), or to 
ever regularly take a multivitamin (p=0.07), or vitamin C (p=0.15) compared to 
controls.  
Effect of methylation in PBLs on adenoma formation 
Figures 5.2 and 5.3 present agarose gel images of MSP products for 
PER1, PER2, PER3 and MINT1, respectively, in a subsample of participants.  
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After adjustment for potential confounding factors, hypomethylation (i.e., no 
methylation detected) in the MINT1 (methylated in tumor1; OR: 5.3, 95% CI: 1.0-
28.2) locus, and the PER1 (Period 1; OR: 2.9, 95% CI: 1.1-7.7), and PER3 
(Period 3; OR: 11.1, 95% CI: 1.6-78.5) clock gene promoters was associated 
with an increased odds of adenoma detection (Table 5.4).  When seven subjects 
with right-sided hyperplastic polyps were excluded, sensitivity analyses yielded 
the following results for hypomethylation of MINT1 (OR: 5.0, 95% CI: 0.9-27.9), 
PER1 (OR: 2.8, 95% CI: 1.1-7.5) and PER3 (OR: 9.8, 95% CI: 1.4-70.6, data not 
shown).  The time of day of sample collection or working at least one year of shift 
work did not modify the relationship between clock gene (PER1, PER3) promoter 
methylation and adenoma case status (data not shown). 
The sensitivity, specificity, PPV, and NPV for hypomethylation of MINT1, 
PER1, PER3, and their combinations are presented in Table 5.5. PER1, PER3, 
or MINT1 hypomethylation correctly identified 16% to 45% of individuals with 
adenomas. Among patients without adenomas, specificity ranged from 71% to 
97%. When evaluated in combination, hypomethylation of these genes yielded 
sensitivities ranging from 53% to 74%, and specificities ranging from 9% to 36% 
(Table 5.5). Among the possible combinations, PER3/MINT1 yielded the highest 
sensitivity (74%), and the PER1/PER3/MINT1 combination had the highest 
specificity (36%).  
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Concordance of methylation in PBLs, normal GI tissue, and polyp tissue 
MINT1, PER1, and PER3 did not exhibit significant agreement within 
PBLs (Table 5.6).  No significant concordances were observed when comparing 
PBLs with polyp tissue and normal tissue with polyp tissue.  
Effect of methylation on mRNA expression in PBLs, normal GI tissue, and polyp 
tissue 
Table 5.7 presents information on PER1 and PER3 mRNA expression by 
their respective methylation status.  Although PER1 expression in normal GI 
tissue was lower in methylated samples compared to hypomethylated samples 
(1.04 fold change in PER1 expression vs 1.01 fold change in PER1 expression), 
this finding was only marginally statistically significant (p-value: 0.06).  PER1 
methylation in normal GI tissue also explained the largest amount of variance 
(approximately 26%) across the three tissue types and among the three markers.  
No significant differences in expression by methylation status were found in 
PBLs, normal GI tissue, and polyp tissue. 
Effect of mRNA expression in PBLs on adenoma formation 
Fold change in expression for PER1 and PER3 by case status are found 
in Table 5.8.  Adjusted analyses show that for a one-unit increase in expression 
in PER1 and PER3, there was reduction in the odds of having an adenoma; 
however, these findings were not statistically significant. 
Correlation of mRNA expression in PBLs, normal GI tissue, and polyp tissue 
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 Table 5.9 presents Spearman correlations in expression levels across 
PBLs, normal GI tissue, and polyp tissue.  Significant correlations were seen only 
between normal GI and polyp tissues, with correlation coefficients ranging from 
0.62 – 0.93.  No significant correlations within PBLs and between PBLs and any 
tissue were detected. 
5.5 Discussion 
Identification of novel genes associated with adenoma risk may lead to a 
better understanding of carcinogenesis pathways and subsequently improve 
CRC screening and prevention efforts. Several studies have targeted blood-
based epigenetic biomarkers to identify CRC cases, and only a few have used 
this approach to evaluate the formation of colorectal adenomas, which serve as 
precursor lesions for 70-90% of CRC cases. This exploratory case-control study 
found that hypomethylation in the MINT1 locus and the PER1 and PER3 clock 
gene promoters was more common among adenoma cases relative to controls. 
Additional analyses showed minimal agreement between PBLs and both normal 
tissues and polyp tissues, though few paired samples were available.  However, 
strong, positive correlations were observed across normal tissues and polyp 
tissues, suggestive that genetic/epigenetic changes that occur during the 
carcinogenesis process can also be observed in normal tissue.  Furthermore, 
promoter methylation did not fully explain the variation in expression of their 
respective gene, nor did gene-specific expression yield an association with case 
status. 
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The MINT1 locus is one of several markers used to characterize CIMP 
status among CRC cases.132, 269 Aberrant DNA methylation is considered an 
early event in the adenoma→carcinoma sequence,241 and changes in CIMP 
markers have been identified in aberrant crypt foci and in colorectal 
adenomas.134, 270-272 MINT methylation in adenomas or associated CRC tissue 
has been linked with down regulation of mismatch repair (MLH1) protein 
expression, microsatellite instability, and BRAF (V600E) mutation relative to 
normal tissue.273 However, prevalence of the CIMP phenotype is variable in 
adenomas (0-44%)133, 134 as well as normal gastrointestinal tissues.274 To our 
knowledge, the MINT1 locus has not been examined as a circulatory marker for 
adenoma risk and thus results obtained in the present study require confirmation.   
Two of the three candidate genes associated with adenomas in this study 
(PER1, PER3) are members of the clock gene family. Clock gene expression is 
involved in the maintenance of endogenous circadian rhythms, as well as the 
regulation of cellular processes that are considered hallmarks of carcinogenesis 
(cell cycle control, DNA damage response, apoptosis).275-277  In colon and other 
cancer cell lines, PER1 insertion can activate cell cycle checkpoint proteins, 
sensitize cells to ionizing radiation-induced apoptosis, and exert an 
antiproliferative effect.116 A hypomethylation zone in the PER1 promoter has 
been associated with uncoupling of PER1 transcription from promoter 
methylation in cervical cancer cells,243 and may have played a role in the lack of 
association between methylation and expression in PER1 in the present study. 
Structural or epigenetic variability in E-boxes, particularly the E-box closest to the 
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promoter, may play a role in these processes, and mutations within this element 
may lead to a reduction of PER1 promoter activity.243, 278  PER1 and PER2 
mutations occur in human colorectal tumors,18 and PER expression is reduced in 
colorectal adenomas or tumors relative to normal tissue.104, 279-283 In mice, a 
mutation in the PER2 gene (PER2m/m) results in altered diurnal rhythms, 
deregulated expression of cell cycle control genes, tissue hyperplasias and 
tumors,94, 284 and increased colon polyp formation.285 Polymorphisms in the 
PER3 gene have been associated with increased odds of adenoma formation,283 
and aberrant methylation of PER genes has been observed among leukemia and 
other cancer patients.30, 33, 113, 114, 286  However, to the authors’ knowledge, no 
studies have examined epigenetic modifications in the PER or other clock genes 
in relation to adenoma formation.277, 283  
Clock genes facilitate the circadian expression of ~5-10% of the 
mammalian transcriptome, and clock-controlled genes include known tumor 
suppressors (e.g., p21, Chk2, XPA, ATM) and oncogenes (e.g., β-catenin, c-Myc, 
WEE-1).276 Circadian patterns of clock-controlled gene expression occur via 
rhythmic epigenetic modification of histones and chromatin.276, 277, 287  Histone 
modification may play a role in tumorigenesis,288 although few studies have 
examined the role of circadian histone modifications in relation to adenoma or 
CRC development.277 Animal model studies have suggested that gene regulation 
in the mouse liver is mediated by clock gene interactions with the histone 
methyltransferase, MLL3 (mixed lineage leukemia 3), a tumor suppressor that 
has been associated with CRC and other cancers.287, 289 PER complexes recruit 
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histone-modifying proteins that help orchestrate the circadian expression of core 
clock genes, although it is not known whether this function extends to clock-
controlled, cancer-related genes.277, 290   
This study had several noteworthy strengths and limitations. Strengths 
included the valid ascertainment of adenoma cases and statistical adjustment for 
known and suspected adenoma risk factors.  The sample size limited power and 
precluded examination of the relationship between methylation patterns and 
adenoma status within factors that may influence epigenetic processes and 
detecting differences in expression by both methylation and case status. 
Although each candidate gene was selected a priori following a literature review, 
this study was exploratory in nature and the potential for spurious or false 
positive findings cannot be eliminated. Also, methylation among specific white 
blood cell subsets was not quantified. Methylation patterns do not always vary 
among T-cell subsets, and the extent to which methylation differs among PBL 
subtypes for PER1, PER3, or MINT1 is not known. This cellular heterogeneity 
could play a role in the poor agreement in methylation between PBLs and tissues 
within subject and lack of a relationship between methylation and expression 
found in the present study, phenomena that have been previously observed.291-
293  It is further supported by the strong correlations in expression between 
normal and polyp tissues, but not between PBLs and normal and/or polyp 
tissues.  Nonetheless, a lack of standardization for these potential differences 
represents a study uncertainty.258, 294, 295  The pattern of promoter 
hypomethylation that was observed for PER1 and PER3 in this study was not 
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consistent with that expected for a tumor suppressor. Other studies that targeted 
clock genes in PBLs indicated that DNA hypomethylation was associated with 
breast cancer diagnoses (CLOCK),296 or with advanced stage (II-IV) breast 
cancer (TIMELESS),297 whereas promoter hypermethylation was associated with 
postmenopausal breast cancer (CRY2),296 and with chronic myeloid leukemia 
(PER3)33 relative to controls. The mechanism through which PER1 or PER3 
gene methylation may impact adenoma formation is unknown and may depend 
on tissue context, timing of expression relative to other cellular processes, 
location of epigenetic changes within the gene, or other factors that may disrupt 
clock gene expression, such as shift work.276, 277  Time of day of sample 
collection in the present study did not modify the relationship between PER1 or 
PER3 promoter methylation and adenoma case status (data not shown). 
However, more detailed genetic and epigenetic studies of the duration, phase 
and amplitude of PER1 and PER3 expression in conjunction with cancer-related, 
clock-controlled genes are suggested to help elucidate their role in adenoma 
formation. Methylation of non-target tissue (i.e., PBLs) can be influenced by 
psychosocial or environmental stressors, or lifestyle risk factors (e.g., diet, 
smoking). For example, cancer risk factors that can alter clock gene expression, 
such as shiftwork or sleep disturbances, also may exert epigenetic effects.298-302  
Global DNA hypomethylation in PBLs was recently observed among night 
workers relative to those working days, and among the clock genes examined, 
the largest differences in hypomethylation were observed within PER3 loci.300 In 
the present study, neither the proportion of current shiftworkers nor those who 
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engaged in at least one year of shiftwork (3% and 42% of the study population, 
respectively, Table 1) differed by adenoma case status, or by MINT1, PER1, or 
PER3 methylation status (data not shown).  Future studies would need to 
consider the role of these factors when examining the independent effect of 
promoter methylation status on health outcomes. 
In summary, the identification of peripheral epigenetic markers that are 
associated with adenoma risk may lead to a deeper understanding of colorectal 
carcinogenesis and facilitate CRC prevention. Results from this study suggest 
the need for follow-up blood-based monitoring of MINT1, PER1, and PER3 to 
examine their role in adenoma formation and CRC risk, along with an 
examination in the relationship between their corresponding normal and polyp 
tissues. 
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Figure 5.1. Flow chart of participant recruitment and participation in the 
Epigenetics and Diet in the Carcinogenesis Process (EDCaP) study. 
 
 
 
 
Contacted:
n=256
Consented:
n=154
Survey Data:
n=138
Complete Data:
n=107
Controls: 
n=69
No polyp or Normal 
Finding:   
n=37
Hyperplastic Polyp: 
n=32
Adenoma Cases: 
n = 38
No Blood or Poor 
Quality DNA:
n=31
Incomplete Survey 
Data:
n=16
Declined:
n=102
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Figure 5.2. QIAxel gel analysis for the methylation-specific polymerase chain reaction 
(MSP) of PER1 (A) and PER2 (B). Black arrows indicate MSP products of PER1 and 
PER2. (A) Lanes 1 and 2 represent a positive control and negative control, respectively.  
Lanes 3 through 10 represent a subsample of participants and PER1 methylation. 
Subjects #28 and #48 exhibited no methylation; subjects #49, #63, #71, #72, and #74 
exhibited low/medium methylation; and subject #48 exhibited high methylation. (B)  
Lanes 1 through 10 represent a subsample of participants and PER2 methylation.  All 
subjects with the exception of subjects #75 and #84 exhibited low/medium methylation.  
Subjects #75 and #84 had high methylation.
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Figure 5.3. QIAxel gel analysis for the methylation-specific polymerase chain reaction 
(MSP) of PER3 (A) and MINT1 (B). Black arrows indicate MSP products of PER3 and 
MINT1. (A) Lanes 1 through 10 represent a subsample of participants and PER3 
methylation. Subjects #85 and #112 exhibited no methylation; subjects #83, #84, #90, 
#91 exhibited low/medium methylation; and subjects #75, #102, #117, and #132 
exhibited high methylation.  (B)  Lanes 1 through 10 represent a subsample of 
participants and MINT1 methylation.  Subject #112 had no methylation; subjects #83, 
#84, #85, #90, #91, and #102 exhibited low/medium methylation; and subjects #75, 
#117, and #132 exhibited high methylation.
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Table 5.1.  Primers for Methylation-Specific PCR 
Gene Name Forward (5’ -> 3’) Reverse (5’ -> 3’) Amplicon (bp) 
APC TATTGCGGAGTGCGGGTC TCGACGAACTCCCGACGA 98 
BRCA1 TCGTGGTAACGGAAAAGCGC AAATCTCAACGAACTCACGCCG 86 
CDKN2A (p16) TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 150 
CYP24 TGTTGATTTTGTGAGTTTAATTCGA AAACTTTAATATCCGCCCTACGTA 142 
CYP27B1 GGTAGTATTTTTCGTTTGTTTGC TCAAAACCTCTCTAATCATCTCGAT 139 
ER-alpha ACGAGTTTAACGTCGCGGTC ACCCCCCAAACCGTTAAAAC 110 
IGF2 TAAGTTTGGTTTAGATTCGG AAACCCCTAAACTCGAACGA 197 
MGMT TTTCGACGTTCGTAGGTTTTCGC GCACTCTTCCGAAAACGAAACG 81 
MINT1 GTATTTGTTATTTGGTTTTTGTCGT GCTCCTCAATTCTAATTAATCGAA 121 
MLH1 ACGTAGACGTTTTATTAGGGTCGC CCTCATCGTAACTACCCGCG 115 
NGFR GAGGGTTTATGTAGATACGA TATAATCGTACACTTACGTA 176 
PER1 ATTTAGGTTTACGTGCGTTC GATTAACTAAAAATCTCTTCCCGAC 95 
PER2 GTTTTTGGTCGGTGGTCGG CGAAACTCCTACGCACCTCC 92 
PER3 CGTCGGTTTGTTGGGATTG AAACCGACTCCGCAAACC 160 
SEPT9 TTTTTTTATTATTGTTTGCGTTATTC CAAATAATCATTTATTCTCCCTACG 112 
SFRP4 AAGATTTGGCGTTGGGCGGGACGTTC ACTCCAACCCGAACCTCGCCGTACG 120 
SFRP5 TCGAGGATTTAGCGGTAAGTATC GAAACCGAAAACAAAAAATAACG 136 
TIMP3 TTCGTTATGTCGTTTGTTTTTTTC AATAACCCTACGTTCCTTACTCGA 137 
TMEFF2 GTATTATCGGATAGTCGAGTTTCGA AATAATAACTCCTATTCCTCCTCCG 142 
WIF1 TCGTGGTAACGGAAAAGCGC AAATCTCAACGAACTCACGCCG 176 
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Table 5.2.  Gene-specific primers for PER1, PER3, and  β-Actin and qPCR cycling information 
Gene Forward sequence Reverse sequence Annealing 
temperature 
(oC) 
Number 
of cycles 
Amplicon 
(bp) 
PER1 ATTTGGCTGCTCATGGCCA
ATGCT 
ATCCTGCTTCAGCACAGAGGT
CAT 
63 40 90 
PER3 TATGCAGGGCATCCTCCCT
TTGAA 
TATGCAGGGCATCCTCCCTTT
GAA 
60 40 121 
β-
Actin 
CATGTACGTTGCTATCCAG
GC 
CTCCTTAATGTCAGGCACGAT 60 40 250 
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Table 5.3.  Characteristics of EDCaP study participants 
Variable 
Total 
population 
(n = 107) 
Controls 
(n = 69) 
Cases 
(n = 38) 
Controls vs. 
Cases 
p-value1 
n (%) n (%) n (%)  
Gender    0.33 
     Male  58 (54) 35 (51) 23 (61)  
     Female 49 (46) 34 (49) 15 (39)  
Race    0.55 
     European American  78  (73) 49 (71) 29 (76)  
     African American  29  (27) 20 (29) 9 (24)  
Married    0.16 
     Yes 85 (79) 52 (75) 33 (87)  
     No 22 (21) 17 (25)   5 (13)  
Education    0.62 
     Up to High School  32 (30) 21 (30) 11 (29)  
     Some College           28 (26) 16 (23) 12 (32)  
     College Undergraduate 
or          
     Post-Graduate Degree 
47 (44) 32 (46) 15 (40)  
Income Level    0.86 
     Under $50,000 33 (33) 21 (33) 12 (33)  
     ≥$50,000 to $100,000 44 (44) 29 (46) 15 (42)  
     ≥$100,000 22 (22) 13 (21)   9 (25)  
Age Group (Years)    0.07 
     <54 28 (26) 20 (29) 8 (21)  
     55-64 46 (43) 33 (48) 13 (34)  
     ≥65 33 (31) 16 (23) 17 (45)  
Body Mass Index (kg/m2)     0.57 
     Underweight or normal 20 (19) 14 (20)  6 (16)  
     Overweight or obese 87 (81) 55 (80) 32 (84)  
History of Smoking    0.02 
     Ever 57 (53) 31 (45) 26 (68)  
     Never 50 (47) 38 (55) 12 (32)  
Current alcohol 
consumption    0.13 
     Yes 46 (43) 26 (38) 20 (53)  
     No 61 (57) 43 (62) 18 (47)  
Ever regularly taken a 
multivitamin    0.07 
     Yes 68 (64) 40 (58) 28 (76)  
     No 38 (36) 29 (42)   9 (24)  
Ever regularly taken a 
vitamin C supplement    0.15 
     Yes 31 (29) 17 (25) 14 (38)  
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Table 5.3.  Characteristics of EDCaP study participants 
Variable 
Total 
population 
(n = 107) 
Controls 
(n = 69) 
Cases 
(n = 38) 
Controls vs. 
Cases 
p-value1 
n (%) n (%) n (%)  
     No 75 (71) 21 (75) 23 (62)  
Ever regularly taken a 
vitamin D supplement    <0.01 
     Yes 22 (21) 20 (29) 2 (5)  
     No 84 (79) 49 (71) 35 (95)  
Hemorrhoids    0.18 
     Yes 67 (63) 40 (58) 27 (71)  
     No 40 (37) 29 (42) 11 (29)  
Procedure reason    <0.01  
     Routine 
screening/Symptoms2 34 (32) 30 (43) 4 (11)  
     Elevated Risk3 73 (68) 39 (57) 34 (89)  
Time of day blood was 
collected    0.23 
     Morning 83 (78) 56 (81) 27 (71)  
     Afternoon  24 (22) 13 (19) 11 (29)  
Worked >1 year of shift 
work over lifetime    0.99 
     Yes 45 (42) 29 (42) 16 (42)  
     No 62 (58) 40 (58) 22 (58)  
Current Work Shift    0.31 
     Days 53 (47) 33 (48) 20 (53)  
     Other 4 (3) 4 (6) 0 (0)  
     Unemployed/Retired  50 (50) 32 (46) 18 (47)  
 1Χ2 test for differences in proportions between cases and controls.; 2Three 
subjects exhibited symptoms (presence of gastrointestinal bleeding, 
hematochezia, melena, fecal occult blood, iron deficiency, or constipation) and 
were collapsed into screening category;  3Subject had a previous adenomatous 
polyp detected (n = 59) and/or a family history of colorectal cancer (n = 20)  
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Table 5.4.  Unadjusted and adjusted odds Ratios for leukocyte DNA promoter 
methylation relative to adenoma case status 
Candidate 
Gene 
Controls 
(n = 69) 
n (%) 
Cases 
(n = 
38) 
n (%) 
Crude OR 
(95% CI) 
p-
value 
Adjusted OR 
(95% CI) 
p-
value 
Hypomethylation*  
APCa 44 (64) 23 (61) 0.9 (0.4 – 2.0) 0.74 
1.0 (0.4 – 
2.5) 0.97 
BRCA1b 31 (44) 18 (47) 1.1 (0.5 – 2.4) 0.81 
1.5 (0.6 – 
3.9) 0.36 
MINT1d 4 (6) 7 (18) 3.7 (1.0 – 13.5) 0.05 
5.3 (1.0 – 
28.2) 0.05 
PER1e 20 (29) 17 (45) 2.0 (0.9 – 4.5) 0.10 
2.9 (1.1 – 
7.7) 0.03 
PER3f 2 (3) 6 (16) 6.3 (1.2 – 32.9) 0.03 
11.1 (1.6 – 
78.5) 0.02 
SFRP4e 12 (17) 5 (29) 0.7 (0.2 – 2.2) 0.57 1.1 (0.3 – 3.8) 0.89 
SFRP5b 5 (7) 5 (29) 1.9 (0.5 – 7.2) 0.32 3.7 (0.8 – 17.1) 0.09 
TIMP3g 42 (61) 25 (66) 1.2 (0.5 – 2.8) 0.61 
1.2 (0.4 – 
3.0) 0.78 
TMEFF2h 33 (48) 21 (55) 1.4 (0.6 – 3.0) 0.46 
1.5 (0.6 – 
3.4) 0.36 
WIF1i 24 (35) 15 (39) 1.2 (0.5 – 2.8) 0.63 
1.3 (0.5 – 
3.2) 0.56 
Hypermethylation 
CDKN2A 
(p16)j 28 (41) 
17 
(45) 0.8 (0.4 – 1.9) 0.68 
0.8 (0.3 – 
1.9) 0.54 
CYP27B1l 58 (84) 31 (82) 1.2 (0.4 – 3.4) 0.74 
0.8 (0.2 – 
3.0) 0.72 
ER alphaj 31 (45) 20 (53) 0.7 (0.3 – 1.6) 0.45 
0.6 (0.3 – 
1.5) 0.27 
IGF2e 52 (75) 28 (74) 1.1 (0.4 – 2.7) 0.85 
0.8 (0.3 – 
2.0) 0.57 
MGMTh 28 (41) 16 (42) 0.9 (0.4 – 2.1) 0.88 
0.9 (0.4 – 
2.1) 0.80 
MLH1l 63 (91) 34 (89) 1.2 (0.3 – 4.7) 0.76 
0.7 (0.2 – 
3.1) 0.67 
NGFRa 20 (29) 12 (32) 0.9 (0.4 – 2.1) 0.78 
0.9 (0.3 – 
2.2) 0.75 
PER2g 62 (90) 35 (92) 0.8 (0.2 – 3.1) 0.70 
0.6 (0.1 – 
3.0) 0.56 
SEPT9a 32 (46) 18 (47) 1.0 (0.4 – 2.1) 0.92 
0.9 (0.4 – 
2.1) 0.81 
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* - Odds of adenoma status given no methylation detected in the candidate 
gene. Note: CYP24A was not included in the table due to all subjects being 
unmethylated in the promoter. Adjusted for: a – vitamin D and multivitamin use; 
b – vitamin C and vitamin D use and physical activity; c –  multivitamin , vitamin 
C, and vitamin D use, physical activity, ever smoking, currently drinking 
alcohol, being married, and age group; d –  multivitamin use, vitamin C and D 
use, and ever smoking; e – vitamin C and D use and physical activity; f –  
multivitamin use, vitamin C use, vitamin D use, physical activity, ever smoking, 
age, and being married; g –  multivitamin and vitamin D use, physical activity, 
and age group; h –  vitamin D use; i – vitamin D use and age group; j -  vitamin 
d use, physical activity and age; k -  vitamin C and D use, physical activity and 
age; l – vitamin D use, current drinking alcohol, and age group. OR: odds ratio; 
CI: confidence interval 
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Table 5.5.  Sensitivity, specificity, positive predictive value, and negative predictive value of PER1, PER3, and MINT1 
 Controls 
(n) 
Cases 
(n) 
Total 
(n) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
 
PER1 Hypomethylation 
Present 20 17 37  
45 
 
71 
 
46 
 
70 Absent 49 21 70 
Total 69 38 107 
 
PER3 Hypomethylation 
Present 2 6 8  
16 
 
97 
 
75 
 
68 Absent 67 32 99 
Total 69 38 107 
 
MINT1 Hypomethylation 
Present 4 7 11  
18 
 
94 
 
64 
 
68 Absent 65 31 96 
Total 69 38 107 
 
PER1/PER3 
Hypomethylation 
Present 49 21 70  
55 
 
29 
 
30 
 
54 Absent 20 17 37 
Total 69 38 107 
 
PER1/MINT1 
Hypomethylation 
Present 45 20 65  
53 
 
35 
 
31 
 
57 Absent 24 18 42 
Total 69 38 107 
 
PER3/MINT1 
Hypomethylation 
Present 63 28 91  
74 
 
9 
 
31 
 
38 Absent 6 10 16 
Total 69 38 107 
 
PER1/PER3/MINT1 
Hypomethylation 
Present 44 19 63  
50 
 
36 
 
30 
 
57 Absent 25 19 44 
Total 69 38 107 
PPV: Positive predictive value; NPV: Negative predictive value 
 
  
 
153 
Table 5.6. Concordance of methylation in matched PBLs, normal GI tissue, and polyp tissue 
  
 Normal GI Tissue 
  
npairs = 35 Hypomethylated Hypermethylated Kappa Coefficient p-value 
P
B
Ls
 
MINT1 Hypomethylated 0 4 -0.11 0.52 
 Hypermethylated 3 28   
PER1 Hypomethylated 7 5 0.22 0.18 
 Hypermethylated 8 15   
PER3 Hypomethylated 2 2 0.12 0.40 
 Hypermethylated 9 22   
   Polyp Tissue 
  npairs = 12 Hypomethylated Hypermethylated Kappa Coefficient p-value 
P
B
Ls
 
MINT1 Hypomethylated 0 0 0 1.00 
 Hypermethylated 1 11   
PER1 Hypomethylated 1 1 -0.09 0.58 
 Hypermethylated 7 3   
PER3 Hypomethylated 1 1 0.25 0.37 
 Hypermethylated 2 8   
   Polyp Tissue 
  npairs = 4 Hypomethylated Hypermethylated Kappa Coefficient p-value 
N
or
m
al
 G
I 
Ti
ss
ue
 
MINT1 Hypomethylated 0 1 0 1.00 
 Hypermethylated 0 3   
PER1 Hypomethylated 2 0 0.5 0.25 
 Hypermethylated 1 1   
PER3 Hypomethylated 1 2 0.2 0.51 
 Hypermethylated 0 1   
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Abbreviations: PBLs, peripheral blood leukocytes; GI, gastrointestinal 
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Table 5.7.  Adjusted means of fold change expression for PER1 and PER3 by methylation status 
   Fold Change in Expression p-value Explained Variance (%) 
PBL Marker  n Mean (SD)   
PER1 Hypermethylated 57 0.99 (0.05) 0.62 0.18 
 Hypomethylated 26 1 (0.02)   
PER3 Hypermethylated 77 0.99 (0.03) 0.82 0.06 
 Hypomethylated 6 0.99 (0.04)   
Normal GI Tissue Marker      
PER1 Hypermethylated 8 1.01 (0.02) 0.06 25.88 
 Hypomethylated 6 1.04 (0.02)   
PER3 Hypermethylated 10 1.02 (0.04) 0.29 9.18 
 Hypomethylated 4 1.05 (0.06)   
Polyp Tissue Marker      
PER1 Hypermethylated 2 1.02 (0.07) 0.66 16.04 
 Hypomethylated 6 0.99 (0.02)   
PER3 Hypermethylated 5 0.99 (0.05) 0.82 0.91 
 Hypomethylated 3 1 (0.04)   
Note: MINT1 expression could not be measured. 
Abbreviations: SD, standard deviation; PBL, peripheral blood leukocyte; GI, gastrointestinal 
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Table 5.8.  Unadjusted and adjusted odds ratios* for gene expression relative to adenoma case status (N = 83) 
Candidate Gene Crude OR 95% CI Adjusted OR 95% CI 
PER1a 0.003 <0.01 – 181.72 <0.01 <0.01 – 1.86 
PER3b 0.06 <0.01 – >999.99 0.34 <0.01 – >999.99 
Note: MINT1 expression was not measured.  
Abbreviations: OR, odds ratio; CI, confidence interval; * - Odds of adenoma status given for a one unit increase in 
expression in the candidate gene. Adjusted for: a – ever smoking, physical activity, and vitamin C and vitamin D use; b 
– ever smoking, being married, age, physical activity, ever taking a multivitamin, and vitamin C and vitamin D use 
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Table 5.9.  Spearman’s correlations of PER1 and PER3 expression in PBLs, 
normal GI tissue, and polyp tissue 
 
   PBLs Normal Tissue Polyp Tissue 
 
   PER1 PER3 PER1 PER3 PER1 PER3 
P
B
Ls
 
PER1 
Spearman's 
rho 1 -0.04 0.26 -0.05 0 0.26 
p-value 
 
0.69 0.34 0.85 1 0.42 
npairs 83 83 16 16 12 12 
PER3 
Spearman's 
rho -0.04 1 0.4 -0.37 0.13 0.53 
p-value 0.69   0.12 0.16 0.70 0.08 
npairs 83 83 16 16 12 12 
N
or
m
al
 T
is
su
e PER1 
Spearman's 
rho 0.26 -0.05 1 0.64 0.79 0.93 
p-value 0.34 0.85 
 
0.01 0.04 <0.01 
npairs 16 16 16 16 7 7 
PER3 
Spearman's 
rho 0.40 -0.37 0.64 1 0.43 0.71 
p-value 0.12 0.16 0.01   0.34 0.07 
npairs 16 16 16 16 7 7 
P
ol
yp
 T
is
su
e PER1 
Spearman's 
rho 0 0.26 0.79 0.93 1 0.62 
p-value 1 0.42 0.04 <0.05 
 
0.03 
npairs 12 12 7 7 12 12 
PER3 
Spearman's 
rho 0.13 0.53 0.43 0.71 0.62 1 
p-value 0.70 0.08 0.34 0.07 0.03   
npairs 12 12 7 7 12 12 
Note: MINT1 expression could not be measured. 
Abbreviations: PBLs, peripheral blood leukocytes; GI, gastrointestinal 
 
 
 
158 
 
Chapter 6  
Case-Control Study of the PERIOD3 Clock Gene Length Polymorphism and 
Colorectal Adenoma Formation4 
                                                          
4 Alexander M, Burch JB, Steck SE, Chen CF, Hurley TG, Cavicchia P, Ray M, 
Shivappa N, Guess J, Zhang H, Youngstedt SD, Creek KE, Lloyd S, Yang X, 
Hébert JR. Accepted at Oncology Reports. Reprinted here with permission of 
publisher (Appendix B). 
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6.1  Abstract 
Introduction: Clock genes are expressed in a self-perpetuating, circadian 
pattern in virtually every tissue including the human gastrointestinal tract.  They 
coordinate cellular processes critical for tumor development, including cell 
proliferation, the DNA damage response, and apoptosis. Circadian rhythm 
disturbances have been associated with an increased risk for colon cancer and 
other cancers. This mechanism has not been elucidated, but may involve 
mutation or dysregulation of the ‘period’ (PER) clock genes, which have tumor 
suppressor properties. A variable number tandem repeat (VNTR) in the 
PERIOD3 (PER3) gene has been associated with sleep disorders, differences in 
diurnal hormone secretion, and increased premenopausal breast cancer risk. 
Colorectal tumors have reduced PER3 expression relative to normal tissue. 
However, gene expression or susceptibility related to PER3 has not been 
examined in conjunction with adenomatous polyps. This exploratory case-control 
study was the first to test the hypothesis that the 5-repeat PER3 VNTR sequence 
is associated with increased odds of adenoma formation among 146 
colonoscopy patients.  Materials and Methods: Information on demographics, 
medical history, occupation, and lifestyle was collected prior to colonoscopy.  
Cases (n=49) were individuals with at least one histopathologically confirmed 
adenoma. Controls (n=97) included patients with normal findings or hyperplastic 
polyps not requiring enhanced surveillance.  Unconditional multiple logistic 
regression was used to calculate odds ratios (ORs) with 95% confidence 
intervals (CIs), after adjusting for potential confounding. Results: Adenomas 
were detected in 34% of participants (average age: 59±9 years; 65% European 
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American [EA]; 72% male). Cases were more likely to possess the 5-repeat 
PER3 genotype relative to controls (4/5 OR: 2.1, 95% CI: 0.9-4.8; 5/5 OR: 5.1, 
95% CI: 1.4-18.1; 4/5+5/5 OR: 2.5, 95% CI: 1.7-5.4). Examination of the 
Oncomine microarray database indicated that PERIOD gene expression in 
adenomas was reduced relative to adjacent normal mucosa in several studies. 
Discussion: Results suggest a need for follow-up in a larger sample.  
6.2 Introduction 
According to recent estimates, over 143,000 new patients and more than 
51,000 deaths occurred in 2012 in the United States due to colorectal cancer 
(CRC), which makes it the third most common and deadly cancer among both 
men and women.1 Colorectal adenomatous polyps are the primary precursor 
lesions for CRC, accounting for 85-90% of cases.244 Developing a better 
understanding of factors related to adenoma susceptibility and progression thus 
represents an important goal for CRC prevention.   
Disruption of circadian rhythms or clock gene expression is emerging as a 
novel and potentially modifiable cancer risk factor, although the 
pathophysiological mechanism is incompletely understood.275, 298 The central 
circadian pacemaker is located in the suprachiasmatic nuclei (SCN) of the 
anterior hypothalamus. Generation of circadian rhythms is accomplished 
primarily via photic input from the retina, which synchronizes the reciprocal 
transcriptional-translational expression of at least nine core clock genes: PER1, 
PER2, PER3, CRY1, CRY2, CLOCK, BMAL1, TIM, and CK1ε.275, 298, 303  In most 
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tissues, this system facilitates the diurnal expression of ~10% of the entire 
mammalian genome via genetic and epigenetic regulation of clock-controlled 
genes. 89, 304-307 Various factors, such as shiftwork, late bedtimes, or poorly timed 
light exposure can disrupt endogenous circadian timing, thus altering clock gene 
expression and the cellular processes they help regulate.298  Because clock 
genes regulate processes that are considered hallmarks of carcinogenesis (cell 
cycle control, DNA damage response, apoptosis), their dysregulation may serve 
as an underlying biological mechanism linking altered circadian rhythms with 
cancer.298, 308-312 Clock gene polymorphisms have been associated with non-
Hodgkin’s lymphoma and cancers of the breast and prostate.298 Clock gene 
polymorphic variation also influences sleep regulation,303, 313, 314 which may 
contribute to increases in cancer susceptibility that have been observed among 
people who experience circadian rhythm disturbances or sleep disruption.45, 315, 
316  For example, shiftwork and sleep disturbances have been associated with 
increased CRC risk,106, 316-318 and truncated sleep (<6 hours per night) has been 
associated with an increased odds of colorectal adenoma formation relative to 
adenoma-free controls.45  
The Period (PER) clock genes have immunomodulatory303, 319, 320 and 
tumor suppressor properties.29, 298, 308, 315, 321  Mutation or altered expression of 
PER genes has been observed among cancer patients relative to controls, within 
human tumors relative to adjacent normal tissue, and in experimental cancer 
bioassays.19, 29, 31, 32, 104, 105, 116, 298, 308, 322, 323 Whether differential expression of 
PER or other clock genes occurs in human adenomas versus normal tissue is 
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not known. The PER3 variable number tandem repeat (VNTR, rs57875989) 
length polymorphism contains 4 or 5 copies of a 54-bp sequence encoding 18 
amino acids. The 5-repeat variant adds several potential phosphorylation motifs 
to the gene, and PER3’s interaction with circadian processes may be enhanced 
among those individuals.313, 324 The 5-repeat PER3 allele is associated with a 
relatively penetrant phenotype that includes morning circadian preference,38, 313, 
325 increased cognitive decline in response to sleep deprivation,313 differences in 
levels or timing of melatonin or cortisol secretion,40, 324, 326 and a tendency 
towards depressive symptoms or an earlier onset of bipolar disorder.24, 327  PER3 
is considered a candidate tumor suppressor gene, 19, 29, 321 and the 5/5 PER3 
VNTR genotype has been associated with increased premenopausal breast 
cancer risk,19 though not consistently.328, 329 Recently, the relationship between 
the PER3 VNTR and CRC risk was examined in Greece and no association was 
observed, although a relatively small portion of the study population was 
homozygous for the 5-repeat allele (<2%), and differences in genotype frequency 
among cases and controls were not adjusted for potential confounding.330  The 
role of PER3 or other clock genes in human adenoma formation has yet to be 
examined in detail. Therefore, this exploratory study tested the hypothesis that 
adenoma cases are hetero- or homozygous for the 5-repeat PER3 variant 
relative to adenoma-free controls.  
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6.3 Materials and Methods 
Participants and data from two different endoscopy centers in the 
Columbia, SC metropolitan area were pooled for this analysis; the South Carolina 
Medical Endoscopy Center Site 1, n=93), and the WJB Dorn Veterans 
Administration Medical Center (Site 2, n=53). Participants completed an on-site 
interview to collect information on: demographic (sex, marital status, income, 
race/ethnicity), lifestyle (smoking history, diet, physical activity), and occupational 
(employment status, job industry, type of shift, history of shiftwork) factors, as 
well as personal and family medical history (ever being diagnosed with other 
diseases, personal history of cancer, family history of CRC). Cases were defined 
as individuals with at least one histologically confirmed adenoma, and controls 
were subjects with a normal colonoscopy, or a normal biopsy not requiring 
heightened surveillance (e.g., hyperplastic polyp).   
Genotyping procedure 
Genomic DNA was extracted and genotyping for the PER3 VNTR 
sequence was performed using previously described methods.24, 331  For 
participants recruited from Site 1, the PER3 VNTR sequence was amplified via 
polymerase chain reaction (PCR) using the following forward (5′-
CAAAATTTTATGACACTACCAGAATGGCTGAC-3′ and reverse (5′-
AACCTTGTACTTCCACATCAGTGCCTGG-3′) primers.19,328 The reactions were 
heated to 94°C for 2 minutes followed by 35 cycles at 94°C for 30 seconds, 60°C 
for 30 seconds, and 72°C for 45 seconds. Finally, the reactions were extended 
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for 7 minutes at 72°C. PCR products were then separated by electrophoresis on 
a 3% agarose gel. The PCR primers used for Site 2 assays were: forward, 5’-
TGGCAGTGAGAGCAGTCCT-3’ and reverse 5’-
AGTGGCAGTAGGATGGGATG-3’. PCR cycling conditions were as follows: 3 
minutes at 94°C ; 35 cycles of 30 seconds at 94°C, 30 seconds at 58°C, and 30 
seconds at 72°C; and at 72°C for 30 seconds, PCR products were extended.  A 
2% agarose gel stained with ethidium bromide was used to separate and 
visualize the PCR fragments at 220V for 30 minutes.  Both primers provide valid 
characterization of the PER3 VNTR19, 24, 35, 328, 330-332 and amplicons from both 
methods were confirmed via Sanger sequencing. Duplicate genotyping was 
performed in 10% of all samples from both sites for quality control purposes, and 
there was 100% concordance among duplicates.24 DNA sequences of amplicons 
produced by each set of primers were verified via Sanger sequencing.  Hardy-
Weinberg equilibrium (HWE) was examined, and gene frequencies for the PER3 
VNTR were in HWE among the entire study population (p=0.74), and among 
controls from both sites (p=0.99) or within each site (Site 1: p=0.94; Site 2: 
p=0.82, Table 6.1).   
Methylation assays 
A peripheral whole blood sample was collected from each participant in 
Site 1 using vacutainers containing EDTA anticoagulant. Genomic DNA was 
isolated using the PUREGENE genomic DNA purification kit (Gentra Systems, 
Minneapolis, MN) according to the manufacturer’s protocol from peripheral whole 
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blood, normal GI tissue, and polyp tissue.  Sodium bisulfite conversion of DNA 
was performed using EpiTect kits (QIAGEN, Germantown, MD, USA). Briefly, 
DNA (2 µg) was added to the reaction buffer and bisulfite DNA conversion was 
conducted in a Bio-Rad S1000 thermal cycler (Bio-Rad Laboratories, Hercules, 
CA, USA) using the manufacturer’s suggested program for the conversion 
reaction. Converted DNA was eluted from a spin column in TE buffer and either 
used immediately or stored at –20°C.  DNA oligonucleotides for primer pairs 
were purchased from Integrated DNA Technologies (Coralville, IA, USA, Table 
6.2). To ensure that the polymerase chain reaction (PCR) primers were specific 
for the detection of methylated DNA, a control human DNA set (EpiTect Control 
DNA, QIAGEN Sciences, Germantown, MD) containing positive (bisulfite 
converted, 100% methylated) and negative (bisulfite converted, 0% methylated) 
control DNA was used. To quantify methylation specific PCR (MSP) results, the 
QIAxcel system was used (QIAGEN Sciences, Germantown, MD), which utilizes 
a multiplexed fluorescence detection method with a resolution of 3-5 bp for DNA 
fragments. The detection sensitivity of QIAxcel system was 0.1 ng/μl DNA in 
undiluted amplification reactions. The QIAxcel system was equipped with the 
BioCalculator software that produces a tabular display of a variety of peak 
properties, including number of peaks as well as the height, width, and area of 
each peak. The height of the peak was used for separation of the results into 
three methylation categories: high (peak height >0.30), medium (peak height 
0.29-0.05), and low (peak height <0.05), or none (no methylation detected). 
Results were categorized as either unmethylated or methylated (combination of 
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medium/low, and high methylation categories). The methylation status of each 
sample was normalized via a two-step process. First, a NanoDrop™ Lite 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) was used to 
measure concentrations of the DNA templates.  Subsequent experiments used 
the same amount of DNA template for each MSP reaction. To facilitate 
quantification, equal volumes of the MSP products were loaded on the QIAxcel 
system for analysis. Second, BRCA1 gene methylation was used as an internal 
standard since the same amount of DNA template had extremely high 
methylation in each sample.  The measured peak height of BRCA1 methylation 
was then used to normalize the methylation of the genes of interest for each 
sample.  All methylation assays were performed blinded to case status. 
Real-time quantitative PCR (qPCR) 
RNA was extracted from PAXgene tubes using PAXgene Blood RNA Kit 
from QIAGEN (Germantown, MD, USA) from participants in Site 1.  RNA quality 
was checked via Agilent Bioanalyzer 2100 and concentration was quantified on 
NanoDrop.  cDNA was synthesized from total RNA using gene-specific primers 
according to the Verso cDNA Kit (Abgene, Rochester, New York).  Reverse 
transcriptase reactions contained 1 μg of total RNA (1-5 μl of total RNA), 4 μl 5X 
cDNA synthesis buffer, 1 μl 5 μM dNTP mix, 1 μl 400 ng/μl random hexamers, 1 
μl RT Enhancer, 1 μl Verso Enzyme Mix, and a variable amount of PCR grade 
water to have a total of a 20 μl.  The 20 μl reactions were incubated in an MJ 
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Research PTC-225 Thermo Cycler in a 96-well plate for 30 min at 42°C, 2 min at 
95°C, and then held at 4°C.  cDNAs were stored at -20 oC.  
Gene-specific primers were created using Primer3 software.  Forward and 
reverse sequences were confirmed for their presence within exons and lack of 
single nucleotide polypmorphisms using NCBI’s Basic Local Alignment Search 
Tool (BLAST).  PCR cycling information is found in Table 6.3.  All reactions were 
performed in singleplex mode.  Each reaction contained 10 μl 2x SYBR Green 
PCR master mix (Bio-Rad Laboratories, Hercules, CA), 2 μl of each primer, 0.5-2 
μl of cDNA template, and a variable amount of PCR grade water to have a total 
reaction amount of 20 μl. The standard curve method was employed and β-actin 
was used as the endogenous control to determine levels of expression of cDNA 
in study participants.  A two-fold 10-point serial dilution was created through the 
use of diluted PCR products of β-actin and markers who presented an 
association with polyp status.  The standard curve produces a linear relationship 
between number of threshold cycles (Ct) and the initial known amounts of cDNA, 
allowing the determination of the cDNA concentration of unknown samples based 
on their Ct value, thereby also giving the number of mRNA copies for each gene 
present in unknown samples.  The threshold cycle (Ct) is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold.  
Each sample was analyzed in duplicate, with a negative template control 
included in each run to check for DNA contamination. 
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Statistical analysis 
Statistical analyses were performed using the Statistical Analysis Software 
(SAS®) computer program (version 9.2, Cary, NC) and the R meta-analysis 
package (version 2.14.1, http://cran.r-project.org). Potential differences between 
study variables by case status within the entire study population, and within each 
site separately, were examined using the chi-squared test for differences 
between proportions. Differences in median shiftwork duration by PER3 
genotype were compared using the Wilcoxon rank sum test. Unconditional 
multiple logistic regression was used to estimate odds ratios (ORs) with 95% 
confidence intervals (95% CIs) for PER3 VNTR genotype among adenoma cases 
relative to controls using the 4/4 genotype as referent.19, 24 Covariates considered 
for inclusion in adjusted models were known or suspected adenoma or CRC risk 
factors ( age, sex, race, body mass index [BMI], CRC family history, smoking 
history, work-related factors, diet, vitamin and supplement use, physical activity, 
sociodemographic characteristics [income, education], personal medical history) , 
and variables that differed among participants and non-participants (sex, 
personal cancer history, ulcer diagnosis, lactose intolerance, secondhand smoke 
exposure, recruitment site).   Final models included variables that were 
statistically significant (p≤0.05) in the saturated model, or produced at least a 
10% change in the parameter estimate for genotype (decision latitude at work, 
procedure reason, recruitment site).  Ancillary analyses examined relationships 
between lifetime shiftwork and adenoma status; or PER3 genotype and adenoma 
status after stratification by procedure reason (screening vs. surveillance 
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colonoscopy), shiftwork (none vs. any, or median split on years of lifetime 
shiftwork), and methylation status in PER1, PER2, or PER3. Random-effects 
meta-analysis was used to evaluate the study hypothesis since recruitment 
occurred at two separate sites.  The I2 and Q statistics were used to assess 
heterogeneity between sites.  Oncomine,333 a publically accessible gene 
expression microarray database, was queried to examine potential differential 
expression of PER1, PER2, and PER3 clock genes in adenomas versus adjacent 
normal tissue.  Expression levels of PER1, PER2, and PER3 were also 
examined for differences by genotype in a subset of participants.   
6.4 Results 
The median age of the participants was 58 years (25th percentile: 53 
years, 75th percentile: 64 years), and they were primarily European American 
(65%), and male (72%). Most (69%) participants had engaged in at least one 
year of shiftwork (median: 3 years; 25th percentile: 0 years; 75th percentile: 12.3 
years). Adenomas were detected in 34% of participants (females: 28%, males: 
36%). Compared to controls, cases were more likely to have smoked (78% vs. 
56%), have higher decision latitude (57% vs. 29%), and have undergone a 
surveillance relative to a screening colonoscopy (59% vs. 40%, Table 6.4).   
Additional results on characteristics by site and by case status within each site 
are found in Tables 6.5 and 6.6, respectively. 
Overall PER3 VNTR genotype frequencies (4/4: 47%, 4/5: 42%, 5/5: 11%) 
were consistent with those reported elsewhere (4/4: 35-74%, 4/5: 25-46%, 5/5: 2-
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18%).327, 328, 334, 335 Adenoma cases were more likely than controls to possess 
one or two copies of the 5-repeat sequence (5/5 OR: 5.1, 95% CI: 1.4-18.1; 
4/5+5/5 OR: 2.5; 95% CI: 1.7-5.4, Table 6.7). Shiftwork, or the combined effect of 
shiftwork and genotype was not related to adenoma case status (data not 
shown).   
When analyses were stratified by procedure reason, the 5/5 genotype was 
associated with adenoma status among screening patients (OR: 10.7, 95% CI: 
1.4-80.7), whereas no statistically significant relationship was observed among 
those with the 5/5 genotype receiving a surveillance colonoscopy (OR: 2.3, 95% 
CI: 0.5-11.4), or among the other genotypes for either procedure reason (Table 
6.8). After stratification by methylation status of PER1, PER2, and PER3 
methylation status (hypomethylation or hypermethylation), no statistically 
significant relationships were observed (Table 6.9). 
The distribution of lifetime shiftwork history varied by PER3 VNTR 
genotype (Table 6.10). Those with the 4/4 genotype had greater median lifetime 
years of shiftwork (5 years) compared to those with the 4/5 (2 years, p=0.02), 5/5 
(0.75 years, p=0.05), or the combined genotype (4/5+5/5: 1 year, p<0.01).  When 
the data were evaluated using meta-analytic methods, adenoma cases were ~2-
3 times more likely than controls to have at least one 5-repeat allele, although the 
confidence intervals were wide and did not achieve statistical significance (4/5 
OR: 2.27, 95% CI: 0.43-11.62, pheterogeneity: 0.12, I2: 60%; 5/5 OR: 3.02, 95% CI: 
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0.72-12.71, pheterogeneity: 0.84, I2: 0%; 4/5+5/5 OR: 2.35, 95% CI: 0.60-9.21, 
pheterogeneity: 0.14, I2: 54%).  
Data for PER1, PER2, and PER3 expression in adenomas relative to 
normal tissue retrieved from the Oncomine microarray database are presented in 
Table 6.11.336-338  A statistically significant reduction in PER3 expression was 
observed in adenomas relative to normal tissue among each of the available data 
sets, and similar differences were noted for PER1 and PER2 expression (Table 
6.11).  
Expression levels of PER1, PER2, and PER3 were stratified by genotype 
(4/4 genotype vs. 4/5 or 5/5 genotype, Figure 6.1).  Those expression levels were 
slightly higher for those with at least one 5-repeat allele, the only statistically 
significant difference was observed in PER1 expression (p ≤ 0.05).  That is, 
individuals with at least one 5-repeat allele had higher levels of PER1 expression 
compared to individuals without a 5-repeat PER3 genotype.  
6.5 Discussion 
Few studies have examined the role of the PER3 VNTR on cancer-related 
outcomes.19, 328-330 To our knowledge, this exploratory study is the first to 
examine the relationship between the PER3 VNTR and human adenoma risk. 
Adenoma cases were ~2-5 times more likely to possess the 5-repeat PER3 
length polymorphism compared to controls. There are several noteworthy 
strengths, limitations and uncertainties associated with this study. Quality criteria 
for genotyping and screening colonoscopy adenoma detection rates were 
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satisfactory,339, 340 and adjustment for potential confounding by known or 
suspected adenoma risk factors did not alter the interpretation of the results. The 
meta-analysis indicated that the strength of association between PER3 genotype 
and adenoma status was generally consistent with the main analysis and the 
results were not strongly impacted by heterogeneity between the sites. Some 
imprecise risk estimates with wide confidence intervals were observed due to a 
limited sample size, particularly for the stratified analyses. Thus, examination of 
possible effect modification by factors such as race, chronotype, procedure 
indication (screening versus surveillance), or methylation would benefit from a 
larger sample in future studies. Nonetheless, the lower bound of the confidence 
intervals suggest a ~40% increased risk for adenoma formation among the 5-
repeat PER3 variants. PER gene expression was not performed among cases 
and controls in the present study, thus changes in expression relative to the 
PER3 VNTR genotype could not be evaluated. However, our query of the 
Oncomine database indicated that PER3 and to a lesser extent PER1 and PER2 
expression was reduced among adenomas compared to normal mucosa, which 
is consistent with previous studies that observed a reduction in PER1 and PER3 
expression in human colorectal tumors relative to adjacent normal tissue.32, 104, 
341  However, findings from the Oncomine query somewhat contradict findings 
from Figure 6.1, which show increased PER1 expression among those with at 
least one 5-repeat allele.  This is an unexpected finding because those with at 
least one 5-repeat allele should be at an increased risk for adenoma formation, 
and those individuals should have lower PER1 expression. Further investigation 
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in the relationships between PER3 VNTR variation and expression of the PER 
genes is warranted. 
The spectrum of known genetic susceptibility markers does not fully 
account for all CRC cases.  For example, 10 loci identified from genome-wide 
association studies had population attributable risks ranging from 1.7% to 
11.9%,342 and another previous study estimates that up to 35% of CRC cases 
are due to heritable factors.343  The current study mirrors previous investigations 
that have examined clock gene polymorphisms in conjunction with cancer 
susceptibility,19, 298, 328, 330 including one that identified an association between the 
5-repeat PER3 VNTR sequence and increased odds of premenopausal breast 
cancer.19 Evidence suggests that PER3 may function as a tumor suppressor. A 
recent study among PER3 knockout mice indicated that 36% of the homozygous 
null variants developed chemically-induced mammary tumors compared to 12% 
among heterozygotes and 0% among wild-type mice.29 Another recent study 
used methylation arrays and stringent selection criteria to screen >14,000 genes 
to identify putative tumor suppressors associated with human hepatocellular 
carcinoma; PER3 was one of only three candidate tumor suppressor genes 
identified.321 Chronic gastrointestinal inflammation is important for adenoma and 
CRC development,244, 344 and since PERIOD genes play a role in immune system 
regulation, their expression may influence these processes.303, 319, 320  Recently, 
another PER3 polymorphism (rs2797685) was associated with inflammatory 
bowel disease, a known CRC risk factor.345  The current study attempted to look 
at joint effects of the PER3 VNTR and methylation status of PER1, PER2, and 
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PER3.   Though no statistically significant findings were observed when 
examining the joint effect of genetic and epigenetic variation (Table 6.9), future 
larger studies should examine these interactive effects since the mechanism 
whereby PER3 may exert a tumor suppressor function is currently unknown.  
The clock genes exert genetic and epigenetic regulatory effects that 
facilitate the circadian expression of ~5-10% of the entire mammalian 
transcriptome,89, 304-307 including other known tumor suppressors and oncogenes 
(e.g., c-Myc, p53).26, 31, 346  Clock genes also help regulate cellular processes that 
are active during carcinogenesis (cell proliferation, DNA damage response, 
apoptosis), and clock gene dysregulation may foster adenoma formation by 
influencing these pathways.298, 308, 310, 312 
Individuals with the 5-repeat PER3 VNTR sequence tend to have relatively 
penetrant phenotypic characteristics including delayed sleep phase syndrome, 
increased susceptibility to cognitive impairment after sleep deprivation, morning 
circadian preference, and differences in the timing or levels of circadian hormone 
secretion,40, 313, 324 although some inconsistencies have been reported.36, 38, 347, 348 
Whether alterations in sleep and other circadian processes can increase cancer 
susceptibility remains to be determined. Studies of shift work and cancer 
incidence suggest this is possible.349 In the present study, participants with the 5-
repeat allele reported less cumulative shiftwork experience relative to those with 
the 4/4 genotype (Table 6.10). Additional research is needed to determine 
whether this is a chance finding or if individuals carrying these variants are less 
tolerant of shiftwork compared to those with the 4/4 genotype. Individuals with 
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the 5-repeat allele may be more susceptible to disturbances in circadian 
timekeeping.40, 313, 324, 326   For example, those carrying the 5/5 PER3 variant 
were sensitive to light-induced melatonin suppression whereas 4/4 homozygotes 
were not responsive.326 Because melatonin has potent antioxidant, anti-
proliferative and anti-inflammatory properties in the gastrointestinal tract, a 
reduction in its secretion (e.g., by exposure to light at night) may facilitate 
physiologic changes that predispose to increased risks for CRC or other 
cancers.106, 275, 298, 316, 317 Although the PER3 has tumor suppressor properties 
and its length polymorphism tends to have relatively penetrant phenotypic 
characteristics, the role of these factors in cancer susceptibility, if any, remains to 
be characterized.  
In conclusion, results from this study indicate that individuals with the 5-
repeat PER3 length polymorphism may be more susceptible to adenoma 
formation. The results are consistent with Oncomine data indicating that PERIOD 
clock gene expression is reduced in adenomas relative to normal GI tissue. 
Further interrogation of interrelationships between the PER3 VNTR and genetic 
or epigenetic pathways that may facilitate adenoma risk, such as changes in the 
expression of clock-controlled, cancer-related genes, is recommended.  Further 
elucidation of the PER3 VNTR genotype in relation to circadian rhythm or clock 
gene dysregulation may lead to development of novel, modifiable targets for 
adenoma and CRC prevention.  
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Figure 6.1.  Differences in fold change expression of the PER gene family in 
blood by PER3 VNTR genotype.   
Note: *p≤ 0.05 
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Table 6.1.  PER3 VNTR gene frequencies among study participants 
 Entire Population  
(n = 146) 
All Controls  
(n = 97) 
Recruitment Site 1 
(n = 62) 
Recruitment Site 2 
(n = 35) 
Genotype n (%) HWE p-value n (%) HWE p-value n (%) HWE p-value n (%) HWE p-value 
4/4 68 (47) 
0.74 
52 (54) 
0.99 
29 (47) 
0.94 
23 (44) 
0.82 4/5 62 (42) 38 (39) 27 (43) 11 (31) 
5/5 16 (11) 7 (7) 6 (10) 1 (3) 
Abbreviation: HWE, Hardy-Weinberg equilibrium 
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Table 6.2.  Primers for Methylation-Specific PCR 
Gene Name Forward (5’ -> 3’) Reverse (5’ -> 3’) Amplicon (bp) 
PER1 ATTTAGGTTTACGTGCGTTC GATTAACTAAAAATCTCTTCCCGAC 95 
PER2 GTTTTTGGTCGGTGGTCGG CGAAACTCCTACGCACCTCC 92 
PER3 CGTCGGTTTGTTGGGATTG AAACCGACTCCGCAAACC 160 
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Table 6.3.  Gene-specific primers for PER1, PER3, and  β-Actin and qPCR cycling information 
Gene Forward sequence (5’ -> 3’) Reverse sequence (5’ -> 3’) Annealing 
temperature 
(oC) 
Number 
of cycles 
Amplicon 
(bp) 
PER1 ATTTGGCTGCTCATGGCCAA
TGCT 
ATCCTGCTTCAGCACAGAG
GTCAT 
63 40 90 
PER3 TATGCAGGGCATCCTCCCTT
TGAA 
TATGCAGGGCATCCTCCCTT
TGAA 
60 40 121 
β-Actin CATGTACGTTGCTATCCAGG
C 
CTCCTTAATGTCAGGCACGA
T 
60 40 250 
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Table 6.4.  Demographic characteristics of study population 
Variable1 
Total 
Population 
(n = 146) 
Controls 
(n = 97) 
Cases 
(n = 49) 
Cases vs. 
Controls  
p-value2 
N (%) N (%) N (%)  
Sex    0.32 
Male  105 (72) 67 (70) 38 (78)  
Females 40 (28) 39 (30) 11 (22)  
Race    0.12 
European American 94 (65) 58 (60) 36 (73)  
African American  51 (35) 38 (40) 13 (27)  
     
Marital Status    0.46 
Unmarried 38 (26) 27 (28) 11 (22)  
Married 107 (74) 69 (72) 38 (78)  
Education    0.75 
Up to High School  52 (36) 34 (35) 18 (37)  
Some College           40 (28) 25 (26) 15 (31)  
College 
Undergraduate or 
Post-Graduate 
Degree 
53 (37) 37 (39) 16 (33) 
 
Income level    0.37 
Under $50,000 63 (46) 40 (45) 23 (49)  
≥$50,000 to 
$100,000 
53 (39) 38 (43) 15 (32)  
≥$100,000 20 (15) 11 (12)   9 (19)  
Body Mass Index  
(kg/m2) 
   0.22 
Underweight or 
normal 
 33 (23) 19 (20) 14 (29)  
Overweight 113 (77) 78 (80) 35 (71)  
Family History of 
Colorectal Cancer 
   0.84 
Yes  25 (17) 17 (18)  8 (16)  
No 120 (83) 79 (82) 41 (84)  
Diagnosis of 
Diabetes 
   0.15 
Yes 42 (29) 24 (25) 18 (38)  
No 102 (81) 71 (75) 31 (62)  
History of Smoking    0.01 
Ever 91 (63) 53 (56) 38 (78)  
Never 53 (37) 42 (44) 11 (22)  
Work Decision 
Latitude 
   0.03 
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Table 6.4.  Demographic characteristics of study population 
Variable1 
Total 
Population 
(n = 146) 
Controls 
(n = 97) 
Cases 
(n = 49) 
Cases vs. 
Controls  
p-value2 
N (%) N (%) N (%)  
Unknown 74 (51) 51 (53) 23 (47)  
Never or Sometimes 21 (14) 18 (19)   3 ( 6)  
Often or Always 51 (35) 28 (29) 23 (57)  
Age Group    0.11 
30-54 45 (31) 34 (35) 11 (22)  
55-65 66 (46) 44 (46) 22 (45)  
> 65 34 (23) 18 (19) 16 (33)  
Reason for 
Colonoscopy 
   0.03 
Symptoms/Screening 78 (53) 58 (60) 20 (41)  
Surveillance 68 (47) 39 (40) 29 (59)  
 Median (25th percentile, 75th 
percentile) 
 
Lifetime Shiftwork 
(Years) 
3 (0, 12.3) 5 (0, 15) 2 (0, 10) 0.10 
1Number of subjects for each variable category may not equal total number of 
subjects due to missing data;  2Chi-squared test for differences in proportions 
or Wilcoxon rank sum test for differences in medians between cases and 
controls 
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Table 6.5.  Differences in patient characteristics by site 
 Recruitment Site 
1 
(N = 93) 
Recruitment Site 
2 
 (N = 53) 
p-value2 
Variable1 N (%) N (%)  
Sex   <0.0001 
Male  52 (57)   53 (100)  
Female 40 (43) 0 (0)  
Race   0.02 
European American 66 (72) 28 (53)  
African American  26 (28) 25 (47)  
Marital Status   0.02 
Unmarried 18 (20) 20 (38)  
Married 74 (80) 33 (62)  
Education   0.06 
Up to High School  28 (30) 24 (45)  
Some College           24 (26) 16 (30)  
College Undergraduate 
or Post-Graduate 
Degree 
40 (43) 13 (25)  
Income level   <0.0001 
Under $50,000 26 (31) 37 (70)  
≥$50,000 to $100,000 40 (48) 13 (25)  
≥$100,000 17 (20) 3 (6)  
Body Mass Index  
(kg/m2) 
  0.10 
Underweight or normal3 17 (18) 16 (30)  
Overweight 76 (82) 37 (70)  
Family History of 
Colorectal Cancer 
  0.60 
Yes 17 (18)   8 (15)  
No 75 (82) 45 (85)  
Diagnosis of Diabetes   0.58 
Yes 28 (31) 14 (26)  
No 64 (69)  39 (74)  
History of Smoking   0.01 
Ever 51 (55) 40 (77)  
Never 41 (45) 13 (23)  
Work Decision Latitude   0.27 
Unknown 43 (47) 31 (58)  
Never or Sometimes 16 (17) 5 (9)  
Often or Always 34 (37) 17 (32)  
Age group   0.04 
30-54 23 (25) 22 (42)  
55-65 42 (46) 24 (45)  
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Table 6.5.  Differences in patient characteristics by site 
 Recruitment Site 
1 
(N = 93) 
Recruitment Site 
2 
 (N = 53) 
p-value2 
Variable1 N (%) N (%)  
>65 27 (29)   7 (13)  
Reason for Procedure   <0.0001 
Screening/Symptoms 25 (27) 53 (100)  
Surveillance 68 (73) 0 (0)  
Case Status4   0.94 
Controls 62 (67) 35 (66)  
Adenomas 31 (33) 18 (34)  
 Median (25th percentile, 75th percentile)  
Lifetime Shiftwork 
(Years) 
1 (0, 10) 6 (2, 17) 0.0004 
11Number of subjects for each variable category may not equal total number of 
subjects due to missing data ;  2 Chi-squared test for differences in proportions 
or Wilcoxon rank sum test for differences in medians between Site 1 and Site 
2; 3Three subjects who were in the underweight BMI category (≤18.5 kg/m2);  
4No polyps or hyperplastic polyp(s) only 
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Table 6.6.  Differences in patient characteristics by case status and site 
 Recruitment Site 1 Recruitment Site 2 
 Total 
population  
(n = 93) 
Controls1  
(n = 62) 
Cases 
(n = 31) 
p-
value3 
Total 
population 
(n = 53) 
Controls1  
(n = 35) 
Cases 
(n = 18) 
p-
value3 
Variable2 n (%) n (%) n (%)  n (%) n (%) n (%)  
Sex    0.27    1.00 
Male  52 (57) 32 (52) 20 (65)  53 (100) 35 (100) 18 (100)  
Female 40 (43) 29 (48) 11 (35)  0 (0) 0 (0) 0 (0)  
Race    0.18    0.39 
European American 66 (72) 41 (67) 25 (81)  28 (53) 17 (49) 11 (61)  
African American  26 (28) 20 (33)  6 (19)  25 (47) 18 (51)  7 (39)  
Marital Status    0.25    0.90 
Unmarried 18 (20) 14 (23)   4 (13)  20 (38) 13 (37)   7 (39)  
Married 74 (80) 47 (77) 27 (87)  33 (62) 22 (63) 11 (61)  
Education    0.60    0.50 
Up to High School  28 (30) 20 (33)  8 (26)  24 (45) 14 (40) 10 (56)  
Some College           24 (26) 14 (23) 10 (32)  16 (30) 11 (31) 5 (28)  
College Undergraduate or 
Post-Graduate Degree 40 (43) 27 (44) 13 (42)  13 (25) 10 (29) 3 (17)  
Income level    0.40    0.07 
Under $50,000 26 (31) 19 (35) 7 (24)  37 (70) 21 (60) 16 (89)  
≥$50,000 to $100,000 40 (48) 26 (48) 14 (48)  13 (25) 12 (34) 1 (6)  
≥$100,000 17 (20) 9 (17)  8 (28)  3 (6) 2 (6) 1 (6)  
Body Mass Index  (kg/m2)    0.85    0.11 
Underweight or normal4 17 (18) 11 (18) 6 (19)  16 (30) 8 (23) 8 (44)  
Overweight 76 (82) 51 (82) 25 (33)  37 (70) 27 (77) 10 (56  
         
Family History of 
Colorectal Cancer 
   0.68    0.82 
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Table 6.6.  Differences in patient characteristics by case status and site 
 Recruitment Site 1 Recruitment Site 2 
 Total 
population  
(n = 93) 
Controls1  
(n = 62) 
Cases 
(n = 31) 
p-
value3 
Total 
population 
(n = 53) 
Controls1  
(n = 35) 
Cases 
(n = 18) 
p-
value3 
Variable2 n (%) n (%) n (%)  n (%) n (%) n (%)  
Yes 17 (18) 12 (20)  5 (16)   8 (15)  5 (14)  3 (17)  
No 75 (82) 49 (80) 26 (84)  45 (85) 30 (86) 15 (83)  
Diagnosis of Diabetes    0.01    0.25 
Yes 28 (31) 13 (22) 15 (48)  14 (26) 11 (31) 3 (17)  
No 64 (69) 39 (78) 16 (52)  39 (74) 24 (69) 15 (83)  
History of Smoking    0.03    0.14 
Ever 51 (55) 29 (48) 22 (71)  40 (77) 24 (71) 16 (89)  
Never 41 (45) 32 (52) 9 (29)  13 (23) 11 (29) 2 (11)  
Missing 1 1 0  0 0 0  
Work Decision Latitude    0.08    0.26 
Unknown 43 (46) 31 (50) 12 (39)  31 (58) 20 (57) 11 (61)  
Never or Sometimes 16 (17) 13 (21)  3 (10)   5 (9)  5 (14)  0  (0)  
Often or Always 34 (37) 18 (29) 16 (52)  17 (32) 10 (29)  7 (39)  
Age group         
30-54 23 (25) 16 (26)  7 (23) 0.65 22 (42) 18 (51) 4 (22) 0.03 
55-65 42 (46) 29 (48) 13 (42)  24 (45) 15 (43) 9 (50)  
>65 27 (29) 16 (26) 11 (35)  7 (13)   2  ( 6) 5 (28)  
Reason for Procedure         
Screening/Symptoms 25 (27) 23 (37)  2  ( 6) 0.002 53 (100) 35 (100) 18 (100) 1.00 
Surveillance 68 (73) 39 (63) 29 (94)  0 (0) 0 (0) 0 (0)  
 Median (25th percentile, 75th 
percentile) 
 Median (25th percentile, 75th 
percentile) 
 
Lifetime Shiftwork (Years) 1 (0, 10) 1 (0, 10) 0.50 (0, 7) 0.36 6 (2, 17) 10 (3, 18) 
3.5 (1, 
12) 0.11 
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Table 6.6.  Differences in patient characteristics by case status and site 
 Recruitment Site 1 Recruitment Site 2 
 Total 
population  
(n = 93) 
Controls1  
(n = 62) 
Cases 
(n = 31) 
p-
value3 
Total 
population 
(n = 53) 
Controls1  
(n = 35) 
Cases 
(n = 18) 
p-
value3 
Variable2 n (%) n (%) n (%)  n (%) n (%) n (%)  
1No polyps or hyperplastic polyp(s) only;  2 Number of subjects for each variable category may not equal total number of 
subjects due to missing data;  3Chi-squared test for differences in proportions or Wilcoxon rank sum test for differences 
in medians between cases and controls; 4Three subjects who were in the underweight BMI category (≤18.5 kg/m2);   
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Table 6.7.  PER3 VNTR genotype by adenoma status 
Genotype 
Controls 
(n = 97) 
Cases 
(n = 49) Crude OR 95% CI p-value Adjusted OR1 95% CI p-value 
n (%) n (%) 
4/4 52 (54) 16 (33) Ref -- -- Ref -- -- 
4/5 38 (39) 24 (49) 2.1 0.9 –  4.4 0.06 2.1 0.9 –  4.8 0.07 
5/5  7 ( 7)   9 (18) 4.2 1.3 – 13.0 0.01 5.1  1.4 – 18.1 0.01 
4/5 or 5/5 45 (46) 33 (67) 2.4 1.7 –  4.9 0.02 2.5 1.7 –  5.4 0.02 
Abbreviations: OR, Odds ratio; CI, Confidence interval; VNTR: Variable number tandem repeat 
1Adjusted for: decision latitude at work, recruitment site, procedure reason.  
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Table 6.8. Relationship between PER3 VNTR genotype and adenoma status: stratified by procedure reason 
  Controls Cases Crude 
OR1 95% CI 
p-
value 
Adjusted 
OR2 95% CI p-value n (%) n (%) 
Screening 
(ncases = 
20; 
ncontrols = 
58) 
4/4 34 (59) 7 (35) Ref -- -- Ref -- -- 
4/5 21 (36) 9 (45) 2.1 0.7 – 6.4 0.20 2.2 0.7 – 7.1 0.19 
5/5 3 (5) 4 (20) 6.5 1.2 – 35.6 0.03 10.7 1.4 – 80.7 0.02 
4/5 or 5/5 24 (41) 13 (65) 2.6 0.9 – 7.6 0.07 2.9 0.9 – 8.7 0.07 
Surveillan
ce 
(ncases 
=29; 
ncontrols = 
39) 
4/4 18 (46) 9 (31) Ref -- -- Ref -- -- 
4/5 17 (44) 15 (52) 1.8 0.6 – 5.1 0.29 1.9 0.6 – 5.6 0.29 
5/5 4 (10) 5 (17) 2.5 0.5 – 11.7 0.24 2.3 0.5 – 11.4 0.30 
4/5 or 5/5 21 (54) 20 (69) 1.9 0.7 – 5.2 0.21 2.0 0.7 – 5.6 0.20 
Abbreviations: OR, Odds ratio; CI, Confidence interval; VNTR: Variable number tandem repeat 
1 - Unconditional logistic regression with Firth’s bias correction; 2 - Adjusted for decision latitude at work, recruitment 
site.  
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Table 6.9. Relationship between PER3 VNTR genotype and adenoma status: stratified by methylation status in PER1, 
PER2, and PER3 
Methylation 
Marker 
Methylation 
Status 
Genotype Controls Cases Crude OR1 
(95% CI) p-value 
Adjusted OR2 
(95% CI) p-value n (%) n (%) 
PER1 
Hypomethylation 
(ncases = 12; 
ncontrols = 13) 
4/4 8 3 Ref -- Ref -- 
4/5 4 6 3.51 (0.57 – 
21.46) 
0.17 2.18 (0.25 – 
18.79) 
0.48 
5/5 1 3 5.67 (0.48 – 
69.20) 
0.17 5.90 (0.35 – 
98.45) 
0.22 
4/5 or 5/5 5 9 4.20 (0.77 – 
22.84) 
0.10 2.99 (0.40 – 
22.38) 
0.29 
Hypermethylation 
(ncases = 19; 
ncontrols = 42) 
4/4 18 7 Ref -- Ref -- 
4/5 19 9 1.20 (0.37 – 
3.88) 
0.76 1.72 (0.48 – 
6.11) 
0.40 
5/5 5 3 1.57 (0.30 – 
8.29) 
0.60 1.84 (0.29 – 
11.59) 
0.52 
4/5 or 5/5 24 12 1.26 (0.42 - 
3.81) 
0.68 1.75 (0.53 – 
5.77) 
0.36 
PER2 
Hypomethylation 
(ncases = 2;  
ncontrols = 5) 
4/4 3 1 Ref -- Ref -- 
4/5 2 1 1.40 (0.06 – 
33.29) 
0.84 0.62 (0.00 – 
220.41) 
0.87 
5/5 0 0 9.52 (0.95 – 
95.79) 
0.06 2.74 (0.59 – 
12.60) 
0.20 
4/5 or 5/5 2 1 1.40 (0.06 – 
33.29) 
0.84 0.62 (0.00 – 
220.41) 
0.87 
Hypermethylation 
(ncases = 29; 
ncontrols = 50) 
4/4 23 9 Ref -- Ref -- 
4/5 21 14 1.67 (0.60 – 
4.63) 
0.33 1.79 (0.59 – 
5.42) 
0.30 
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Table 6.9. Relationship between PER3 VNTR genotype and adenoma status: stratified by methylation status in PER1, 
PER2, and PER3 
Methylation 
Marker 
Methylation 
Status 
Genotype Controls Cases Crude OR1 
(95% CI) p-value 
Adjusted OR2 
(95% CI) p-value n (%) n (%) 
5/5 6 6 2.47 (0.63 – 
9.70) 
0.19 2.74 (0.59 – 
12.61) 
0.20 
4/5 or 5/5 27 20 1.84 (0.71 – 
4.81) 
0.21 2.01 (0.71 – 
5.71) 
0.19 
PER3 
Hypomethylation 
(ncases = 5;  
ncontrols = 2) 
4/4 1 2 Ref  -- Ref -- 
4/5 1 2 1.00 (0.04 – 
27.26) 
1.00 0.30 (0.00 – 
32.83) 
0.62 
5/5 0 1 1.98 (0.01 – 
358.88) 
0.80 4.34 (0.02 – 
1118.84) 
 
4/5 or 5/5 1 3 1.40 (0.06 – 
33.27) 
0.84 1.02 (0.03 – 
30.00) 
0.99 
Hypermethylation 
(ncases = 26; 
ncontrols = 53) 
4/4 25 8 Ref -- Ref -- 
4/5 22 13 1.80 (0.63 – 
5.11) 
0.27 1.91 (0.60 – 
6.03) 
0.27 
5/5 6 5 2.54 (0.61 – 
10.54) 
0.20 2.34 (0.48 – 
11.43) 
0.29 
4/5 or 5/5 28 18 1.95 (0.73 – 
0.5.22) 
0.18 2.02 (0.68 – 
5.98) 
0.20 
Abbreviations: OR, Odds ratio; CI, Confidence interval; VNTR: Variable number tandem repeat 
1 - Unconditional logistic regression with Firth’s bias correction; 2 - Adjusted for decision latitude at work, recruitment 
site, and procedure reason.  
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Table 6.10.  Relationship between PER3 VNTR genotype and lifetime shiftwork 
exposure 
  Lifetime Shiftwork in Years 
p-value1 n (%) Median  25th 
percentile 
75th 
percentile 
4/4 67 (47) 5  1 15 -- 
4/5 61 (42) 2 0 10 0.02 
5/5 16 (11) 0.75 0 8.5 0.05 
4/5 or 5/5 77 (53) 1 0 10 <0.01 
1Wilcoxon rank sum test for group differences in medians by genotype 
compared to those with the 4/4 genotype; 2 subjects missing information on 
lifetime shiftwork; VNTR: Variable number tandem repeat 
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Table 6.11.  PERIOD gene expression in human adenomas vs. normal tissue1 
Referent Tissue Pathological Tissue Type PER1 p-value PER2 
p-
value PER3 p-value Reference 
Normal colon 
epithelium (n=22) 
Colorectal adenoma 
epithelium (n=56) -1.3 <0.01 -1.2 0.05 N/A N/A 
336
 
Normal colon 
(n=32) Colon adenoma (n=25) -1.7 <0.01 -1.2 <0.01 -2.3 <0.01 
337
 
Normal colon 
(n=32) Rectal adenoma (n=7) -1.9 <0.01 1.3 0.88 -1.7 <0.01 
337
 
Normal colon 
(n=10) Colon adenoma (n=5) -1.0 0.37 1.6 0.99 -2.1 <0.01 
338
 
Normal colon 
epithelium (n=10) 
Colorectal adenoma 
epithelium (n=5) -1.2 0.05 1.2 0.94 -1.7   <0.01 
338
 
1Fold change in mRNA expression in adenomas relative to adjacent normal tissue (number of tissue samples evaluated in 
parentheses).  Source: www.oncomine.com 
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Chapter 7 
Conclusion 
This dissertation project aimed to accomplish two goals: 1) understand the 
scope of sleep disorders in a national sample, and 2) elucidate the genetic and 
epigenetic mechanisms of clock genes and their role in adenoma formation, a 
precursor lesion for CRC. Sleep disruption has been previously linked to 
increased cancer risk, potentially through circadian rhythm disruption; therefore it 
is necessary to characterize populations at risk (e.g., shift workers, people with 
sleep disorders).   
The first project aimed at characterizing sleep disorders over time in a 
national sample of veterans.  This project found that the prevalence of sleep 
disorders have increased nearly six-fold from FY2000 to FY2010.  As expected, 
apneas were the most commonly-diagnosed sleep disorder, followed by 
insomnia.  However, it is not known whether or not this increase in sleep 
disorders were a true increase due to certain factors (increasing trends in 
obesity, PTSD, etc.), increased awareness, or a combination of both.  In this 
national sample of veterans, PTSD tripled over time; and those with PTSD had 
the highest prevalence of sleep disorders (16%).  Increase in awareness could 
also be attributed to the surge in sleep disorder prevalence, as a national sleep 
medicine training and certification program was initiated in 2004-2005.350  Using
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this national sample, etiological models for sleep disorders were also created, as 
there is a dearth in the literature on risk factors for sleep disorders, while 
simultaneously accounting for other factors.  Pre-existing history of PTSD and 
being obese resulted in a more than doubling of odds of developing a sleep 
disorder in FY2010.  Future research will need to be conducted in large, national 
samples to confirm findings in the present studies.   
Because people with sleep disorders may have genetic alterations or 
epigenetic changes that could increase their risk for cancer, the second part of 
this dissertation examined relationships in a set of genes involved in the 
regulation of circadian rhythms. Circadian rhythms are established in the central 
pacemaker, located in the SCN of the anterior hypothalamus, via photic input. 
Nine core clock genes have been found to play a role in circadian oscillation: 
PER1, PER2, PER3, CRY1, CRY2, CLOCK, BMAL1, TIM, and CK1ε.33  ~2-10% 
of the diurnal gene expression in most tissues is controlled by this set of genes.89  
In particular, the Period (Per) gene family plays a role in immunomodulation20-25 
and tumor suppression.26, 27 However, environmental (e.g., shiftwork) 91-93 and/or 
genetic factors (genetic polymorphisms or epigenetic modifications)30, 94 can 
confuse the master clock, affecting physiological processes involved in 
tumorigenesis, such as cell proliferation and apoptosis.95 Disruption of these 
processes has been suspected of increasing the risk of cancer in certain 
populations (e.g., shiftworkers),96 and these effects have been confirmed in 
animal model studies.97  Previous research found that genetic polymorphisms,19, 
28, 29 variable expression in tumor tissues,30-32 and aberrant methylation33 within 
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the Per genes have shown some promise as novel biomarkers of cancer, which 
warranted the second project.   
In a case-control pilot study where the methylation status of 20 candidate 
markers in PBLs were examined for their relationships with adenoma formation, 
individuals with hypomethylation in the promoters of three markers (PER1, 
PER3, and MINT1)  were 3 to 11 times more likely to have adenomas compared 
to adenoma-free controls, after controlling for multiple confounders.     Although 
aberrant methylation of PER genes has been observed among leukemia and 
other cancer patients,30, 33, 113, 114, 286 little is currently known about the MINT1 
locus, and all three markers had not been previously examined in PBLs in 
relation to adenoma formation.  It is suspected that clock-controlled genes, which 
include known tumor suppressors (e.g., p21, Chk2, XPA, ATM) and oncogenes 
(e.g., β-catenin, c-Myc, WEE-1),276  may be dysregulated, thus potentially 
promoting a carcinogenic microenvironment.   
In addition to examining epigenetic variation and adenoma risk, an 
additional study of the second project was undertaken, specifically focusing on 
the PER3 VNTR, a tandem repeat that contains four or five copies of a 54-bp 
sequence encoding 18 amino acids, with the 5-repeat variant adding several 
phosphorylation motifs.  In this study, subjects with adenomas were anywhere 
from 2 to 5 times more likely to possess at least one 5-repeat variant compared 
to controls.  This association may be partially mediated by alterations in circadian 
processes (i.e., delayed sleep phase syndrome, cognitive impairment after sleep 
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deprivation, morning circadian preference, and differences in the timing or levels 
of circadian hormone secretion)40, 117, 313 among those with at least one 5-variant 
repeat.  Although this finding was not consistent with a previous study that 
examined PER3 VNTR polymorphisms and CRC,351 a prior study has observed 
an association between the 5-repeat variant and premenopausal breast cancer,19 
suggesting that PER3 may act as a tumor suppressor; however, more studies will 
need to confirm findings observed in this study. 
In closing, although it is unclear as to why sleep disorder prevalence is 
increasing over time, it is clear that a subset of the population may be increasing 
their risk for adverse health events, including cancer, and genetic and/or 
epigenetic mechanisms may be partially mediating this pathway.  Elucidation of 
these mechanisms may not only allow for understanding the association between 
circadian disturbances and cancer, but to also develop novel biomarkers from 
readily-accessible sources, such as blood.
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